KOL | Rikard HolmdahlNational and Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China | Medical ... |
Kol CV for Rikard Holmdahl
| Year | |
|---|---|
| 2022 | National and Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China Medical Inflammation Research, MediCity Research Laboratory, University of Turku, Turku, Finland |
| 2021 | The Second Affiliated Hospital of Xi’an Jiaotong University (Xibei Hospital), Xi’an, China Department Medical Biochemistry and Biophysics, Division Medical Inflammation Research, Karolinska Institute, 171 77 Stockholm, Sweden;, (M.A.);, (X.C.);, (B.X.);, (G.F.L.);, (M.Y.B.);, (Y.H.);, (L.B.) Division of Medical Inflammation Research, Dept. of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden |
| 2020 | Dept. of Medical Inflammation Research, Section of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm Section for Medical Inflammation Research, BMCI11, Lund University, Lund, Sweden National & Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital, Xi'an Jiaotong University, 710004 Xi’an, China Karolinska Institutet |
| 2019 | Section for Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Solnavägen 9, 171 65, Solna, Sweden Center for Medical Inflammation Research, Southern Medical University, Guangzhou, China R. Holmdahl and C.I. Svensson contributed equally to this paper. |
| 2018 | School of Pharmaceutical Science, Southern Medical University, Guangzhou, China Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 17177, Sweden. Electronic address: Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden Medicity Research Laboratory, University of Turku, Turku, Finland |
| 2017 | Karolinska Institutet Division of Medical Inflammation Research Stockholm Sweden Center for Medical Immunopharmacology Research, Southern Medical University, 510515 Guangzhou, China. Medicity Research Laboratory, University of Turku, Turku, Finland, . |
Rikard Holmdahl: Påvirke statistikk
Kjør rapport
| Concept | World rank |
|---|---|
| cia40 | #1 |
| mechanism autoimmune | #1 |
| rats clec4b | #1 |
| c3hnb mice | #1 |
| nodq nod | #1 |
| rats ncf1 gene | #1 |
| antigenic adjuvant | #1 |
| psoriasis single locus | #1 |
| pia experimental chromosomes | #1 |
| anticii antibody response | #1 |
| fecq3 | #1 |
| development inflammatory attack | #1 |
| environments mice | #1 |
| inability collagen | #1 |
| aq molecule | #1 |
| 256 270 | #1 |
| arthritis arthritis loci | #1 |
| mmc transgene | #1 |
| non‐mhc genes | #1 |
| nox2derived ros | #1 |
| cii cartilage | #1 |
| glycosylated epitope | #1 |
| serum chromosome | #1 |
| deficient ncf1 | #1 |
| epitopes cii | #1 |
| saline arthritis | #1 |
| ncf1m1j mice ncf1 | #1 |
| data act389949 | #1 |
| macrophages autoimmune priming | #1 |
| rats antibody response | #1 |
| collagen autoantibody | #1 |
| cd2 human cells | #1 |
| effects ciif4 | #1 |
| ros continental ancestry | #1 |
| toxin‐1‐producing staphylococci | #1 |
| enhanced autoimmunity | #1 |
| chronic development | #1 |
| ciic1scfv | #1 |
| suppression collagen | #1 |
| cii disease | #1 |
| cia pathogenesis | #1 |
| antitlr3 antibody | #1 |
| presentation arthritis | #1 |
| eae3 chromosome | #1 |
| mutant p47phox | #1 |
| arthritis pristane | #1 |
| arthritis adjuvants | #1 |
| cb268 | #1 |
| experimental autoimmunity cells | #1 |
| nodp nod | #1 |
| myelomonocytic arthritis interleukin2 | #1 |
| keratinocytes dth reaction | #1 |
| double deficiency qa2 | #1 |
| models rheumatoid arthritis | #1 |
| human immunopeptidome lung | #1 |
| rats pia9 alleles | #1 |
| rat cii arthritis | #1 |
| cia homologous cii | #1 |
| cxiia | #1 |
| tlr3 flss | #1 |
| cia | #1 |
| b10riii riiis | #1 |
| severe arthritis immunization | #1 |
| beta 812 | #1 |
| autoantibody formation cia | #1 |
| cryogel column antibodies | #1 |
| lewis rat cia | #1 |
| sensitive wkymvm | #1 |
| cii peptides | #1 |
| peritonitis sod3 | #1 |
| day acute arthritis | #1 |
| cii 256270 peptide | #1 |
| caia model | #1 |
| cii matrix protein | #1 |
| cii olive oil | #1 |
| cia9 | #1 |
| dth antibody response | #1 |
| chromosome f1 males | #1 |
| act389949 agonist | #1 |
| arthritis darkness | #1 |
| enhanced autoimmunity arthritis | #1 |
| patients china cohort | #1 |
| headache paradigm | #1 |
| t‐cell epitope cii260‐270 | #1 |
| genetic encephalomyelitis autoimmune | #1 |
| mice cryogels | #1 |
| visual signs arthritis | #1 |
| incidence nod | #1 |
| severe polyarthritis | #1 |
| ciiinduced | #1 |
| susceptible collagen | #1 |
| large numbers hybridomas | #1 |
| cxi arthritis | #1 |
| single monoclonal | #1 |
| m1s1a | #1 |
| oestrogen cia | #1 |
| caia induced | #1 |
| hfdmets | #1 |
| cii peptide molecules | #1 |
| f1 hybrids disease | #1 |
| publication animals arthritis | #1 |
| bb2bb3 regulation | #1 |
| chronic arthritis development | #1 |
| physiological doses development | #1 |
| disease development effects | #1 |
| dominant traits | #1 |
| dominant susceptibility loci | #1 |
| dth mice trait | #1 |
| nzb dth | #1 |
| cii caia | #1 |
| arthritis antibody | #1 |
| severity ides | #1 |
| anticardiolipin antibodies p005 | #1 |
| pia eae | #1 |
| b10qbalb | #1 |
| denidritic cells | #1 |
| pinealectomy exposure | #1 |
| anticd4 treatment immunization | #1 |
| arthritis monoclonal | #1 |
| surface redox levels | #1 |
| transgenic nadph | #1 |
| epitopes arthritis | #1 |
| 371115tetramethyl2hexadecene1ol | #1 |
| ciid3 | #1 |
| pia4 | #1 |
| arthritogenic antibodies | #1 |
| reactivity cii | #1 |
| protein expression genes | #1 |
| arthritis mcaia | #1 |
| cia22 | #1 |
| da1f | #1 |
| ncf1 polymorphisms | #1 |
| e3xda | #1 |
| ciispecific antibodies | #1 |
| cia rat cii | #1 |
| cells autologous cii | #1 |
| pia rats arthritis | #1 |
| p47phoxv232 | #1 |
| cii molecule | #1 |
| pia blocking arthritis | #1 |
| h2q c3hnb | #1 |
| epitopes vivo | #1 |
| mice developed | #1 |
| cii h2q | #1 |
| hydrolyzed igg | #1 |
| cia ul1 | #1 |
| tnfα tlr3 expression | #1 |
| arthritis | #1 |
| h2p h2q haplotype | #1 |
| aq glycopeptide | #1 |
| plasminogen deficiency cia | #1 |
| dba 1 background | #1 |
| genes animal models | #1 |
| cia mip | #1 |
| dth nzb mice | #1 |
| position mouse cii | #1 |
| anticii abs | #1 |
| psicoch2 | #1 |
| rheumatoid disease models | #1 |
| collagen reactive | #1 |
| ciispecific monoclonal | #1 |
| socalled collagen antibody | #1 |
| cii saline | #1 |
| strong response epitopes | #1 |
| h‐2q | #1 |
| inclusion negative predictive | #1 |
| native comp | #1 |
| ciif4 mab | #1 |
| day ciispecific cells | #1 |
| genetic control pia | #1 |
| cia comp | #1 |
| polyi pia rats | #1 |
| ifnbeta deficiency | #1 |
| caia mutant mice | #1 |
| immunization rat | #1 |
| b10q h2q | #1 |
| pc117 extracellular structures | #1 |
| collagen dendritic cells | #1 |
| suppressive development | #1 |
| susceptibility cia | #1 |
| cells cii | #1 |
| hg6pi | #1 |
| mhc aq | #1 |
| cix cii | #1 |
| dominant hypersensitivity dth | #1 |
| pepsin arthritis | #1 |
| b10q strain | #1 |
| reactivity cb268 | #1 |
| f1 males influence | #1 |
| caia experimental arthritis | #1 |
| cells caia | #1 |
| fcγr3 | #1 |
| cia caia | #1 |
| eae2 chromosome | #1 |
| fecq4 | #1 |
| congenic strains rats | #1 |
| ncf1da | #1 |
| cia13 | #1 |
| cii antigen presentation | #1 |
| severity cia | #1 |
| idd5 loci | #1 |
| oestrogen induced | #1 |
| arthritis incidence | #1 |
| cia ros | #1 |
| abetachains | #1 |
| qtl positional cloning | #1 |
| collagen type cii | #1 |
| nox2complex | #1 |
| nox2 complex ncf4 | #1 |
| collagen‐induced arthritis | #1 |
| loci sialadenitis | #1 |
| sialadenitis congenic mice | #1 |
| presentation cii | #1 |
| autoimmunity mineral oils | #1 |
| arthritis control mice | #1 |
| collagen hybridomas | #1 |
| mhc class injections | #1 |
| act389949 fpr | #1 |
| psich2nh2 | #1 |
| acute phase arthritis | #1 |
| bb2bb3 | #1 |
| sialadenitis nodq | #1 |
| 270 peptide | #1 |
| established pia disease | #1 |
| qa2 natural mutations | #1 |
| placental mhc class | #1 |
| 237 females | #1 |
| lnchc cholesterol metabolism | #1 |
| glut4dependent glucose transport | #1 |
| arthritis protection | #1 |
| pia rheumatoid arthritis | #1 |
| chemical collagen | #1 |
| ctbcii | #1 |
| position ciilysdnp | #1 |
| heterologous collagen | #1 |
| rat cii | #1 |
| induced arthritis | #1 |
| adjuvanticity autoimmunity | #1 |
| c3bireceptors | #1 |
| mip cia | #1 |
| function targeted deletion | #1 |
| ala261gly262 | #1 |
| cia oestrogen | #1 |
| inflammation caia | #1 |
| arthritis estrogen treatment | #1 |
| injection mannan | #1 |
| cii ncf1 | #1 |
| pparγ cbrh7919 cells | #1 |
| mice arthritis | #1 |
| arthritis intraperitoneal injection | #1 |
| partial advanced intercross | #1 |
| hladrbound peptides | #1 |
| greater osteoclasts | #1 |
| immune priming events | #1 |
| h2p susceptibility | #1 |
| b10riii | #1 |
| sialadenitis strains | #1 |
| chromosomes eae loci | #1 |
| type collagens rats | #1 |
| cii severity | #1 |
| cxb10qf2 | #1 |
| biodegradation cryogels | #1 |
| cia recognition | #1 |
| 339 polymorphism | #1 |
| caia monoclonal | #1 |
| rats antibody cartilage | #1 |
| ym1deficient mice | #1 |
| tolerance cia | #1 |
| immunization rat cii | #1 |
| cia model strains | #1 |
| cxi pia | #1 |
| arthritis autoantibody | #1 |
| cii immunization treatment | #1 |
| recombinant vaccine inflammation | #1 |
| citrullination cii | #1 |
| cii citrullinated | #1 |
| b10qacb | #1 |
| controlling collagen | #1 |
| mice burkholderia cepacia | #1 |
| cell recognition carbohydrates | #1 |
| mbq mouse macrophages | #1 |
| new therapy arthritis | #1 |
| 2 nox2 | #1 |
| position cii256270 | #1 |
| nod nss1 loci | #1 |
| loci arthritis | #1 |
| cells arthritis progression | #1 |
| arthritis rat strains | #1 |
| presence sex hormones | #1 |
| antibodies cii | #1 |
| tlr3 pristane | #1 |
| cb11 fragment | #1 |
| nadph activation | #1 |
| nox2 function | #1 |
| collagen type‐ii epitope | #1 |
| functional ncf1 | #1 |
| sialadenitis cell phenotypes | #1 |
| ros adaptive immunity | #1 |
| new loci controlling | #1 |
| cii cia | #1 |
| arthritis pepsin | #1 |
| psiechch | #1 |
| pia7 | #1 |
| disease monitoring rats | #1 |
| predominant selection | #1 |
| cia olive oil | #1 |
| region eae3 | #1 |
| cells mouse cii | #1 |
| transgenic tolerance tlymphocytes | #1 |
| arthritis susceptibility rats | #1 |
| comp mabs | #1 |
| riiis segment chromosome | #1 |
| flss polyi | #1 |
| autoimmune response cii | #1 |
| presence mhv | #1 |
| caia cia | #1 |
| arthritis qtl chip | #1 |
| endos hydrolyzed igg | #1 |
| arthritis animals | #1 |
| ros immunohistochemistry implants | #1 |
| pia cii | #1 |
| arthritogenic mabs cii | #1 |
| g6pi chronic arthritis | #1 |
| cartilage cii | #1 |
| hiit nox2 activity | #1 |
| cia cells | #1 |
| role ncf1 | #1 |
| arthritis development severity | #1 |
| ltabncr3 | #1 |
| collagen‐induced | #1 |
| lewis oia | #1 |
| hydrocarbon oil structure | #1 |
| development collagen | #1 |
| fpr act389949 | #1 |
| 4 histone deacetylases | #1 |
| fcbinding | #1 |
| encephalomyelitis arthritis | #1 |
| mutated ncf1 | #1 |
| nzb mice trait | #1 |
| ncf1 p47phox | #1 |
| glycosylation cell recognition | #1 |
| carbohydrates cii | #1 |
| collageninduced arthritis | #1 |
| functional selective fpr1 | #1 |
| b10q | #1 |
| h2r h2q | #1 |
| activation cii | #1 |
| paamcryogel | #1 |
| tlr3 upregulation flss | #1 |
| induced relapsing | #1 |
| defined polymeric adjuvant | #1 |
| synthetic peptides cii | #1 |
| rats pia | #1 |
| targeted mutation ncf4 | #1 |
| c57bl strains loci | #1 |
| arthritis locus | #1 |
| congenic cia40 | #1 |
| arthritis collagen | #1 |
| ul1 ciif4 mab | #1 |
| b10q mice ncf1 | #1 |
| ifa cii ifa | #1 |
| il10 cia | #1 |
| galactosylated peptide | #1 |
| rats cxi | #1 |
| animal epitopes injections | #1 |
| role eosinophilia | #1 |
| liver histone deacetylase | #1 |
| ncf1 mice wt | #1 |
| ciispecific cells | #1 |
| ncf1 339 | #1 |
| driven psoriatic arthritis | #1 |
| alpha type collagen | #1 |
| dth dominant hypersensitivity | #1 |
| increased incidence cia | #1 |
| cii 256 | #1 |
| proteins gay | #1 |
| rat placenta uterus | #1 |
| induction phase cia | #1 |
| citc1iiip | #1 |
| ncf1 gene | #1 |
| cells cia | #1 |
| frequency igaproducing cells | #1 |
| phenotypes ncf1m1j mice | #1 |
| immunization heterologous peptide | #1 |
| findings new therapy | #1 |
| genetic regions | #1 |
| tlr3 tlr3 expression | #1 |
| mice c3h background | #1 |
| dependent autoimmune | #1 |
| polymorphic fragment | #1 |
| vivo monoclonal | #1 |
| pia3 pia4 | #1 |
| mhc genetic region | #1 |
| ros glucose transporter | #1 |
| cii pia | #1 |
| experimental autoantigens | #1 |
| vivo treatment | #1 |
| methods | #1 |
| cii256270 | #1 |
| cd200 btla | #1 |
| kgf cia | #1 |
| polymer adjuvant activity | #1 |
| complex cia | #1 |
| il10 mmc | #1 |
| eae b10riii mice | #1 |
| disease transgenic models | #1 |
| rat type collagen | #1 |
| dimethyl6n | #1 |
| major cii | #1 |
| pc4 pc8 | #1 |
| cii cb fragments | #1 |
| cia2 arthritis | #1 |
| rats chronic disease | #1 |
| humanized models disease | #1 |
| congenic polymorphism illness | #1 |
| epitopes cb10 fragment | #1 |
| congenic mice vdr | #1 |
| proteolipoprotein peptide | #1 |
| cii cells | #1 |
| collagen antibodies | #1 |
| nonglycosylated peptide | #1 |
| diabetes sialadenitis | #1 |
| hyaluronanreceptor cd44 | #1 |
| phosphatase 22 | #1 |
| congenic fragment | #1 |
| positional identification | #1 |
| development cia | #1 |
| eae chromosomes | #1 |
| glycosylated epitope structures | #1 |
| m1j | #1 |
| col2259 | #1 |
| modified glycopeptides | #1 |
| collagen epitope expression | #1 |
| 2 months beta | #1 |
| ncf1 mutant | #1 |
| ros nox2 complex | #1 |
| cia12 | #1 |
| glycoprotein alpha1microglobulin | #1 |
| susceptible strain cross | #1 |
| collageninduced arthritis loci | #1 |
| mcaia ncf1 | #1 |
| caia acute arthritis | #1 |
| lymphocytes collagen | #1 |
| rats congenic arthritis | #1 |
| carcinoma tumors ros | #1 |
| ul1 vivo | #1 |
| ifnbeta arthritis | #1 |
| gergaagiagpk | #1 |
| arthritis pia | #1 |
| exacerbation arthritis | #1 |
| collagen reactivity cxi | #1 |
| macrophages hladr1transgenic mice | #1 |
| authors hgpi325339 peptide | #1 |
| cia ifa | #1 |
| response splenocytes | #1 |
| ciic1 mabs | #1 |
| bal cells work | #1 |
| mumt mice oestrogen | #1 |
| controlling onset | #1 |
| estrogeninduced suppression | #1 |
| arthritis naive mice | #1 |
| chronic arthritis mice | #1 |
| cii259273 peptide | #1 |
| phagocyte oxidative burst | #1 |
| autologous type collagen | #1 |
| compdeficient mice | #1 |
| mir144 tlr2 expression | #1 |
| pia4 chromosome | #1 |
| minor cartilage proteins | #1 |
| cii mouse | #1 |
| mhc mbp | #1 |
| spread induced psoriasis | #1 |
| cd4 treatment | #1 |
| cia locus | #1 |
| eae39 locus cia | #1 |
| ncf1deficient mice | #1 |
| differences ncf1 | #1 |
| pristane hexadecane | #1 |
| cia melatonin | #1 |
| collagen langerhans cells | #1 |
| nfr origin | #1 |
| cii immunization mice | #1 |
| epitopes collagen | #1 |
| ros autoimmune diseases | #1 |
| ciispecific cell responses | #1 |
| cii rats | #1 |
| cii h2p | #1 |
| ftirm ciic1 | #1 |
| tlr3 expression flss | #1 |
| snat proteins | #1 |
| sle‐prone mrl | #1 |
| macrophages cii | #1 |
| tlr3 synovium | #1 |
| tolerance immunodominant | #1 |
| mcia1 | #1 |
| cii260‐270 | #1 |
| pristane stimulation | #1 |
| minimal glycopeptide core | #1 |
| phemagelatin | #1 |
| presence arthritogenic mabs | #1 |
| function p47phox | #1 |
| alphachains cell surface | #1 |
| anticii antibodies | #1 |
| milk titers | #1 |
| kgf chondrocytes | #1 |
| qa2 gene clusters | #1 |
| arthritis tlr3 | #1 |
| type disease | #1 |
| arthritis male | #1 |
| genes ncf1 | #1 |
| major epitopes | #1 |
| strains nodq | #1 |
| caia effects | #1 |
| ethylene isostere | #1 |
| hyaluronanreceptor | #1 |
| single bout hiit | #1 |
| cia32 | #1 |
| induced arthritis rats | #1 |
| mab mab ciic1 | #1 |
| hladr1transgenic mice | #1 |
| major role rp | #1 |
| g6pi peptide | #1 |
| kupffer cells mir144 | #1 |
| cells chronic arthritis | #1 |
| type cii | #1 |
| pristaneinduced arthritis rats | #1 |
| ztmrhd | #1 |
| chlorophyll component | #1 |
| tlr3 expression tnfα | #1 |
| nodq nod nodp | #1 |
| periodontitis pristaneinduced arthritis | #1 |
| eae2 eae3 | #1 |
| autologous cii | #1 |
| avridine arthritis | #1 |
| arthritis cia | #1 |
| spe acute phase | #1 |
| cii arthritis | #1 |
| epitope type | #1 |
| synovium pia rats | #1 |
| fecq4 fragment | #1 |
| ciic1 m2139 | #1 |
| mouse cii | #1 |
| disease susceptibility castration | #1 |
| eae2 resistant locus | #1 |
| rats established pia | #1 |
| rats arthritis | #1 |
| heterologous cii cells | #1 |
| rats synthetic peptide | #1 |
| cii rheumatoid autoantibodies | #1 |
| mouse chromosome eae39 | #1 |
| pristane primed | #1 |
| mice mutated cii | #1 |
| ncf1 ncf1 mice | #1 |
| features arthritis | #1 |
| identification genetic regions | #1 |
| qtl animal genes | #1 |
| arthritis ul1 | #1 |
| cii ecm | #1 |
| arthritis ncf1 | #1 |
| cia opportunities | #1 |
| cii monoclonal arthritis | #1 |
| g6pi acute arthritis | #1 |
| igg1 igg2b isotypes | #1 |
| signaling characterization | #1 |
| healthy nzw | #1 |
| phytol arthritis | #1 |
| cb268 cii | #1 |
| arthritis autoimmune | #1 |
| impact topoisomerase antagonist | #1 |
| expression ncf1 | #1 |
| idiotype‐specific binding | #1 |
| illness cia | #1 |
| ncf1 sle | #1 |
| experimental arthritis articular | #1 |
| locus cia development | #1 |
| psa mip | #1 |
| elisagenetyping | #1 |
| acpa discriminate | #1 |
| drb10401 col2259 | #1 |
| macrophages cii degradation | #1 |
| nox2 complex addition | #1 |
| ncf1 mutated | #1 |
| spleen pristane injection | #1 |
| animal histocompatibility | #1 |
| emerging glyco‐based strategies | #1 |
| peritonitis transgenic | #1 |
| ox8 monoclonal | #1 |
| ciif4 cartilage damage | #1 |
| arthritis experimental | #1 |
| ncf1 association | #1 |
| arthritis induced | #1 |
| arthritis ncf1 allele | #1 |
| pristane hydrocarbon oils | #1 |
| pia cia13 pia7 | #1 |
| ciipeptide cells | #1 |
| arthritis multiple | #1 |
| cia experimental arthritis | #1 |
| genetic control sialadenitis | #1 |
| wild type ncf1 | #1 |
| chromosome cia | #1 |
| nod nss1 | #1 |
| 6 cii | #1 |
| comp disease monitoring | #1 |
| rats pristaneinduced arthritis | #1 |
| cartilage explants ciic1 | #1 |
| onset animals arthritis | #1 |
| tolerance induction cii | #1 |
| nrc ova | #1 |
| induction cii | #1 |
| contrast nodq | #1 |
| severity arthritis | #1 |
| rt1l haplotypes | #1 |
| terpenes toll | #1 |
| siliac | #1 |
| caia riiis segment | #1 |
| spontaneous tissue inflammation | #1 |
| immunodominant cii | #1 |
| congenic fragments | #1 |
| promoter regions antigens | #1 |
| injection lewis rat | #1 |
| arthritis estrogen | #1 |
| rats comp | #1 |
| mbpc5a | #1 |
| effects fab2 | #1 |
| realtime pcr flss | #1 |
| h‐2q mice | #1 |
| collagen chains antibody | #1 |
| peptides aq | #1 |
| antibody cartilage blymphocyte | #1 |
| arthritis loci | #1 |
| arthritis injection | #1 |
| chronic stage arthritis | #1 |
| downregulating oestradiol | #1 |
| specific cii | #1 |
| pia9 | #1 |
| arthritis castration | #1 |
| arthritis animal | #1 |
| bond requirements | #1 |
| collagen induced | #1 |
| lew1w rt1u | #1 |
| autoimmune accelerating | #1 |
| cii cxi | #1 |
| inflammatory phase arthritis | #1 |
| ciiglycopeptides | #1 |
| rheumatoid arthritis immunization | #1 |
| mice l012 | #1 |
| strains polychondritis | #1 |
| arthritis toe stiffness | #1 |
| mice interferon gamma | #1 |
| mir144 tlr2 | #1 |
| tolerance collagen | #1 |
| maintenance arthritis | #1 |
| h2q haplotype | #1 |
| cia chromosome | #1 |
| rp autoimmune disease | #1 |
| tolerance arthritis | #1 |
| spleen cluster | #1 |
| targeted deletion ncf1 | #1 |
| ciif4 adverse effects | #1 |
| ciispecific | #1 |
| human α‐enolase | #1 |
| oia induction | #1 |
| antibody responses cii | #1 |
| pia rats tlr3 | #1 |
| multiple sclerosis rabeximod | #1 |
| disease suggestive locus | #1 |
| pc4 pc117 | #1 |
| mice ncf1 | #1 |
| acpas specificity | #1 |
| cxi collagen fibers | #1 |
| ym1 alternative activation | #1 |
| relapsing arthritis | #1 |
| type collagen cii256−270 | #1 |
| monoclonal arthritis arthritis | #1 |
| rats rheumatoid | #1 |
| arthritis severity rats | #1 |
| collagen 256 | #1 |
| fumia | #1 |
| glycosylated cii | #1 |
| cii dendritic cells | #1 |
| dth nzb | #1 |
| chronic pristane | #1 |
| suggestive locus chromosome | #1 |
| dba mouse epitopes | #1 |
| mice salt concentrations | #1 |
| antigen presentation cii | #1 |
| l012 vivo imaging | #1 |
| locus arthritis | #1 |
| etoposide topoisomerase antagonist | #1 |
| ll37 rcramp | #1 |
| oxidases receptors | #1 |
| disease cd8 deficiency | #1 |
| mice salt intake | #1 |
| antibodies citrullinated peptide | #1 |
| cartilage‐specific antibodiesis | #1 |
| cii antibodies | #1 |
| neonatal mortality milk | #1 |
| ciic1 mab ciif4 | #1 |
| ifa rats | #1 |
| cii experimental arthritis | #1 |
| mem lglutamine | #1 |
| active arthritis complex | #1 |
| w33t | #1 |
| arthritis caia | #1 |
| δ228 | #1 |
| arthritis incidence severity | #1 |
| potent disease accelerator | #1 |
| ros experimental arthritis | #1 |
| polychondritis mice | #1 |
| cell recognition cii | #1 |
| caia gene segments | #1 |
| synovial cells macrophages | #1 |
| arthritis epitopes | #1 |
| daxlewf1 | #1 |
| fecq4 locus | #1 |
| ncf1mutation | #1 |
| liver contributes hfdmets | #1 |
| skg mutation | #1 |
| congenic strains cia | #1 |
| ncf1m1j mice | #1 |
| cii specific | #1 |
| inflammatory phase cia | #1 |
| immunization type | #1 |
| inflammatory tissue attack | #1 |
| cia5 cia21 | #1 |
| cxi 6 | #1 |
| citrullinated type collagen | #1 |
| cii mab | #1 |
| mediate pulmonary inflammation | #1 |
| u1 antibodies patients | #1 |
| autoantibodies cartilage | #1 |
| thps cii | #1 |
| oestrogen‐induced | #1 |
| partial advanced | #1 |
| oxidative burst disease | #1 |
| anticcp2negative patients | #1 |
| cia congenic arthritis | #1 |
| salivary glands antigen | #1 |
| rabeximod arthritis | #1 |
| genetic background rats | #1 |
| cii cross reactivity | #1 |
| intracellular processing cii | #1 |
| animal epitopes | #1 |
| confers arthritis susceptibility | #1 |
| copy variation ncf1 | #1 |
| act389949 | #1 |
| preformed cartilage | #1 |
| pepsin cii | #1 |
| arthritis driven | #1 |
| severe arthritis | #1 |
| type collagen cxi | #1 |
| cholera toxin study | #1 |
| innate rats | #1 |
| pristaneinduced arthritis | #1 |
| cii histocompatibility complex | #1 |
| treatment pia | #1 |
| cii cartilage explants | #1 |
| mice darkness | #1 |
| glycosylation hla | #1 |
| pathogenesisis | #1 |
| cartilage damage vivo | #1 |
| autoimmunogenic hydrocarbon oils | #1 |
| cxi chronic arthritis | #1 |
| cii259 | #1 |
| function nox2 | #1 |
| rats mhc genes | #1 |
| spread psoriasis | #1 |
| specific antibody protection | #1 |
| satellite encephalomyelitis autoimmune | #1 |
| citrullinated type | #1 |
| manifestations lupus disease | #1 |
| oxa backcrosses | #1 |
| macrophage ros | #1 |
| arthritis development immunisation | #1 |
| disease dba 1jpfp | #1 |
| cii immunization | #1 |
| immunization mouse cii | #1 |
| nss1 | #1 |
| satellite encephalomyelitis | #1 |
| cia vivo priming | #1 |
| m2139 ciic1 | #1 |
| arthritis males | #1 |
| h2p mice cia | #1 |
| dba1 mice | #1 |
| peptide characterisation | #1 |
| experimental collagen | #1 |
| hfdmets expression | #1 |
| rs201802880 | #1 |
| collagens antibody | #1 |
| damage type collagen | #1 |
| ncf1 ptpn22 | #1 |
| ciic1 fab | #1 |
| cell specificity cii | #1 |
| dba 1 | #1 |
| ncf1 lyme arthritis | #1 |
| insulitis strains | #1 |
| dr4 glycopeptides | #1 |
| cartilaginous joints | #1 |
| eae2 locus | #1 |
| mice ncf4 | #1 |
| nonglycosylated epitope | #1 |
| collagen citrullination | #1 |
| eae strains severity | #1 |
| development collageninduced arthritis | #1 |
| lower capacity ros | #1 |
| ncf1339 allele | #1 |
| c1iii | #1 |
| sterically privileged | #1 |
| swr nfr | #1 |
| cii256 | #1 |
| collagen immunization | #1 |
| ncf1m1j mutation | #1 |
| development aureus arthritis | #1 |
| cia12 pia4 | #1 |
| disease th1 immunity | #1 |
| ciic1 antibody | #1 |
| experimental chromosomes | #1 |
| lack arthritis | #1 |
| cii pepsin | #1 |
| models collagen | #1 |
| established arthritis | #1 |
| genes arthritis | #1 |
| functional nox2 | #1 |
| innate‐associated disease | #1 |
| nephritis nodq | #1 |
| native cii | #1 |
| concentrations rat cii | #1 |
| rat cb10 cb11 | #1 |
| chromosome congenic strains | #1 |
| adjuvant oils | #1 |
| mice h2q | #1 |
| pc117 | #1 |
| eae39 | #1 |
| daiu | #1 |
| induction oia | #1 |
| specificity arthritis | #1 |
| lewis rats pepsin | #1 |
| selfcii | #1 |
| animal genes cia | #1 |
| acute arthritis neutrophils | #1 |
| compsufficient mice | #1 |
| cells cb11 | #1 |
| cii mabs | #1 |
| tracheolaryngeal | #1 |
| susceptible cia | #1 |
| arthritis suppression | #1 |
| protein ncf1m1j mice | #1 |
| ncf1 mutation mice | #1 |
| h2p h2q | #1 |
| immunization lathyritic cii | #1 |
| early onset development | #1 |
| protective alleles eae2 | #1 |
| cell‐deficient mice | #1 |
| plcpip | #1 |
| chromosome pia | #1 |
| nasal treatment ctbcii | #1 |
| disease genotype immunoglobulin | #1 |
| cii vivo | #1 |
| arthritis estrus cycle | #1 |
| rat cii cii | #1 |
| glycopeptide stimulation | #1 |
| evokes peptide | #1 |
| pristane cell death | #1 |
| haplotype ltab | #1 |
| major locus cia | #1 |
| hla–dr1 | #1 |
| cartilagespecific protein | #1 |
| monoclonal cartilage cattle | #1 |
| rheumatoid arthritis complexity | #1 |
| dnp epitopes lysine | #1 |
| arthritis gene regions | #1 |
| eae mtx | #1 |
| cia21 lymph nodes | #1 |
| m1j mice | #1 |
| cii experimental autoantigens | #1 |
| functional nox2 complex | #1 |
| caia lps | #1 |
| animal immunosuppressive agents | #1 |
| antibodies pc4 | #1 |
| mucosal tolerance cii | #1 |
| collagen antibody arthritis | #1 |
| pepsin lewis | #1 |
| cia rheumatoid autoantibodies | #1 |
| cell tolerance cii | #1 |
| lys264 | #1 |
| experimental autoantibodies | #1 |
| dapia3 | #1 |
| experimental arthritis autoimmune | #1 |
| oils induce | #1 |
| b10q mice | #1 |
| cia mtx | #1 |
| epitope cartilage | #1 |
| existence periodontitis | #1 |
| transient joint inflammation | #1 |
| post‐partum exacerbation | #1 |
| ros rns inflammation | #1 |
| caia kgf | #1 |
| cii responsiveness | #1 |
| reproductive performance identification | #1 |
| h2g7 haplotype nod | #1 |
| anti type | #1 |
| streptococcal endo | #1 |
| rns type collagen | #1 |
| autoantibody responses cii | #1 |
| flss tlr3 expression | #1 |
| c3hnb | #1 |
| transgenic mice mhcii | #1 |
| blocking arthritis | #1 |
| hufcgammariia | #1 |
| normal cartilage arthritis | #1 |
| specificity ros rns | #1 |
| haplotypes h2q | #1 |
| female preponderance development | #1 |
| cix disease | #1 |
| nzw parental | #1 |
| bcell activities | #1 |
| bqncf1m1j | #1 |
| arthritis tlr3 upregulation | #1 |
| cryogel matrix cells | #1 |
| pregq2 | #1 |
| congenic arthritis | #1 |
| polymorphism ncf1 | #1 |
| oestrogen lupus disease | #1 |
| peptide agonist fmlf | #1 |
| tracheolaryngeal cartilage | #1 |
| inconsistent susceptibility | #1 |
| estrogenmediated suppression | #1 |
| comp experimental autoantibodies | #1 |
| nox2derived ros mice | #1 |
| hdac3 pparγ | #1 |
| cell determinants cii | #1 |
| chromosome arthritis severity | #1 |
| position 264 | #1 |
| oestradiol exacerbation | #1 |
| olive oil arthritis | #1 |
| mabs cii | #1 |
| new arthritis | #1 |
| genetic variants ncf1 | #1 |
| rats hfdmets | #1 |
| recombinants rt1u | #1 |
| b10qnss1 | #1 |
| cia rheumatoid arthritis | #1 |
| concentrations cii | #1 |
| maintained pregnancy levels | #1 |
| stages arthritis | #1 |
| mab ciif4 ciic1 | #1 |
| ppt medium | #1 |
| vridine‐induced arthritis | #1 |
| effector phase arthritis | #1 |
| immune response mbp | #1 |
| cii induce | #1 |
| cii immunisation | #1 |
| ciilysdnp mice | #1 |
| cia antibody response | #1 |
| engagement fcgammar | #1 |
| mice functional ncf1 | #1 |
| cartilage specific | #1 |
| dba 1jpfp cia | #1 |
| sod3 peritonitis | #1 |
| ros antigens | #1 |
| genome b10riii | #1 |
| antiidiotypic antibodies cd4 | #1 |
| collagen cii | #1 |
| cii chronic | #1 |
| cii lewis rats | #1 |
| cells mgps | #1 |
| arthritis immunization | #1 |
| mhc cii | #1 |
| comp arthritis models | #1 |
| genetic association ncf1 | #1 |
| tolerance arthritis susceptibility | #1 |
| cii swr mice | #1 |
| diagnostic accuracy acpa | #1 |
| congenic c57bl mice | #1 |
| p47phox mutant | #1 |
| cells heterologous cii | #1 |
| genes congenic | #1 |
| b10q1 | #1 |
| arthritis genetics | #1 |
| region eae2 | #1 |
| cia11 | #1 |
| citrullinated cii | #1 |
| antitype collagen | #1 |
| arthritogenic mabs | #1 |
| cxi cii | #1 |
| position ros production | #1 |
| cia tsc transgenic | #1 |
| chondrocytes kgf | #1 |
| homologous type pia | #1 |
| ncf1 genes | #1 |
| autoimmune priming | #1 |
| mutation ptdins3pbinding site | #1 |
| oxidases polymers | #1 |
| cia ul1 mab | #1 |
| cells dba mouse | #1 |
| rat pristaneinduced arthritis | #1 |
| oestradiol suppression | #1 |
| model rheumatoid | #1 |
| mrl mice estrogen | #1 |
| mice anticd4 treatment | #1 |
| cxi comp | #1 |
| ciipeptide | #1 |
| cii261 | #1 |
| inflammatory arthritis assessment | #1 |
| complex aq molecules | #1 |
| mhc‐congenic mouse strains | #1 |
| congenic mice genes | #1 |
| collagen iiinduced arthritis | #1 |
| restricted role fcγr | #1 |
| cii ciif4 | #1 |
| day cii immunisation | #1 |
| cells arthritogenicity | #1 |
| ros ncf1 | #1 |
| cii comp | #1 |
| cnbr‐fragment | #1 |
| animals arthritis | #1 |
| ccp2 negative | #1 |
| dapia6 | #1 |
| genistein collagen | #1 |
| denatured cii | #1 |
| ciiinduced arthritis | #1 |
| concentrations mouse cii | #1 |
| autoimmune arthritis activation | #1 |
| major epitopes patients | #1 |
| cathelicidin expression blood | #1 |
| ncf1 | #1 |
| cageeffects | #1 |
| lew ztm ncf1 | #1 |
| periodontitis rats pia | #1 |
| arthritis humans | #1 |
| b10dr4ncf1 | #1 |
| cia animal models | #1 |
| b10dr4ncf1 mice | #1 |
| fibroblasts ifnbetadeficient mice | #1 |
| genetic crossbreeding | #1 |
| rat cii response | #1 |
| anti cii acpa | #1 |
| chemical cartilage | #1 |
| oestradiol dth | #1 |
| rt1u lew1w | #1 |
| arthritis encephalomyelitis | #1 |
| decreasing activation | #1 |
| cells ncf1 | #1 |
| mcii707 | #1 |
| rheumatoid arthritis cii | #1 |
| arthritogenicity cells | #1 |
| cia caia model | #1 |
| immune cartilage | #1 |
| adaptive immunity fcγrs | #1 |
| p47phox ncf1 | #1 |
| deficient neonatal | #1 |
| oxidative burst inducers | #1 |
| cia eae39 | #1 |
| macrophages mannans | #1 |
| increase ncf1 | #1 |
| lew avridineinduced arthritis | #1 |
| immunisation cells | #1 |
| loci eae39 | #1 |
| mice ncf1m1j mutation | #1 |
| tregs ros | #1 |
| animal models arthritis | #1 |
| rt1ba | #1 |
| cii heterologous cii | #1 |
| autoimmune arthritis apcs | #1 |
| obs electrophoresis | #1 |
| histology vaccination | #1 |
| olive oil cii | #1 |
| treatment physiological doses | #1 |
| rats ncf1 | #1 |
| ncf1 nos2 | #1 |
| arthritis susceptibility mice | #1 |
| cb11 sequence cii | #1 |
| qa2 ncf1 | #1 |
| respiratory burst severity | #1 |
| reduced oxidative burst | #1 |
| arthritis immunisation | #1 |
| da1u rat liver | #1 |
| polychondritis autoimmune disease | #1 |
| citrulline collagen | #1 |
| development pristaneinduced arthritis | #1 |
| cia reduction | #1 |
| tcell hybridomas cells | #1 |
| rheumatoid arthritis eae | #1 |
| eae39 study | #1 |
| fecq3 locus | #1 |
| lpscaia | #1 |
| vivo monoclonal mouse | #1 |
| rt1f haplotype | #1 |
| nzw parental strain | #1 |
| dba 1 mouse | #1 |
| pathogenesis cia | #1 |
| comp cxi | #1 |
| caia cii | #1 |
| nox2 complex | #1 |
| arthritis rat | #1 |
| ftirm mice | #1 |
| tlr3 rna interference | #1 |
| cii epitope | #1 |
| igg response cii | #1 |
| csfspecific | #1 |
| cii articular cartilage | #1 |
| marginal ankylosis | #1 |
| pregq2 fragment | #1 |
| mice deficient ncf1 | #1 |
| expression liver receptor | #1 |
| cii triple | #1 |
| rat comp arthritis | #1 |
| melatonin release pinealectomy | #1 |
| arthritogenic antibody | #1 |
| cia31 | #1 |
| urokinase enzyme | #1 |
| tolerance arthritis protection | #1 |
| rat cb11 immunization | #1 |
| vivo experimental arthritis | #1 |
| phase arthritis | #1 |
| mouse cii reactivity | #1 |
| chromosome caia | #1 |
| mbq mouse | #1 |
| rats rt1f mhc | #1 |
| citrullinated collagen arthritis | #1 |
| u1 epitope | #1 |
| administration antibodies hyaluronanreceptor | #1 |
| animal models acpa | #1 |
| cii development | #1 |
| cia7 chromosome | #1 |
| gene ncf1 | #1 |
| igg2a vivo | #1 |
| arthritis anticii abs | #1 |
| rats pristane | #1 |
| c3hq mice | #1 |
| estrogen physiological doses | #1 |
| therapeutic cleavage igg | #1 |
| cia experimental autoantibodies | #1 |
| genes antibodies | #1 |
| cii human | #1 |
| arthritis congenic | #1 |
| beta 10b beta | #1 |
| cartilage collagen type | #1 |
| representative swedish | #1 |
| cia5 region | #1 |
| autoimmune diseases cnvs | #1 |
| induce arthritis | #1 |
| c4bp alternative pathway | #1 |
| suppression collagen arthritis | #1 |
| ncf1 ncf1m1j mutation | #1 |
| mbp c5a | #1 |
| lps caia | #1 |
| clever1 type macrophages | #1 |
| insulitis nodq | #1 |
| new arthritis therapy | #1 |
| rheumatoid drug evaluation | #1 |
| cii major epitope | #1 |
| cia h2p | #1 |
| fibroblast induced arthritis | #1 |
| arthritis rabeximod | #1 |
| major antigenic epitope | #1 |
| ros mip | #1 |
| pia3 | #1 |
| ncf1 mice | #1 |
| cii ros | #1 |
| ncf1m1j m1j mice | #1 |
| rats terpenes | #1 |
| constant light order | #1 |
| cd68‐expressing cells | #1 |
| plasminogendeficient mice arthritis | #1 |
| nod loci genes | #1 |
| mab ecm | #1 |
| rheumatoid arthritis autoimmunity | #1 |
| nox2 functionality | #1 |
| valphachain | #1 |
| b10q b10riii | #1 |
| cia molecular basis | #1 |
| cii cell | #1 |
| phase cia | #1 |
| expressions cyp7a1 | #1 |
| ul1 ciif4 | #1 |
| development humanized models | #1 |
| tcell experimental cartilage | #1 |
| ncf1 mutant mice | #1 |
| celldependent disease | #1 |
| ncf1 deficient | #1 |
| striking phenotypic similarities | #1 |
| c3hq mice cii | #1 |
| cells galactosylated peptide | #1 |
| type collagen cia | #1 |
| arthritis‐susceptibility loci | #1 |
| qtl chip | #1 |
| humans animals arthritis | #1 |
| phagocytic nox2 complex | #1 |
| rabeximod treatment | #1 |
| cia compdeficient mice | #1 |
| 1 ncf1 | #1 |
| mice b10q | #1 |
| hexadecane induce arthritis | #1 |
| b10qnfr | #1 |
| rats severity | #1 |
| glycosylated determinant peptides | #1 |
| cartilage stability cartilage | #1 |
| nox2 complex–derived ros | #1 |
| cii severe arthritis | #1 |
| clec4b ncf1 | #1 |
| cii immunodominant | #1 |
| vivo imaging l012 | #1 |
| cia oia | #1 |
| b10qc5δ | #1 |
| arthritis b10q mice | #1 |
| chemiluminescent probe l012 | #1 |
| glycosylated cii259 | #1 |
| sialadenitis arthritis | #1 |
| drb10401positive | #1 |
| antibodies consensus motif | #1 |
| m2139 arthritogenic mab | #1 |
| cii sera | #1 |
| dendritic cells collagen | #1 |
| h2q h2r | #1 |
| da1u rats expression | #1 |
| ncf4 | #1 |
| ncf1 copy variation | #1 |
| pia2–8 | #1 |
| animal models complexity | #1 |
| mannan mice | #1 |
| pathway arthritis | #1 |
| clonal expansion arthritis | #1 |
| oxoethyl6h | #1 |
| cartilage antibody | #1 |
| cii induced | #1 |
| immunization mouse | #1 |
| arthritis animal mice | #1 |
| arthritis aim | #1 |
| transgenic nadph oxidase | #1 |
| ccp positive patients | #1 |
| ox8 antibodies | #1 |
| ifnbeta experimental arthritis | #1 |
| therapeutic c4bp | #1 |
| re04001activatedfpr1 | #1 |
| mhc cia | #1 |
| immunological transmitter | #1 |
| ncf4 mice | #1 |
| h‐2b | #1 |
| disease glycoproteins | #1 |
| gia expansion | #1 |
| inbred strains severity | #1 |
| male mice arthritis | #1 |
| act389949 fpr2 | #1 |
| cii recognition | #1 |
| caia mab | #1 |
| loci controlling diabetes | #1 |
| collagen arthritis iii | #1 |
| pia3 chromosome | #1 |
| collagen cxi | #1 |
| ciispecific cells day | #1 |
| arthritis rheumatoid arthritis | #1 |
| elevated th17 cells | #1 |
| cii256 270 | #1 |
| pia5 | #1 |
| rheumatoid arthritis cia | #1 |
| pristane tlr3 expression | #1 |
| hladrβ10402 | #1 |
| ciic1 ciif4 | #1 |
| clec4b | #1 |
| anti collagen | #1 |
| scarce clinical samples | #1 |
| arthritis development cross | #1 |
| antibody ciic1 | #1 |
| mab cb268 | #1 |
| pristane induced | #1 |
| nodq locus | #1 |
| rat pia | #1 |
| serum interferon activity | #1 |
| isolated fragment chromosome | #1 |
| cii mhc | #1 |
| models rheumatoid | #1 |
| rat comp | #1 |
| arthritis collagen arthritis | #1 |
| ncf1 polymorphism | #1 |
| citrullinated collagen | #1 |
| cii induced arthritis | #1 |
| heterologous cii | #1 |
| ii‐induced arthritis | #1 |
| dth response mrl | #1 |
| synovial membranes joints | #1 |
| cia21 cia22 | #1 |
| antibody response cii | #1 |
| cia induced arthritis | #1 |
| pia disease | #1 |
| cia collagen | #1 |
| cells rat cii | #1 |
| c1iii type collagen | #1 |
| prevents arthritis | #1 |
| dominant hypersensitivity | #1 |
| critical restriction site | #1 |
| ftirm cii | #1 |
| ncf4 gene | #1 |
| emulsions induction | #1 |
| h2w3 | #1 |
| established sialadenitis | #1 |
| cells synthetic glycopeptides | #1 |
| ncf1 mutation | #1 |
| functional ncf1 macrophages | #1 |
| disease c4bp | #1 |
| phytol rna | #1 |
| rat rt1ba genes | #1 |
| congenic arthritis rats | #1 |
| cia cartilage | #1 |
| cii | #1 |
| anticii response | #1 |
| cuiiidaligands | #1 |
| experimental arthritis antibodies | #1 |
| compia | #1 |
| role major epitopes | #1 |
| pv cd4 cells | #1 |
| dependent autoimmune arthritis | #1 |
| disease collagen | #1 |
| acpa general population | #1 |
| response cii | #1 |
| arthritis traits | #1 |
| arthritis qtl pia7 | #1 |
| severity pia | #1 |
| pc8 pc117 | #1 |
| autoantibodies collagen | #1 |
| oxazolone inflammatory response | #1 |
| immunization heterologous cii | #1 |
| recognition lysine | #1 |
| elimination carbohydrates | #1 |
| genetically segregating crosses | #1 |
| arthritis transfer | #1 |
| muscle nox2 | #1 |
| arthritis monoclonal arthritis | #1 |
| cii polymer | #1 |
| ncf1m1j mice function | #1 |
| melatonin cia | #1 |
| eae2 | #1 |
| pia cix | #1 |
| arthritis mhc | #1 |
| comp cii | #1 |
| chromosome 17 mhc | #1 |
| kgf thymus | #1 |
| cia il10 | #1 |
| collagen ii‐induced | #1 |
| cia b10q | #1 |
| pristaneinduced arthritis pia | #1 |
| mice cii immunization | #1 |
| h2p cia | #1 |
| inbred dba cii | #1 |
| tumor colonization | #1 |
| arthritis synovial tlr3 | #1 |
| effects cia | #1 |
| b10q mice authors | #1 |
| rats ncf1 allele | #1 |
| cix cartilage | #1 |
| mcaia | #1 |
| inflammation living mice | #1 |
| arthritis chronic | #1 |
| c3hnb h2p | #1 |
| wo2012127214 | #1 |
| tumors immunosuppressive leukocytes | #1 |
| leukosialin rats | #1 |
| rabeximod inflammatory cells | #1 |
| c3hq | #1 |
| cia dominant epitope | #1 |
| impact etoposide | #1 |
| superovulation rate | #1 |
| region ncf1 | #1 |
| polymorphism autoimmune diseases | #1 |
| hg6pi325 | #1 |
| cii carbohydrates | #1 |
| hybridomas multispecific antibodies | #1 |
| arthritis cell | #1 |
| ncf1 spread | #1 |
| breeding capacity | #1 |
| aq class | #1 |
| developed severe | #1 |
| eae39 control disease | #1 |
| beta haplotype | #1 |
| immunologic animals arthritis | #1 |
| arthritis pnipaam | #1 |
| cia2 cia9 | #1 |
| clec4b activation | #1 |
| strains b10q | #1 |
| h2w17 | #1 |
| b10q dba 1f1 | #1 |
| protective role cia | #1 |
| dancf1da rats | #1 |
| collagen arthritis hyaluronanreceptor | #1 |
| murine psoriasis model | #1 |
| vpba pnipaam | #1 |
| frequency chronic arthritis | #1 |
| argltgrpgda | #1 |
| estrogen manifestations | #1 |
| human gpi protein | #1 |
| arthritis independent | #1 |
| 22 variant r620w | #1 |
| cia cii | #1 |
| chronic arthritis rats | #1 |
| congenic polymorphism | #1 |
| cii treatment | #1 |
| autoantibodies cii | #1 |
| anti comp | #1 |
| illness terpenes | #1 |
| treatment cii immunization | #1 |
| susceptibility collageninduced arthritis | #1 |
| c57bl 10q | #1 |
| anticlever1 antibody treatment | #1 |
| development chronic arthritis | #1 |
| cii256−270 | #1 |
| arthritis amino | #1 |
| chronicity arthritis | #1 |
| sialadenitis incidence | #1 |
| cii rat cii | #1 |
| immunospecific reactions | #1 |
| peripheral cells alphachains | #1 |
| lymphocytes cartilage | #1 |
| pia model rats | #1 |
| cia13 pia7 | #1 |
| human cii cartilage | #1 |
| wt ncf1 | #1 |
| chronic relapsing arthritis | #1 |
| daf2cross | #1 |
| mgpi325 | #1 |
| cii cix | #1 |
| mip ncf4 | #1 |
| cia lysine | #1 |
| rat congenic data | #1 |
| cii u1 | #1 |
| joint proteins | #1 |
| dba 1j | #1 |
| oestrogen‐induced suppression | #1 |
| stromal cells osteoclasts | #1 |
| loci cia2 | #1 |
| type epitopes | #1 |
| rabeximod | #1 |
| ncf1 m1j | #1 |
| mhv runting neonates | #1 |
| cii anticd4 treatment | #1 |
| pristaneprimed cells | #1 |
| collagen arthritis progesterone | #1 |
| cia5 qtl | #1 |
| epitopes cb11 fragment | #1 |
| mabs monoclonal arthritis | #1 |
| citrullinated variants | #1 |
| mice chronic arthritis | #1 |
| arthritis b6n mice | #1 |
| susceptibility collagen | #1 |
| induced arthritis cia | #1 |
| mannaninduced | #1 |
| cia21 | #1 |
| inbred dba pepsin | #1 |
| resistance collageninduced arthritis | #1 |
| developed arthritis | #1 |
| oestrogen treated | #1 |
| pepsin immunization | #1 |
| h2q mice | #1 |
| pristane macrophages | #1 |
| arthritis ides | #1 |
| extraarticular cartilage | #1 |
| anticii autoantibodies | #1 |
| cd43expressing cells | #1 |
| arthritogenic mab ciic1 | #1 |
| cia mhc | #1 |
| tlr expression synovium | #1 |
| cii 6 | #1 |
| rats rt1 | #1 |
| cii259 273 | #1 |
| ciilysdnp | #1 |
| arthritis promoting | #1 |
| therapeutic cleavage | #1 |
| injection adjuvant oils | #1 |
| cii260 | #1 |
| nucleotide reactive | #1 |
| naive experimental chromosomes | #1 |
| cia rat | #1 |
| homologous type | #1 |
| rt1bβ | #1 |
| cxi rats | #1 |
| arthritis onset severity | #1 |
| animal models polychondritis | #1 |
| 17βestradiolregulation | #1 |
| strains developed | #1 |
| ecm mab | #1 |
| joint inflammatory phase | #1 |
| regulates severity | #1 |
| cia development | #1 |
| beta 10b mrl | #1 |
| cii acpa | #1 |
| cii response | #1 |
| cartilage explants mabs | #1 |
| estrogen differential outcome | #1 |
| j1 epitope | #1 |
| tlr3 expression fls | #1 |
| function single | #1 |
| receptor γ pparγ | #1 |
| pia8 | #1 |
| function acpas | #1 |
| ciiderived | #1 |
| chick cii cii | #1 |
| upregulation tlr3 | #1 |
| aq molecules | #1 |
| backcrosses nzb mice | #1 |
| collagen epitopes | #1 |
| immunization heterologous | #1 |
| molecule aq | #1 |
| estrogen immune responses | #1 |
| cia swr mouse | #1 |
| comp lack | #1 |
| phytol molecular pathways | #1 |
| nod incidence | #1 |
| mannan joints | #1 |
| nodq×b10q | #1 |
| formation arthritis | #1 |
| rfig lambda | #1 |
| polymorphism mitochondrial genome | #1 |
| disease arthritis | #1 |
| chronic active arthritis | #1 |
| mice ros | #1 |
| aplec locus | #1 |
| role nox2derived ros | #1 |
| ncf1m1j | #1 |
| inbred dba prolactin | #1 |
| ides treatment severity | #1 |
| cartilage explants m2139 | #1 |
| homologous cii | #1 |
| chronic intervention | #1 |
| development oia | #1 |
| topoisomerase antagonist | #1 |
| ncf1 allele | #1 |
| fab2 ciic1 | #1 |
| ncf1 ros | #1 |
| cia induced | #1 |
| fls ppt medium | #1 |
| b10dr4ncf1 mice cii | #1 |
| b10b | #1 |
| cii antibody | #1 |
| dba 1jpfp | #1 |
| arthritis mutant strains | #1 |
| interacting subloci | #1 |
| arthritismodulating | #1 |
| cia pia | #1 |
| rats adjuvant oil | #1 |
| cia animal epitopes | #1 |
| tissue attack | #1 |
| nox2 agonists | #1 |
| lew mol strain | #1 |
| lathyritic cii | #1 |
| cia f1 males | #1 |
| rats phytol | #1 |
| pia cia | #1 |
| β1helix | #1 |
| methodspurified | #1 |
| tcell congenic arthritis | #1 |
| ifn signature mice | #1 |
| increased salt exposure | #1 |
| inbred strains cia | #1 |
| cii lewis | #1 |
| cartilage‐specific | #1 |
| ciif4 ciic1 | #1 |
| rheumatoid collagen | #1 |
| fpr1 agonist neutrophils | #1 |
| cxi | #1 |
| cii vaccination | #1 |
| induction postpartum flare | #1 |
| innate immunity mip | #1 |
| mice cii epitopes | #1 |
| thymectomy transgenes | #1 |
| pia experimental arthritis | #1 |
| cia antigens haplotypes | #1 |
| ncf4 mip | #1 |
| emission tomography mannan | #1 |
| dth dba 1 | #1 |
| tumor models ncf1 | #1 |
| immunization cii | #1 |
| autologous peptide cells | #1 |
| 15a11 | #1 |
| substrains ztmrhd | #1 |
| experimental collagen type | #1 |
| ros rheumatoid humans | #1 |
| rat recombinants | #1 |
| antibody induced | #1 |
| differential susceptibility cia | #1 |
| congenic | #1 |
| riiis alleles eae2 | #1 |
| lpr mice granulocytes | #1 |
| heterologous peptide response | #1 |
| ym1 pneumonitis | #1 |
| immunization autologous peptide | #1 |
| mhc influence | #1 |
| swr mice immunization | #1 |
| mice th1 cytokines | #1 |
| ciif4 cartilage explants | #1 |
| cii epitopes | #1 |
| psoriasis spread | #1 |
| model rheumatoid arthritis | #1 |
| ability gut protection | #1 |
| mediating arthritis | #1 |
| mannan immune | #1 |
| pia model | #1 |
| oxa nzb mice | #1 |
| ncf4 nox2 complex | #1 |
| myeloid effector functions | #1 |
| experimental carcinogens | #1 |
| animal genetic predisposition | #1 |
| mice mutated type | #1 |
| function ncf1 gene | #1 |
| antibody binding vivo | #1 |
| ncf1 knockout | #1 |
| polyi arthritis | #1 |
| incidence arthritis | #1 |
| kgf treatment onset | #1 |
| disease affinity | #1 |
| homologous type collagen | #1 |
| pia11 | #1 |
| selected anti‐t‐cell | #1 |
| tlr2 tlr2 regulation | #1 |
| autoimmune diseases identification | #1 |
| disease lew | #1 |
| cia mice mice | #2 |
| disease development presence | #2 |
| ros granulomas | #2 |
| antibodies disease onset | #2 |
| lymphoproliferative gene | #2 |
| influence chromosome | #2 |
| microscopic scoring arthritis | #2 |
| heterologous collagens arthritis | #2 |
| dr4 cii259 | #2 |
| comp cartilage | #2 |
| 034positive | #2 |
| osteoclastogenesis endogenous dna | #2 |
| granulomas macrophages | #2 |
| chronic autoimmune polyarthritis | #2 |
| arthritogenic mab cii | #2 |
| ides treatment | #2 |
| intrinsic tolerance | #2 |
| tregs mph | #2 |
| macrophagespecific nox2 | #2 |
| collagen citrullination adhesion | #2 |
| circulating medium | #2 |
| integrin‐binding‐domain | #2 |
| collagen arthritis immunization | #2 |
| lymphocytelike | #2 |
| arthritogenic challenge | #2 |
| sialadenitis mice | #2 |
| mabs collagen | #2 |
| transgenic protein processing | #2 |
| mog79 | #2 |
| selective fpr1 | #2 |
| bmd caia | #2 |
| oestradiol induction phase | #2 |
| mycobacteria granulomas | #2 |
| mbp 87110 peptide | #2 |
| shared epitope cxi | #2 |
| chain l10d9 antibody | #2 |
| epitopes rat | #2 |
| mog rats | #2 |
| ncf1gene | #2 |
| collagen arthritis cii | #2 |
| fil307 | #2 |
| p47phoxmutated | #2 |
| castrated mice day | #2 |
| i‐a molecule | #2 |
| dxea strain | #2 |
| staphylococcal infections mice | #2 |
| alp monoclonal arthritis | #2 |
| hiit skeletal | #2 |
| putative vulnerability locus | #2 |
| ptpn22 ncf1 | #2 |
| eno5 | #2 |
| mabs comp | #2 |
| immunosuppressive leukocytes | #2 |
| agonist study | #2 |
| mhciii | #2 |
| neutrophil functions modulation | #2 |
| cia mechanisms | #2 |
| transgenic oxidases zymosan | #2 |
| higher levels anas | #2 |
| binding cartilage | #2 |
| tregs mph ros | #2 |
| alterations neuroendocrine profile | #2 |
| injection w3 13 | #2 |
| apc naïve cells | #2 |
| wtc5a | #2 |
| rats da1u rats | #2 |
| prophylactic treatment linomide | #2 |
| anticd4 treatment | #2 |
| b10qncf1 mice cia | #2 |
| ros peroxide | #2 |
| hkatpasecontaining vesicles | #2 |
| adjuvant oils arthritis | #2 |
| cd8 cells incidence | #2 |
| nadph oxidase elevations | #2 |
| receptor‐specific manner | #2 |
| ptpn22 disulfide | #2 |
| celldependent phase | #2 |
| sera rheumatoid arthritis | #2 |
| induction p47phoxmutated mph | #2 |
| positive anticcp2 test | #2 |
| arthritis female | #2 |
| da1u rats | #2 |
| mhc iii | #2 |
| granulocytes alp | #2 |
| epitope‐specific recognition | #2 |
| sequences mbp89 | #2 |
| chronic relapsing disease | #2 |
| rt1bb | #2 |
| incidence nephritis | #2 |
| gender rats | #2 |
| design glycopeptides | #2 |
| ß62 | #2 |
| pathogenic igg antibodies | #2 |
| disease humanized mice | #2 |
| hydroxyethylene | #2 |
| snecs neutrophils | #2 |
| matrilin 1 | #2 |
| b10qf1 | #2 |
| salt intake vivo | #2 |
| c129s mutant disulfide | #2 |
| myelin ppd | #2 |
| antipan | #2 |
| implanted melanoma | #2 |
| disease 111 | #2 |
| raloxifene estradiol treatment | #2 |
| epitope glycosylation | #2 |
| anticii antibody | #2 |
| percentage peripheral cells | #2 |
| antibodies development | #2 |
| ability arthritis | #2 |
| multiple sclerosis maps | #2 |
| antileukoproteinase modulation | #2 |
| maintenance induced resistance | #2 |
| comp titers | #2 |
| psoriatic disease models | #2 |
| ccp2 diagnostic accuracy | #2 |
| igsecretors | #2 |
| matrilin vivo | #2 |
| cgd mice kynurenine | #2 |
| terpenes animals | #2 |
| c5ay35 | #2 |
| class immunoenzyme | #2 |
| cii injection | #2 |
| glycopeptides histocompatibility | #2 |
| w3 13 | #2 |
| tracheolaryngeal cartilage rp | #2 |
| nodq | #2 |
| binding sites autoimmune | #2 |
| early onset severity | #2 |
| fpr1 agonist | #2 |
| caia eae | #2 |
| neuroendocrine profile | #2 |
| oxidation c129s | #2 |
| eae dxea strain | #2 |
| ovx ncf1 mice | #2 |
| cii311 | #2 |
| enhanced arthritis | #2 |
| congenic polychondritis | #2 |
| citcii | #2 |
| arthritis mice | #2 |
| symptoms antibodies | #2 |
| lymphocytes animals | #2 |
| antibody cartilage | #2 |
| development combination | #2 |
| egfp cd19 cells | #2 |
| l10d9 antibody cxi | #2 |
| cia monkeys | #2 |
| rats lymphocytes | #2 |
| paws mice | #2 |
| collageninduced arthritis mice | #2 |
| dxeb strain immunization | #2 |
| mhc congenic | #2 |
| mbp peptide eae | #2 |
| c2ta genetic | #2 |
| oestradiol cia | #2 |
| vaccination strategy c5a | #2 |
| antibody‐mediated arthritis | #2 |
| cartilage‐specific autoimmunity | #2 |
| conditions igke promoter | #2 |
| animal model arthritis | #2 |
| exclusive reactivity | #2 |
| incidence insulitis | #2 |
| citcii311 | #2 |
| anti cii | #2 |
| immunocap isac performance | #2 |
| transgenic osteoporosis oestradiol | #2 |
| l10d9 | #2 |
| comp cia | #2 |
| ifngamma spinal cord | #2 |
| flow cytometry ovx | #2 |
| raloxifene oestradiol | #2 |
| smash recommendations | #2 |
| fibroblast induced | #2 |
| mab cii | #2 |
| control subjects samples | #2 |
| h12919 | #2 |
| 18fbicyclo610nonyne | #2 |
| 111 vivo treatment | #2 |
| l10d9 antibody cartilage | #2 |
| vivo cii | #2 |
| antibodies cartilage | #2 |
| rats arthritogenic challenge | #2 |
| arthritis raloxifene | #2 |
| igke promoter expression | #2 |
| sle nadph oxidase | #2 |
| autoimmune recognition | #2 |
| caia effector phase | #2 |
| suggestive locus | #2 |
| antileukoproteinase alp | #2 |
| cia animals | #2 |
| tcells recognition | #2 |
| ros source | #2 |
| cartilage proteins sera | #2 |
| 12 590 | #2 |
| homologous cia | #2 |
| cii citrullination | #2 |
| dancf1da | #2 |
| allelic variant type | #2 |
| mice bacterial infections | #2 |
| derived ros | #2 |
| re04 | #2 |
| titres ccp2 | #2 |
| elastaseinduced emphysema nox2 | #2 |
| nadph oxidase deficiency | #2 |
| nadph oxidase 2 | #2 |
| b10qncf1 mice | #2 |
| rats da1u | #2 |
| arthritis oia | #2 |
| sequence analysis indel | #2 |
| ncf1 oxidation | #2 |
| ala261 | #2 |
| animal granulomatous disease | #2 |
| genotypes ovx | #2 |
| collagen antibody | #2 |
| chitosanagarosegelatin | #2 |
| diseases collagen | #2 |
| tlymphocyte arthritis arthritis | #2 |
| arthritogenic capacity | #2 |
| rheumatoid binding | #2 |
| wildtype mice macrophages | #2 |
| rats heterologous cii | #2 |
| models autoimmune | #2 |
| rats disease onset | #2 |
| animal haplotypes | #2 |
| arthritis progression | #2 |
| ciif4 | #2 |
| cia arthritis | #2 |
| disease cyclosporin treatment | #2 |
| 18ffluoromannan | #2 |
| granulomas cgd mice | #2 |
| peptides chronic eae | #2 |
| fibα580 | #2 |
| eae caia | #2 |
| m2139 ciif4 | #2 |
| eosinophilia arthritis | #2 |
| citrullinated peptides development | #2 |
| multiple antibody reactivities | #2 |
| genetic encephalomyelitis | #2 |
| matrilin cartilage proteins | #2 |
| mbp89 peptides | #2 |
| mice genistein treatment | #2 |
| arthritogenic | #2 |
| arthritis models rats | #2 |
| autoimmune membrane proteins | #2 |
| igkeegfp lentivirus | #2 |
| b10g | #2 |
| mph induction | #2 |
| das28 acpa reactivities | #2 |
| mbp peptides immunization | #2 |
| immunization mbp89 | #2 |
| chromosome rats | #2 |
| citc1359 | #2 |
| beta 10b | #2 |
| pia rat | #2 |
| cytosolic ros production | #2 |
| tgfbeta spinal cord | #2 |
| oestrogen myelin | #2 |
| caia oestradiol | #2 |
| knockout illness | #2 |
| congenic mice autoimmune | #2 |
| cms eae | #2 |
| tolerance cii | #2 |
| antibodies cep1 | #2 |
| symptoms anti ccp2 | #2 |
| type collagen cii | #2 |
| osteoclasts flow cytometry | #2 |
| cartilage respiratory | #2 |
| nox2 complex sle | #2 |
| nox2 neuropathological alterations | #2 |
| disease genotype hybridization | #2 |
| antitoxin immunoglobulin | #2 |
| sle cgd | #2 |
| aetiology2–4 | #2 |
| new immunomodulatory drug | #2 |
| mhcii experimental arthritis | #2 |
| glut4dependent | #2 |
| cii ciic1 | #2 |
| ciic1 | #2 |
| eae cia | #2 |
| endoglycosidase treatment | #2 |
| fibβ36 | #2 |
| pnipaam vpba | #2 |
| dominant suppressive | #2 |
| chronic arthritis treatment | #2 |
| monodeoxygenation | #2 |
| antibody response development | #2 |
| pia rats | #2 |
| arthritis development rats | #2 |
| nox2 macrophages | #2 |
| oxidation increased severity | #2 |
| synovial immune reactions | #2 |
| kinloch | #2 |
| mice collagen | #2 |
| analyses comp | #2 |
| c2ta genetic polymorphisms | #2 |
| immunization mouse collagen | #2 |
| da1u | #2 |
| altered formation | #2 |
| arthritis scoring | #2 |
| murine locus eae2 | #2 |
| arthritis ethanol | #2 |
| rats ifngamma | #2 |
| liver mice rna | #2 |
| experimental cloning | #2 |
| cia anti | #2 |
| cells arthritis | #2 |
| utility comp | #2 |
| c57bl 10 background | #2 |
| oestrogen pregnancy | #2 |
| glycan activation | #2 |
| igke promoter | #2 |
| lack ifngamma | #2 |
| mbp89 | #2 |
| fibß62 | #2 |
| ptpn22 c129s | #2 |
| h2q response | #2 |
| toe stiffness | #2 |
| rats utility | #2 |
| etoposide serum concentrations | #2 |
| arthritis gender | #2 |
| macrophagespecific nox2 development | #2 |
| l10d9 antibody | #2 |
| cep1 fibß62 | #2 |
| antibody fine | #2 |
| c2ta mhcii expression | #2 |
| genetic regions psoriasis | #2 |
| cpg2088 | #2 |
| hladr2dq6 | #2 |
| human lung nox2 | #2 |
| functional ncf1 variants | #2 |
| skg model | #2 |
| cxi l10d9 antibody | #2 |
| anticcp2negative presence | #2 |
| anticcp2negative | #2 |
| fibα563 | #2 |
| α3xi | #2 |
| ptpn22 protein disulfide | #2 |
| immunological requirements | #2 |
| mrl mice stages | #2 |
| fpr1 signaling | #2 |
| suppressive oestrogen | #2 |
| arthritis treatment | #2 |
| collagen ii‐induced arthritis | #2 |
| micro dams transgenic | #2 |
| arthritis g6pi | #2 |
| dxeb | #2 |
| cartilage respiratory tract | #2 |
| antibodies fibß62 | #2 |
| autoimmunity autoantibodies | #2 |
| single nucleotide rats | #2 |
| h2q | #2 |
| linomide homologous cia | #2 |
| neutrophil fpr2 | #2 |
| ere activation treatment | #2 |
| psychosocial stress hpaaxis | #2 |
| increased severity development | #2 |
| igkeegfp lentivirus expression | #2 |
| pristane injection | #2 |
| g6pi arthritis | #2 |
| autoimmune congenic arthritis | #2 |
| induction cia | #2 |
| arthritis fb | #2 |
| cell tolerance c5a | #2 |
| human animal models | #2 |
| lack functional nox2 | #2 |
| galactosyl moiety | #2 |
| mph ros | #2 |
| m2139 | #2 |
| igke | #2 |
| species susceptible haplotypes | #2 |
| lew mol | #2 |
| oestrogen ean | #2 |
| fpr1 neutrophils | #2 |
| snp position | #2 |
| cia day | #2 |
| glycopeptide complexes | #2 |
| c1epitope | #2 |
| iaexpressing cells | #2 |
| cii depletion | #2 |
| adjuvant rats | #2 |
| severity collagen | #2 |
| arthritis antibody response | #2 |
| igg glycosylation arthritis | #2 |
| macrophages enhances | #2 |
| h2q mice mice | #2 |
| rp animal ear | #2 |
| cia disease | #2 |
| granulomas ros | #2 |
| cd19 cells egfp | #2 |
| ncf1 ean6 | #2 |
| mice susceptible | #2 |
| biologicals 24 months | #2 |
| sialadenitis animals | #2 |
| ean6 | #2 |
| mitochondria polymorphism | #2 |
| oestrogen suppressive | #2 |
| disease promoting | #2 |
| cell dependent | #2 |
| das28 values p001 | #2 |
| dxea strain tgfbeta | #2 |
| rno12 | #2 |
| acpa reactivities | #2 |
| rats polymorphism | #2 |
| arthritis heterologous cia | #2 |
| clever1 tumor | #2 |
| caia | #2 |
| redox regulation ptpn22 | #2 |
| liver histone | #2 |
| pristane rats | #2 |
| immunization sch | #2 |
| mannan induced | #2 |
| ncf1 mutants | #2 |
| agonist fpr2 | #2 |
| ros tregs | #2 |
| severity collagen arthritis | #2 |
| das28 24 months | #2 |
| mrl joints stages | #2 |
| hiit skeletal muscle | #2 |
| eae protein rna | #2 |
| total abrogation | #3 |
| disease genotype immunity | #3 |
| cvrelated death adjustment | #3 |
| acpas twins | #3 |
| cd4∶cd8 lineage commitment | #3 |
| keratinocytes langerhans cells | #3 |
| autoimmunity cartilage | #3 |
| immuniozation | #3 |
| rs729749 | #3 |
| lupus nets | #3 |
| apc cia | #3 |
| antigens keratinocytes | #3 |
| mice development | #3 |
| pathogenesis pia | #3 |
| anticollagen antibodies | #3 |
| pia | #3 |
| cbrh7919 cells | #3 |
| hydrocarbon oils | #3 |
| acpa specificities presence | #3 |
| recombination rt1a | #3 |
| immunization addition | #3 |
| cdk6 padi4 | #3 |
| combination acpa | #3 |
| disease immunization | #3 |
| citrullinated peptides time | #3 |
| binding aq | #3 |
| fibα573 fibβ74 | #3 |
| ncf1 cldn4 | #3 |
| disease height | #3 |
| subspecificities occurrence | #3 |
| cytotoxic t‐lymphocyte | #3 |
| vim60 | #3 |
| dthreaction | #3 |
| arthritis animal model | #3 |
| citc1iii fibα573 | #3 |
| swedish patients antibodies | #3 |
| antibodies citc1iii | #3 |
| disease w3 13 | #3 |
| induced immunospecific tolerance | #3 |
| allogeneic pregnancy | #3 |
| cryogel bioreactor | #3 |
| stroke cvrelated death | #3 |
| advanced intercross eae5 | #3 |
| rheumatoid crosses | #3 |
| acpas fine specificities | #3 |
| mice constant light | #3 |
| endogenous ifnbeta | #3 |
| ncf4 rs729749 | #3 |
| height disease | #3 |
| antibodies citrullinated | #3 |
| rats disease | #3 |
| cystatin cdeficient mice | #3 |
| cia strains | #3 |
| genes disease development | #3 |
| 95 cvrelated death | #3 |
| lew ztm | #3 |
| genetic influence susceptibility | #3 |
| acpapositive twins | #3 |
| rheumatoid autoimmune | #3 |
| arthritis susceptible | #3 |
| pia6 | #3 |
| origin suggestive linkage | #3 |
| antibodies vim60 | #3 |
| eae17 genetic heterogeneity | #3 |
| antibodies specific sets | #3 |
| arthritis levels | #3 |
| rheumatoid arthritis complement | #3 |
| allopregnancy | #3 |
| ifngammali neurons | #3 |
| nox2 pathogenesis | #3 |
| neutrophil cytosolic factor | #3 |
| antigens collagen | #3 |
| hladrb104 mann whitney | #3 |
| female immunoenzyme | #3 |
| citrullinated cyclic | #3 |
| response immune response | #3 |
| model arthritis | #3 |
| treatment arthritis | #3 |
| c57bl mice illness | #3 |
| points acs | #3 |
| disease risk subsets | #3 |
| spe dce | #3 |
| disease development contribution | #3 |
| pristane‐induced arthritis | #3 |
| cd8 cells ean | #3 |
| multiple sclerosis hladr2 | #3 |
| cia hdac1 | #3 |
| hdac1 rheumatoid arthritis | #3 |
| nerve terminallike profiles | #3 |
| chromosome eae17 | #3 |
| mca ean | #3 |
| type collagen vivo | #3 |
| nadph oxidase complex | #3 |
| hfdmets rats | #3 |
| autoimmunity pia | #3 |
| ifngammali | #3 |
| acpa titers | #3 |
| db1 treatment day | #3 |
| mhc class betachain | #3 |
| ean mca | #3 |
| aureus arthritis mice | #3 |
| fibα591 vim60 | #3 |
| citrulline inflammation | #3 |
| experimental cell | #3 |
| lew1f | #3 |
| cii species | #3 |
| acpas plasma | #3 |
| neutrophils eae | #3 |
| mmc mice | #3 |
| oxidases reactive | #3 |
| rt11 rats | #3 |
| major cell epitope | #3 |
| wildtype mice granulomas | #3 |
| fibα573 | #3 |
| cd4∶cd8 lineage | #3 |
| cii elisa | #3 |
| disease disease development | #3 |
| cep1 filaggrin | #3 |
| complex genetic control | #3 |
| acpas human serum | #3 |
| experimental arthritis | #3 |
| occurrence subspecificities | #3 |
| development arthritis | #3 |
| ifnbetadeficient mice | #3 |
| eae1 | #3 |
| type c2ta | #3 |
| cyp7a1 abca1 | #3 |
| mice copolymers | #3 |
| dce spe | #3 |
| arthritis susceptibility | #3 |
| inflamed synovial tissues | #3 |
| cia animals arthritis | #3 |
| female preponderance | #3 |
| arthritis autoimmunity | #3 |
| rodents6 | #3 |
| sialadenitis | #3 |
| monoclonal cartilage sections | #3 |
| animal glycosylation humans | #3 |
| ctla4 deletion | #3 |
| isotypes acpas | #3 |
| onset combination | #3 |
| citrullinated peptides multiplex | #3 |
| rs729749 ncf4 | #3 |
| antibodies induce | #3 |
| anticollagen antibody | #3 |
| oxidase 2 | #3 |
| presence drb104 | #3 |
| hladrb104 cochranmantelhaenszel test | #3 |
| cartilage proteins | #3 |
| citc1iii | #3 |
| mice environments | #3 |
| incidence antinuclear antibodies | #3 |
| antigen monoclonal arthritis | #3 |
| acpa multiplex | #3 |
| fibα573 fibα591 | #3 |
| arthritis resistance | #3 |
| models arthritis | #3 |
| crossreactive idiotope | #3 |
| mice rheumatoid | #3 |
| arthritis model | #3 |
| dnfb ears | #3 |
| h2p mice | #3 |
| bcg ros | #3 |
| citc1iii filaggrin | #3 |
| anti‐type | #3 |
| fibβ74 | #3 |
| ros deficiency | #3 |
| arthritis effects | #3 |
| eae31 | #3 |
| eae17 | #3 |
| pfp mice | #3 |
| mnc salivary glands | #3 |
| twins acpas | #3 |
| eae5 ncf1 | #3 |
| differences citrullinated peptides | #3 |
| rtlu | #3 |
| subspecificities associations | #3 |
| restricted role | #3 |
| targeting toll | #3 |
| fibβ62 81b | #3 |
| low production | #3 |
| natural alleles genes | #3 |
| cvrelated death association | #3 |
| antigen presentation mhcii | #3 |
| cells naïve mice | #3 |
| development collagen arthritis | #3 |
| role ros | #3 |
| eae5 pia4 | #3 |
| processing cii | #3 |
| nox2 cgd | #3 |
| development acpas | #3 |
| h2qbearing | #3 |
| ctla4 adult mice | #3 |
| igl genes | #3 |
| genotype knowledge | #3 |
| c2ta | #3 |
| arthritis review | #3 |
| rats rheumatoid arthritis | #3 |
| h2aalpha | #3 |
| loci antibodies | #3 |
| pnippam | #3 |
| ciic1 cii | #3 |
| complex autoimmune diseases | #3 |
| 81b | #3 |
| class antigens keratinocytes | #3 |
| human cii | #3 |
| eae17 chromosome | #3 |
| rheumatoid cloning | #3 |
| disease anti lymphocyte | #3 |
| ifngamma neurons | #3 |
| reactive idiotope | #3 |
| macrophages involvement | #3 |
| levels fibα591 | #3 |
| arthritogenicity | #3 |
| acpa combination | #3 |
| fibα591 | #3 |
| osteoclasts release | #3 |
| chronic collagen | #3 |
| acpa subspecificities | #3 |
| species lymphocytes | #3 |
| cii reactive | #3 |
| clever1 macrophages | #3 |
| rats mog | #3 |
| macroporous gel particles | #3 |
| day disease duration | #3 |
| eae5r1 | #3 |
| vivo control mice | #3 |
| hdac1 pathogenesis | #3 |
| eae16 | #3 |
| db1 treatment | #3 |
| transgenic osteoporosis | #3 |
| rt1a tap2 | #3 |
| cvrelated death | #3 |
| acpas genetic factors | #3 |
| dual manner | #3 |
| activated cells mice | #3 |
| twins acpapositive | #3 |
| minimal adjuvant requirement | #3 |
| glycosylated type | #3 |
| fibβ74 onset | #3 |
| arthritogenic mab | #3 |
| dxea | #3 |
| early phase disease | #3 |
| patients monoclonal chimeric | #3 |
| citcii355 | #3 |
| dancf1e3 | #3 |
| carriers hladrb104 | #3 |
| common mouse model | #3 |
| autoimmune models | #3 |
| stages disease development | #4 |
| acpas serum | #4 |
| immunodominant cell | #4 |
| autoimmunity rats | #4 |
| catabolism kynurenine | #4 |
| estrus cycling | #4 |
| mip mice | #4 |
| cii peptide | #4 |
| arthritis severity | #4 |
| inbred dba peptides | #4 |
| type collagen arthritis | #4 |
| cryogel matrix | #4 |
| adjuvant oil | #4 |
| development sialadenitis | #4 |
| cells maternal origin | #4 |
| citrullinated peptides autoantibodies | #4 |
| collagen rheumatoid | #4 |
| cells cryogel column | #4 |
| immunoglobulin deficient | #4 |
| mhc eae | #4 |
| glands sialadenitis | #4 |
| estrogen levels levels | #4 |
| fibβ62 | #4 |
| cia mouse | #4 |
| response arthritis | #4 |
| arthritis comp | #4 |
| mutation ncf1 | #4 |
| diseases rheumatoid | #4 |
| genetic association vav1 | #4 |
| endos igg | #4 |
| krönke | #4 |
| autoimmune mrl | #4 |
| tsc mice | #4 |
| knowledge genetic association | #4 |
| pathogenesis histone | #4 |
| candidate genes rats | #4 |
| lnchc | #4 |
| cytosolic ros | #4 |
| cii animal epitopes | #4 |
| pathogenic antibody | #4 |
| strains arthritis | #4 |
| cellular transfer | #4 |
| collagen type | #4 |
| treg cells ctla4 | #4 |
| estrogen cia | #4 |
| arthritis mouse | #4 |
| synovial endothelium | #4 |
| shared autoimmunity | #4 |
| collagen immune | #4 |
| dead cell remnants | #4 |
| elimination cd8 cells | #4 |
| cb10 fragment | #4 |
| type collagen rat | #4 |
| cii ifa | #4 |
| autoimmune experimental phenotype | #4 |
| arthritis collageninduced arthritis | #4 |
| tcell activation development | #4 |
| mice etoposide | #4 |
| collagen glycopeptides | #4 |
| genistein addition | #4 |
| ox8 | #4 |
| autoantibodies type collagen | #4 |
| rheumatoid arthritis rats | #4 |
| congenic rats rats | #4 |
| mrl b6 | #4 |
| congenic c57bl | #4 |
| elevated th1 | #4 |
| cia6 | #4 |
| cell response immunization | #4 |
| fcγr regulation | #4 |
| inpp4b474r 548p | #4 |
| anti‐t‐cell | #4 |
| strain eae | #4 |
| interaction monoclonal antibody | #4 |
| onset clinical arthritis | #4 |
| antigen sequence deletion | #4 |
| variance animals arthritis | #4 |
| bxsb chromosome | #4 |
| cia b10q mice | #4 |
| vav1 rheumatoid arthritis | #4 |
| rs12979659 | #4 |
| smoking antibodies | #4 |
| macrophages mycobacteria | #4 |
| mrl dth | #4 |
| mp‐lpr | #4 |
| antibodies citrullinated peptides | #4 |
| rp sle | #4 |
| immune response cii | #4 |
| normal mouse igg | #4 |
| α1ii chain | #4 |
| subsets presence | #4 |
| dth mrl | #4 |
| experimental arthritis cii | #4 |
| cyclic software | #4 |
| locus mouse chromosome | #4 |
| epitope collagen | #4 |
| cells cryogel | #4 |
| affinity case | #4 |
| dae3 | #4 |
| cathelicidins ll37 | #4 |
| rs682626 | #4 |
| species regulate | #4 |
| cia suppression | #4 |
| antitype collagen antibodies | #4 |
| pristane‐induced | #4 |
| cia lia | #4 |
| lxrα pparγ | #4 |
| parathyroid antibodies | #4 |
| arthritis defined | #4 |
| peptide mbp | #4 |
| tnfα p38 mapk | #4 |
| sh3gl1 | #4 |
| glend2 | #4 |
| k8 k8 mice | #4 |
| positional cloning genes | #4 |
| placental mhc | #4 |
| potent immunomodulator | #4 |
| fpr2 recognition | #4 |
| dth reaction | #4 |
| antibody response mog | #4 |
| c129s | #4 |
| il‐4‐deficient mice | #4 |
| cd4 cells stage | #4 |
| experimental cattle cells | #4 |
| multispecific antibodies | #4 |
| ethylene isosteres | #4 |
| citrullinated protein antibodies | #4 |
| type‐ii collagen | #4 |
| type collagen autoimmunity | #4 |
| experimental genetic | #4 |
| experimental arthritis humans | #4 |
| immunization type collagen | #5 |
| lethal inflammatory disorder | #5 |
| multiplex array | #5 |
| resistance cia | #5 |
| development acpa | #5 |
| multiparous mice | #5 |
| mice acpa | #5 |
| hydroxynorvaline | #5 |
| ros mca | #5 |
| il4deficient mice | #5 |
| streptococcus pyogenes ides | #5 |
| pineal gland development | #5 |
| antileukoproteinase | #5 |
| cgd hyperinflammation | #5 |
| citrullinated peptides ccp | #5 |
| wellknown role | #5 |
| immunological involvement | #5 |
| patients acpa levels | #5 |
| recovery ean | #5 |
| nox animal models | #5 |
| low dose tolerance | #5 |
| α10i | #5 |
| severe arthritis mice | #5 |
| lew1n | #5 |
| symptom onset frequency | #5 |
| oia | #5 |
| position type collagen | #5 |
| cbrh7919 | #5 |
| chick cii | #5 |
| higher levels melatonin | #5 |
| collagen anti | #5 |
| smoking prior | #5 |
| measurement nox activity | #5 |
| aureus arthritis | #5 |
| ii‐induced | #5 |
| cia type collagen | #5 |
| cgd mice | #5 |
| tsst1producing | #5 |
| regulating rat | #5 |
| egfp flow cytometry | #5 |
| pathogenesis autoimmune arthritis | #5 |
| puccetti | #5 |
| swr mouse | #5 |
| avridineinduced arthritis | #5 |
| immunized animals controls | #5 |
| ovalbumin pepsin | #5 |
| tubule cells kidney | #5 |
| ros macrophages | #5 |
| symptoms development | #5 |
| severe sialadenitis | #5 |
| collageninduced arthritis cia | #5 |
| type collagen cix | #5 |
| autoimmune disease models | #5 |
| overexpression hdac3 | #5 |
| mrvalues | #5 |
| epitope cii | #5 |
| cd8 deficiency | #5 |
| igg endos | #5 |
| multiplex analyses | #5 |
| o2• h2o2 nox | #5 |
| oxidative radicals | #5 |
| glycopeptidomimetics | #5 |
| oestradiol vehicle | #5 |
| antibodies filaggrin | #5 |
| interaction cartilage | #5 |
| raloxifene disease activity | #5 |
| c‐glycoside analogue | #5 |
| nox o2• h2o2 | #5 |
| immunization male | #5 |
| apc cii | #5 |
| arthritogenic cells | #5 |
| tlr3 macrophages | #5 |
| tcell mrl | #5 |
| cia model | #5 |
| asparaginelinked glycan | #5 |
| congenic nod | #5 |
| tlr3 expression | #5 |
| subsets rheumatoid arthritis | #5 |
| monoclonal antibody alpha | #5 |
| ly female | #5 |
| dba mouse | #5 |
| cartilage type | #5 |
| beta 11 cells | #5 |
| absence c5 | #5 |
| b‐cell epitope | #5 |
| exercise hiit | #5 |
| osteoclasts stromal cells | #5 |
| glycopeptide | #5 |
| painlike behavior | #5 |
| biomarkers 2 polyradiculoneuropathy | #5 |
| field nox | #5 |
| delayed immunization rats | #5 |
| eae5 | #5 |
| tcell hybridomas | #5 |
| dba 1 mice | #5 |
| arthritis rats | #5 |
| classical adjuvant | #5 |
| commonly model | #5 |
| autologous type | #5 |
| chromosome cia7 | #5 |
| glycopeptide fragment | #5 |
| tbb infection | #5 |
| lipidomic remodeling | #5 |
| backcrossed | #5 |
| rt1eu | #5 |
| rats developed | #5 |
| nox complex | #5 |
| experimental breeding | #5 |
| symptoms rheumatoid arthritis | #5 |
| arthritis onset | #5 |
| citrullinated peptides | #5 |
| uterus cells | #5 |
| rheumatoid arthritis comp | #6 |
| cia26 | #6 |
| recombinant rat interferongamma | #6 |
| acpa anti | #6 |
| macrophages mph | #6 |
| pv loss | #6 |
| rcramp | #6 |
| c57bl 6 background | #6 |
| treatment oestradiol | #6 |
| cells affinity surface | #6 |
| murine loci | #6 |
| collagen arthritis | #6 |
| betaoestradiol | #6 |
| k8 mice | #6 |
| peptides arthritis | #6 |
| cell recognition | #6 |
| b10 mouse | #6 |
| arthritis models | #6 |
| cd4∶cd8 | #6 |
| acpa specificities | #6 |
| metabolic nuclear receptors | #6 |
| knockout receptors igg | #6 |
| isotypes patients | #6 |
| dominant suppression | #6 |
| activity neuroinflammation | #6 |
| develop arthritis | #6 |
| collagen cia | #6 |
| mice investigated | #6 |
| heterogeneous stock mice | #6 |
| igg autoantibodies sera | #6 |
| hdac1 class | #6 |
| cartilage collagens | #6 |
| female lymphocyte | #6 |
| controls arthritis | #6 |
| induced psoriasis | #6 |
| ccp2 positive | #6 |
| nox2 mediates | #6 |
| cia cd4 cells | #6 |
| glycoproteins nadph | #6 |
| collagen cells | #6 |
| mice congenic | #6 |
| rheumatoid arthritis collagen | #6 |
| mice sialadenitis | #6 |
| pathogenic events | #6 |
| lys270 | #6 |
| relapsing polychondritis rp | #6 |
| arthritis antibodies | #6 |
| loci controlling | #6 |
| animal genetic | #6 |
| arthritis autoantibodies | #6 |
| l3t4positive cells | #6 |
| tsst1 mice | #6 |
| pyramidal neurons loss | #6 |
| autoimmunity arthritis | #6 |
| mrna tgfbeta | #6 |
| functional selective | #6 |
| ltab | #6 |
| experimental postmenopausal | #6 |
| complex mhc | #6 |
| eae mhc | #6 |
| rheumatoid arthritis model | #6 |
| disease protective | #6 |
| joints rats | #6 |
| affinity ligand protein | #6 |
| contrasting roles | #6 |
| autoimmune experimental genes | #6 |
| active arthritis | #6 |
| pristane squalene | #6 |
| data ros | #6 |
| monoclonal encephalomyelitis autoimmune | #6 |
| anti ccp2 | #6 |
| glycopeptide specificity | #6 |
| erosive polyarthritis | #6 |
| staphylococcus aureus arthritis | #6 |
| mhcii alleles | #6 |
| transgenic mice arthritis | #6 |
| immunization peptides | #6 |
| polychondritis relapsing | #7 |
| autoantibodies lymphocytes | #7 |
| congenic mouse | #7 |
| induction arthritis | #7 |
| nonarthritogenic | #7 |
| psoriasiform skin disease | #7 |
| glycosylated collagen | #7 |
| congenic strains | #7 |
| cii anti | #7 |
| antibodies citrullinated antigens | #7 |
| murine psoriasis | #7 |
| antibodyinduced arthritis | #7 |
| impact cia | #7 |
| cognate activation | #7 |
| autoimmunity collagen | #7 |
| acpa titres | #7 |
| oestrogen rats | #7 |
| 3xi | #7 |
| arthritis strains | #7 |
| mediated vasculitis | #7 |
| g6pi | #7 |
| ciireactive cells | #7 |
| arthritis type collagen | #7 |
| periodontitis arthritis | #7 |
| chronic experimental | #7 |
| collagen arthritis rats | #7 |
| collagen epitope | #7 |
| collagen arthritis cia | #7 |
| arthritis genes | #7 |
| ean animals | #7 |
| impaired induction | #7 |
| locus chromosome | #7 |
| snecs | #7 |
| mice constant darkness | #7 |
| role raloxifene | #7 |
| cab3 | #7 |
| cryogel column | #7 |
| antigens differentiation arthritis | #7 |
| strains disease | #7 |
| rheumatoid arthritis role | #7 |
| mbp peptide | #7 |
| response immunization | #7 |
| animal immunization injections | #7 |
| conventional environment | #7 |
| region syntenic | #7 |
| symptoms disease onset | #7 |
| mouse collagen | #7 |
| macrophages alternative activation | #7 |
| cia mice | #7 |
| autoimmune human | #7 |
| effector phase | #7 |
| regulatory cells macrophages | #7 |
| citrullinated peptide antigens | #7 |
| castrated females | #7 |
| autoantibodies citrullinated peptides | #7 |
| raassociated molecules | #7 |
| rats phases | #7 |
| chronic phase arthritis | #7 |
| hydrolases polymorphism | #7 |
| protective influences | #7 |
| yaa gene | #7 |
| isomerase peptide | #7 |
| cii apc | #7 |
| cia5 | #7 |
| aplec | #7 |
| type collagen | #7 |
| transgenic class | #7 |
| analysis crosses | #7 |
| responses cii | #7 |
| 297 cases | #8 |
| onset incidence | #8 |
| dominant cell epitope | #8 |
| hladrb11001 | #8 |
| diseases loci | #8 |
| 42 rats | #8 |
| cosphox | #8 |
| eae genetic encephalomyelitis | #8 |
| murinised | #8 |
| polymeric cryogels | #8 |
| haematogenously | #8 |
| experimental autoimmune disease | #8 |
| underlying genes | #8 |
| t‐cell priming | #8 |
| rheumatoid autoimmunity | #8 |
| autoantibodies subset | #8 |
| fcγr2b | #8 |
| rheumatoid chromosome | #8 |
| lyme arthritis severity | #8 |
| destructive effects | #8 |
| neutrophil cytosolic | #8 |
| oia2 | #8 |
| hlase alleles | #8 |
| cia2 | #8 |
| humans experimental arthritis | #8 |
| arthritis lymphocytes | #8 |
| parathyroid glands receptors | #8 |
| experimental binding | #8 |
| supermacroporous cryogel | #8 |
| cia animal model | #8 |
| ptpn22620w | #8 |
| chromosomes loci | #8 |
| sialadenitis mrl | #8 |
| expression hdac3 | #8 |
| α1‐microglobulin | #8 |
| typeii collagen | #8 |
| oxidized peptides | #8 |
| murine locus | #8 |
| ros interplay | #8 |
| inflamed synovia | #8 |
| illness igg | #8 |
| persistent joint pain | #8 |
| patients type collagen | #8 |
| mice techniques | #8 |
| heterologous peptide | #8 |
| antigenspecific priming | #8 |
| clinical signs ean | #8 |
| eae3 | #8 |
| autologous peptide | #8 |
| antibody vivo | #8 |
| mbp mog | #8 |
| mice ifnbeta | #8 |
| rats mhc | #8 |
| hybridomas antibodies | #8 |
| b10 background | #8 |
| treatment monoclonal | #8 |
| induced neuropathology | #8 |
| hdac3 expression | #8 |
| autoantibodies collagen type | #8 |
| mumt mice | #8 |
| onset day day | #8 |
| rt1f | #8 |
| autoimmune congenic mice | #8 |
| antibodies acpas | #8 |
| ifa cii | #8 |
| incidence cia | #8 |
| medium mem | #8 |
| non‐mhc | #8 |
| chronic autoimmune arthritis | #8 |
| hitr | #9 |
| loci rats | #9 |
| pristane | #9 |
| specific sets | #9 |
| experimental arthritis rats | #9 |
| experimental genes | #9 |
| posttranslational glycosylation | #9 |
| cia transgenic mice | #9 |
| adaptive inflammation | #9 |
| inbred lew tlymphocytes | #9 |
| bound carbohydrates | #9 |
| arthritis skg mice | #9 |
| induced metabolic syndrome | #9 |
| il10 role | #9 |
| intranasal animals arthritis | #9 |
| rt1u | #9 |
| collagen female | #9 |
| disease strains | #9 |
| animal models urgent | #9 |
| human immunopeptidome | #9 |
| antibodies vivo | #9 |
| mammalian disease models | #9 |
| serum interferon | #9 |
| idiotype‐specific | #9 |
| eae immunization | #9 |
| 2 nadph | #9 |
| alpha1inhibitor3 | #9 |
| ean myelin | #9 |
| early joint erosions | #9 |
| oligomeric matrix | #9 |
| rheumatoid joints | #9 |
| ox19 | #9 |
| oil adjuvants | #9 |
| nodp | #9 |
| psychological tyrosine | #9 |
| b10riii mice | #9 |
| rats rat | #9 |
| inbred dba mice | #9 |
| murine collagen | #9 |
| variants acpa | #9 |
| acpas patients | #9 |
| development autoimmune arthritis | #9 |
| reduced arthritis | #9 |
| histone 1 hdac1 | #9 |
| postmenopausal arthritis | #9 |
| autoimmunogenic | #9 |
| acpas | #9 |
| arthritis cross | #9 |
| illness receptor | #9 |
| class allele | #9 |
| mouse peptide | #9 |
| patients acpas | #9 |
| hgpi325 | #9 |
| specific nox2 | #9 |
| avridine | #9 |
| response mouse | #9 |
| collagen complement | #9 |
| antibody alpha | #9 |
| rheumatoid autoantibodies | #9 |
| differentiation autoimmune | #9 |
| effects mabs | #9 |
| bovine cii | #9 |
| cell‐deficient | #10 |
| immunization rats | #10 |
| mutated mice | #10 |
| cartilage oligomeric | #10 |
| oestrogen | #10 |
| mice nadph | #10 |
| severe erosive | #10 |
| monoclonal arthritis | #10 |
| reactivity acpas | #10 |
| endogenous collagen | #10 |
| mbp peptides | #10 |
| acpa diagnosis | #10 |
| genetic experiments | #10 |
| cells development | #10 |
| citrullinated antigen | #10 |
| o2• h2o2 | #10 |
| cartilage collagen fibrils | #10 |
| native collagen type | #10 |
| extracellular cartilage | #10 |
| hlase smoking | #10 |
| autoimmune disease humans | #10 |
| cii mice | #10 |
| tertbutylacrylamide | #10 |
| prl effects | #10 |
| mice genistein | #10 |
| cd4 cells spleen | #10 |
| knockout nadph | #10 |
| presence acpa | #10 |
| ifnbeta mice | #10 |
| antibodies specific | #10 |
| animal models | #10 |
| mice cii | #10 |
| rheumatoid arthritis dr4 | #10 |
| stock mice | #10 |
| axotomized motor neurons | #10 |
| cells increased production | #10 |
| development severity | #10 |
| passive transfer experiments | #10 |
| onset chromosome | #10 |
| cartilage arthritis | #10 |
| nih heterogeneous stock | #10 |
| beta 11 | #10 |
| acutephase response rats | #10 |
| collagen autoimmunity | #10 |
| abp gene | #10 |
| rats lewis rats | #10 |
| antibody collagen | #10 |
| experimental cartilage | #10 |
| h2ap | #10 |
| activation male | #10 |
| pain animal models | #10 |
| alpha collagen chains | #10 |
| dense fractions | #10 |
| inbred dba | #10 |
| monoclonal antigens rats | #10 |
| cells pia | #11 |
| antibodies association | #11 |
| loci regulating | #11 |
| individuals onset | #11 |
| species respiratory | #11 |
| stromal cells macrophages | #11 |
| mhc control | #11 |
| liver receptor lxrα | #11 |
| antibody type collagen | #11 |
| 2xi | #11 |
| potential autoantigens | #11 |
| arthritis absence | #11 |
| inflammatory arthritis role | #11 |
| fragments anti | #11 |
| chondrocytes ecm | #11 |
| 84–102 | #11 |
| cia30 | #11 |
| gad6 | #11 |
| naïve cells cells | #11 |
| antigen variability | #11 |
| rat liver rats | #11 |
| mice mhc | #11 |
| ptpn22 smoking | #11 |
| mice cd1 | #11 |
| lentiviral vector expression | #11 |
| dss wt | #11 |
| chronic arthritis | #11 |
| rat arthritis | #11 |
| rat collagen | #11 |
| isotypes | #11 |
| development rheumatoid | #11 |
| nodb10h2b mice | #11 |
| monoclonal rheumatoid factors | #11 |
| tailbase | #11 |
| cia7 | #11 |
| serum concentrations comp | #12 |
| natural polymorphism | #12 |
| frequencies antibodies | #12 |
| increased litter size | #12 |
| rats expression | #12 |
| icmediated | #12 |
| bovine type collagen | #12 |
| myelin ean | #12 |
| fpr2 agonists | #12 |
| natural loss | #12 |
| peptide study | #12 |
| reduces severity | #12 |
| immunodominant | #12 |
| rats cia | #12 |
| illness sex characteristics | #12 |
| mutated mouse | #12 |
| major haplotype | #12 |
| animal immunohistochemistry | #12 |
| cii patients | #12 |
| stages pathogenesis | #12 |
| matrilin | #12 |
| role arthritis | #12 |
| stage cia | #12 |
| backgroundantibodies | #12 |
| autoimmune monoclonal antigens | #12 |
| pia1 | #12 |
| qa2 | #12 |
| genetic contamination | #12 |
| structure antibodies | #12 |
| lung macrophages mice | #12 |
| psoriasis arthritis | #12 |
| riiis | #12 |
| study arthritis | #12 |
| α1ii | #12 |
| mice comp | #12 |
| hydroxylysines | #12 |
| mutation nadph | #12 |
| cross rats | #12 |
| mbp response | #12 |
| antibodies structures | #12 |
| onset symptoms | #12 |
| lymphoid cells development | #12 |
| nonselfdiscrimination | #12 |
| type collagen immunization | #12 |
| associations antibodies | #12 |
| treatment experimental arthritis | #12 |
| cell responses cii | #12 |
| loci disease | #12 |
| chronic erosive arthritis | #12 |
| encephalomyelitis induced | #12 |
| psoriasis mouse model | #12 |
| mtec aire | #13 |
| citrullinated | #13 |
| genes mouse chromosome | #13 |
| dr1 transgenic | #13 |
| nos2derived | #13 |
| joints blood | #13 |
| cells salivary glands | #13 |
| hladrb1 ptpn22 | #13 |
| bcelldeficient mice | #13 |
| complement complement activation | #13 |
| nonobese diabetic mouse | #13 |
| dba molecular | #13 |
| t‐cell epitope | #13 |
| mouse strains | #13 |
| anticii | #13 |
| ccp2 antibodies | #13 |
| oxidase nox2 | #13 |
| mannan | #13 |
| major loci | #13 |
| advanced intercross | #13 |
| lew1w | #13 |
| rfigg | #13 |
| macroscopic scoring | #13 |
| arthritis knowledge | #13 |
| species deficiency | #13 |
| immunohistochemistry interferon | #13 |
| expression egfp | #13 |
| sequence collagen | #13 |
| idd5 | #13 |
| cell epitope | #13 |
| factor isotypes | #13 |
| strains incidence | #13 |
| cyclic citrullinated | #13 |
| ho4 | #13 |
| b10p | #13 |
| 24dinitro1fluorobenzene | #13 |
| multispecific | #13 |
| antibodies citrullinated proteins | #13 |
| oxidative regulation | #13 |
| native type collagen | #13 |
| behavioral alterations rats | #13 |
| doses ici | #13 |
| epitope immunization | #13 |
| l012 | #13 |
| levels nabs | #13 |
| development type collagen | #13 |
| μ chain | #13 |
| gut protection | #14 |
| collagen comp | #14 |
| thr233 | #14 |
| deficient production | #14 |
| molecular disease models | #14 |
| immune regulators | #14 |
| antifilaggrin antibodies | #14 |
| cia expression | #14 |
| arthritic paws | #14 |
| collagen disease | #14 |
| presence mcv | #14 |
| experimental interferon | #14 |
| osteoclasts vivo | #14 |
| macrophages immune response | #14 |
| autoimmune arthritis | #14 |
| humans nadph | #14 |
| immunized rat | #14 |
| loci rheumatoid | #14 |
| murine collageninduced arthritis | #14 |
| specific inflammation | #14 |
| efficient promotion | #14 |
| arlacel | #14 |
| smallmolecule compound | #14 |
| autoimmunity animals | #14 |
| mhc class region | #14 |
| sirt1 mmp9 | #14 |
| b6n mice | #14 |
| aggregated nets | #14 |
| involvement cells | #14 |
| loci interaction | #14 |
| protein collagen | #14 |
| nasal inhalation | #14 |
| blymphocyte female humans | #14 |
| candidate autoantigens | #14 |
| peptides anti | #14 |
| apcs macrophages | #15 |
| cdr regions | #15 |
| polychondritis | #15 |
| 2 weight | #15 |
| citrullinated peptides patients | #15 |
| raloxifene estradiol | #15 |
| dcii | #15 |
| mice type collagen | #15 |
| ros cii | #15 |
| mice immunization | #15 |
| rt1a | #15 |
| presence anticarp antibodies | #15 |
| tflask | #15 |
| arthritis role | #15 |
| regulation adaptive immunity | #15 |
| osteoporosis development | #15 |
| rheumatoid arthritis presence | #15 |
| aire mtec | #15 |
| immune complex formation | #15 |
| antigenic epitope | #15 |
| mhc class molecule | #15 |
| type collagen development | #15 |
| nodb10h2b | #15 |
| anticollagen | #15 |
| arthritis development | #15 |
| exaggerates | #15 |
| cultured human chondrocytes | #15 |
| rats monoclonal antigens | #15 |
| murine cia | #15 |
| congenic rats | #15 |
| involvement pathogenesis | #15 |
| lentiviral gene delivery | #15 |
| rat genetics | #15 |
| translationally modified | #15 |
| neuritis rats | #15 |
| integrated bioprocess | #15 |
| antibodies arthritis | #15 |
| treatment cia | #15 |
| amps development | #15 |
| monoclonal arthritis rats | #15 |
| monolithic cryogel | #15 |
| experimental allergic neuritis | #15 |
| lethal inflammatory | #16 |
| rt1 | #16 |
| levels natural antibodies | #16 |
| males onset | #16 |
| epitopes mice mice | #16 |
| indirect genetic predisposition | #16 |
| subspecificities | #16 |
| staphylococcal arthritis | #16 |
| nonglycosylated form | #16 |
| antinuclear autoimmunity | #16 |
| lew1 | #16 |
| rno10 | #16 |
| mumt | #16 |
| class transplantation | #16 |
| arthritis severity mice | #16 |
| congenic mice mice | #16 |
| anti‐t | #16 |
| hla–drb1 shared epitope | #16 |
| development rheumatoid arthritis | #16 |
| oligomeric matrix protein | #16 |
| genes animals | #16 |
| pparγ lxrα | #16 |
| rats experimental arthritis | #16 |
| fewer osteoclasts | #16 |
| rheumatoid factor production | #16 |
| disease mice mice | #16 |
| acute inflammation mice | #16 |
| autologous collagen | #16 |
| mhc genes | #16 |
| rheumatoid arthritis genes | #16 |
| mhcii ciita | #16 |
| cep1 | #16 |
| n305 | #16 |
| matrilin proteins | #16 |
| arthritis cii | #16 |
| h2p | #16 |
| human fcγriia | #17 |
| mice rheumatoid arthritis | #17 |
| cells collagen | #17 |
| cartilage collagen | #17 |
| clever1 | #17 |
| nox2 derived | #17 |
| leuphe | #17 |
| arthritis rheumatoid autoantibodies | #17 |
| ethanol development | #17 |
| strains lymphocytes | #17 |
| onset rheumatoid arthritis | #17 |
| collagen induced arthritis | #17 |
| cab4 | #17 |
| skg | #17 |
| rats lewis | #17 |
| triplehelical conformation | #17 |
| collagen specific | #17 |
| polyphosphate4 | #17 |
| progesterone development | #17 |
| rt1av1 | #17 |
| cells female mice | #17 |
| genistein mice | #17 |
| inbred lew | #17 |
| animals congenic | #17 |
| periodontitis antibodies | #17 |
| rheumatoid arthritis subsets | #17 |
| spleen peyers patches | #17 |
| allergic neuritis | #17 |
| cells presenting cells | #17 |
| native denatured | #17 |
| h2z | #18 |
| day immunization | #18 |
| ealkene | #18 |
| collagen autoantibodies | #18 |
| arthritis anti | #18 |
| short‐term administration | #18 |
| day arthritis | #18 |
| defined epitope | #18 |
| disease duration onset | #18 |
| salivary glands mice | #18 |
| genes spleen | #18 |
| cartilage type collagen | #18 |
| galactose moiety | #18 |
| humanized transgenic mice | #18 |
| cuiiida | #18 |
| adjuvant arthritis rats | #18 |
| hybridomas mice mice | #18 |
| langerhans cells cells | #18 |
| expression lxrα | #18 |
| phenotypic feature | #18 |
| anti cd44 | #18 |
| purified anti | #18 |
| addition ros | #18 |
| moginduced eae | #18 |
| dra0101 | #18 |
| autoimmune illness | #18 |
| ros data | #18 |
| keratinocytes induction | #18 |
| joint inflammatory | #18 |
| three‐dimensional culture | #19 |
| mice develop | #19 |
| mrl mp mice | #19 |
| supermacroporous | #19 |
| inflammatory attack | #19 |
| patients polychondritis | #19 |
| rats snp | #19 |
| single intradermal injection | #19 |
| gly262 | #19 |
| citrullinated proteins acpa | #19 |
| tbetarii gene | #19 |
| peyers patches spleen | #19 |
| trimolecular complex | #19 |
| cia eae | #19 |
| blood monocytes neutrophils | #19 |
| elisa cia | #19 |
| vivo elimination | #19 |
| mice congenic mice | #19 |
| protective alleles | #19 |
| collagen response | #19 |
| future utility | #19 |
| protein comp | #19 |
| cd4 transgenic | #19 |
| new avenues | #19 |
| castrated female rats | #19 |
| beta oestradiol | #19 |
| suppression dth | #19 |
| fls tnfα | #20 |
| mbp rats | #20 |
| human rheumatoid arthritis | #20 |
| pvg1av1 | #20 |
| glycosylated | #20 |
| serm raloxifene | #20 |
| role nox | #20 |
| ncr3 | #20 |
| 5p14 | #20 |
| mice cia | #20 |
| experimental autoimmunity | #20 |
| response mbp | #20 |
| nox1deficient mice | #20 |
| matrilin1 | #20 |
| littermate | #20 |
| antibody treatment | #20 |
| stress phospholipids | #20 |
| progesterone oestrogen | #20 |
| ciita mhcii | #20 |
| loci chromosomes | #20 |
| enhanced tcr | #20 |
| prominent infiltration | #20 |
| development disease | #20 |
| inflammation mice | #20 |
| highly susceptible | #20 |
| monkeys rodents | #20 |
| knockout mice transgenic | #20 |
| mhc class alleles | #20 |
| 5r5 | #20 |
| imaging reactive | #20 |
| underlying gene | #20 |
| rt1d | #20 |
| olahsd | #21 |
| positional cloning | #21 |
| pathogenesis rheumatoid | #21 |
| cells adaptive immune | #21 |
| nox2 mice | #21 |
| n141 | #21 |
| cia treatment | #21 |
| linomide treatment | #21 |
| n286 | #21 |
| triplehelical peptides | #21 |
| nitratenitriteno pathway | #21 |
| ean rats | #21 |
| muscle ros | #21 |
| serum levels comp | #21 |
| drb11001 | #21 |
| onset severity | #21 |
| diseases lymphocytes | #21 |
| experimental rheumatoid | #21 |
| nox2 activity | #21 |
| individual acpa | #21 |
| mice mutant strains | #21 |
| granule mobilization | #21 |
| arthritis pregnancy | #21 |
| α1acidglycoprotein | #21 |
| conserved haplotype | #21 |
| suppressor cytotoxic cells | #21 |
| rats development | #21 |
| illness autoimmune | #21 |
| chronic relapsing | #21 |
| genes controlling | #21 |
| igg fcgammar | #21 |
| supermacroporous cryogels | #21 |
| association pv | #22 |
| ul1 | #22 |
| rats loss | #22 |
| animal epitopes humans | #22 |
| experimental phenotype | #22 |
| 270 | #22 |
| samples onset | #22 |
| induced eae | #22 |
| antiidiotypic antibody | #22 |
| c57bl mice subfamily | #22 |
| semiallogenic | #22 |
| rats nonalcoholic steatohepatitis | #22 |
| identification susceptibility genes | #22 |
| vh j558 | #22 |
| cultured hepatic cells | #22 |
| response myelin | #22 |
| determinant selection | #22 |
| mice independent | #22 |
| 81a | #22 |
| ccp negative | #22 |
| citrullinated epitopes | #23 |
| arthritis type | #23 |
| comp | #23 |
| tgfbeta resistance | #23 |
| mace association | #23 |
| monoclonal antigens autoimmune | #23 |
| lymphocytes amino | #23 |
| animal genes | #23 |
| citrullinated protein | #23 |
| onset cia | #23 |
| antibodies acpa | #23 |
| inflammation absence | #23 |
| loss collagen | #23 |
| cryogel beads | #23 |
| 17 betaoestradiol | #23 |
| anti‐cd5 | #23 |
| experimental chromatography | #23 |
| experimental autoimmune diseases | #23 |
| diseases autoimmunity | #23 |
| rats inbred lew | #23 |
| citrullinated antigens | #23 |
| castration rats | #23 |
| immunopeptides | #23 |
| cells presentation | #23 |
| complex influences | #23 |
| cells b10 | #23 |
| peptide activation | #23 |
| phage clones | #23 |
| 4npa | #23 |
| mbp eae | #23 |
| b10r | #23 |
| mediated arthritis | #24 |
| severity ali | #24 |
| subloci | #24 |
| y35 | #24 |
| controls anti | #24 |
| c57bl 10 mice | #24 |
| ftirm | #24 |
| secondary immune response | #24 |
| new mouse | #24 |
| mouse models development | #24 |
| autoantibodies rheumatoid | #24 |
| animal epistasis | #24 |
| levels comp | #24 |
| cells c3h | #24 |
| rat induction | #24 |
| 339 | #24 |
| experimental lupus | #24 |
| antinuclear apoptosis | #24 |
| flss patients | #24 |
| postpartum flare | #24 |
| monoclonal anti | #24 |
| chronic autoimmune diseases | #24 |
| severity chronicity | #24 |
| loci chromosome | #24 |
| inflammation arthritis | #24 |
| mice nox2 | #24 |
| experimental cells | #24 |
| bnda | #25 |
| interleukin2 mice receptors | #25 |
| immunodominant epitope | #25 |
| complex male | #25 |
| arthritis experimental arthritis | #25 |
| beta lymphocytes | #25 |
| immunization development | #25 |
| parasitemia survival | #25 |
| proteinarginine deiminase type | #25 |
| relapsing polychondritis | #25 |
| autoantibody response | #25 |
| monocytes nadph | #25 |
| autoimmune messenger | #25 |
| cells immunization | #25 |
| common autoimmune disease | #25 |
| collagen cartilage | #25 |
| production monoclonal | #25 |
| 8 antibodies | #25 |
| tolerized rats | #25 |
| rno4 | #25 |
| arginine arthritis | #25 |
| autoimmune diseases humans | #25 |
| cix | #25 |
| massive infiltration | #25 |
| specific epitopes | #25 |
| ros | #25 |
| b6 balb | #25 |
| congenic animals | #25 |
| rat mhc | #25 |
| cell hybridomas | #25 |
| murine lyme arthritis | #25 |
| inbred lew rats | #25 |
| eae development | #26 |
| autoantibodies citrullinated proteins | #26 |
| cells joints | #26 |
| cb11 | #26 |
| polychondritis rp | #26 |
| hydrocarbon oil | #26 |
| nitrophenylalanine | #26 |
| anti citrullinated | #26 |
| post translationally | #26 |
| mice gammadelta cells | #26 |
| granulocytes cells | #26 |
| viable chondrocytes | #26 |
| igg2a mice | #26 |
| glutamax | #26 |
| helperinducer animals antibodies | #26 |
| local exposure | #26 |
| gene regions | #26 |
| ccp2 | #27 |
| intercrossed | #27 |
| physiological level | #27 |
| individuals antibodies | #27 |
| perforin deficiency | #27 |
| immunospecific | #27 |
| hladrb1 shared epitope | #27 |
| c1i | #27 |
| innate interleukin10 | #27 |
| pannus tissue | #27 |
| nonmhc genes | #27 |
| trypsination | #27 |
| disease immunoglobulin | #27 |
| rheumatoid factor isotypes | #27 |
| pointmutation | #27 |
| interleukin21 tlymphocytes | #27 |
| immunodominant response | #27 |
| antibodies type | #27 |
| nr8383 | #28 |
| antibodies mab | #28 |
| cia3 | #28 |
| rat strain | #28 |
| mediated effects | #28 |
| cartilage vivo | #28 |
| w3 25 | #28 |
| severity day | #28 |
| upregulation cytokines | #28 |
| lysine position | #28 |
| anti rat | #28 |
| protein peptides | #28 |
| animal models neurodegeneration | #28 |
| autoimmune inflammatory | #28 |
| chronicity | #28 |
| eae susceptibility | #28 |
| mrna ifngamma | #28 |
| onset day | #28 |
| antily6g | #28 |
| ros induction | #28 |
| antigenspecific tolerance | #28 |
| parotid secretory protein | #29 |
| absence inflammation | #29 |
| smoking presence | #29 |
| phenomes | #29 |
| ros production macrophages | #29 |
| membrane lymphocytes | #29 |
| peptide anti | #29 |
| cfa cia | #29 |
| rfigm | #29 |
| acpa | #29 |
| antibody producing cells | #29 |
| immunopathogenicity | #29 |
| ls2616 | #29 |
| mice mab | #29 |
| suboptimal doses | #29 |
| 246trinitrophenyl | #29 |
| glucose transport capacity | #29 |
| chronic dss | #29 |
| hiit exercise | #29 |
| presence synovial fluid | #29 |
| variable heavy chain | #30 |
| paws | #30 |
| ctla4 mice | #30 |
| development experimental | #30 |
| cultivation cells | #30 |
| vpba | #30 |
| chronic autoimmune | #30 |
| hlase | #30 |
| acpa fine | #30 |
| disease immunity | #30 |
| linkage disease | #30 |
| synovial cells patients | #30 |
| treatment raloxifene | #30 |
| increased salt | #30 |
| dba mice | #30 |
| adult thymectomy | #30 |
| chain collagen | #30 |
| vivo exercise | #30 |
| plasminogendeficient mice | #30 |
| translational rats | #30 |
| alphabetat | #30 |
| 11 cells | #30 |
| metabolic syndrome rats | #30 |
| vgenes | #30 |
| drugs addition | #31 |
| expressing cells | #31 |
| acute‐phase response | #31 |
| immunization | #31 |
| disease development | #31 |
| selfprotein | #31 |
| perpetuated | #31 |
| nox2 nox1 | #31 |
| synovial fluid blood | #31 |
| monoclonal antibody production | #31 |
| apc development | #31 |
| ige cd23 | #31 |
| human type collagen | #31 |
| trimolecular | #31 |
| hiit training | #31 |
| common chain | #31 |
| pristaneinduced lupus | #31 |
| phytol | #31 |
| rats autoimmune | #31 |
| comparative genetic analysis | #31 |
| littermate controls | #31 |
| psoriasis model | #31 |
| bound peptides | #32 |
| ra33 | #32 |
| caia mice | #32 |
| methods serum samples | #32 |
| presence acpas | #32 |
| cells uterus | #32 |
| differentiation arthritis | #32 |
| role osteoclastogenesis | #32 |
| type antibody | #32 |
| ros rns | #32 |
| rt11 | #32 |
| 11 cell | #32 |
| receptor preference | #32 |
| hladrb104 | #32 |
| congenic mice | #32 |
| specificity function | #32 |
| nodes mice | #32 |
| arthritis therapy | #32 |
| acpa rheumatoid arthritis | #32 |
| steen | #32 |
| mucosal tolerance | #32 |
| genomewide genotyping | #32 |
| nonb cells | #32 |
| polymorphic genes | #32 |
| cell ratio | #32 |
| nadph oxidases nox | #32 |
| beta mice | #32 |
| epitope antibodies | #32 |
| influence genes | #32 |
| h2aq | #32 |
| modified collagen | #33 |
| skews | #33 |
| type cross | #33 |
| epitopes antibodies | #33 |
| autoantibody activity | #33 |
| tcell receptor | #33 |
| tolerance immunization | #33 |
| autoimmune demyelinating disease | #33 |
| role vav1 | #33 |
| cytosolic factor | #33 |
| antigenpresenting cells cells | #33 |
| multiplex analysis | #33 |
| delayed type | #33 |
| induced immunization | #33 |
| rheumatoid joint | #33 |
| arthritic mice | #33 |
| cells dendritic cells | #34 |
| joint pathology | #34 |
| c4bp | #34 |
| nox2 deficiency | #34 |
| heterogeneous stock | #34 |
| promiscuous expression | #34 |
| chronic polyarthritis | #34 |
| fpr1 | #34 |
| neurodegeneration role | #34 |
| patients animal models | #34 |
| interferon activity | #34 |
| natural antibodies nabs | #34 |
| accessible sites | #35 |
| complex arthritis | #35 |
| arthritis disease | #35 |
| destructive arthritis | #35 |
| patients populations | #35 |
| vdr cells | #35 |
| psoriasiform skin | #35 |
| triple helical | #35 |
| hybridomas | #35 |
| nets neutrophils | #35 |
| monoclonal rheumatoid | #35 |
| autoreactive | #35 |
| antiarthritis | #35 |
| major regulators | #35 |
| antirat | #35 |
| acs stroke | #35 |
| infectious disease models | #35 |
| phagotope | #35 |
| 1xi | #35 |
| development chronic | #35 |
| plasminogen deficiency | #35 |
| female histocompatibility | #36 |
| arthritis cartilage | #36 |
| oxidases rna | #36 |
| h2r | #36 |
| induction tregs | #36 |
| comparative genetics | #36 |
| animals antigen | #36 |
| protein specific | #36 |
| variance animals antibodies | #36 |
| flow cytometry expression | #36 |
| nk cells recognition | #36 |
| cartilage joints | #36 |
| dth | #36 |
| h2g7 | #36 |
| dinitro1 | #36 |
| phagocyte | #36 |
| tolerance tlymphocytes | #36 |
| techniques mice | #36 |
| cii cfa | #36 |
| specificity sera | #36 |
| immunopathological features | #37 |
| acpa positive | #37 |
| lymphocytes disease | #37 |
| synthetic glycopeptides | #37 |
| genetic control | #37 |
| encephalomyelitis | #37 |
| joint cartilage | #37 |
| susceptibility autoimmune diseases | #37 |
| mif pathogenesis | #37 |
| dba1 | #37 |
| oxidases oxidation | #37 |
| recombinant vaccine | #37 |
| spontaneous arthritis | #37 |
| role gamma interferon | #37 |
| rich lipid | #37 |
| peptides binding | #37 |
| cii protein | #37 |
| c129 | #37 |
| target autoantigens | #38 |
| snat | #38 |
| sialophorin | #38 |
| human blood neutrophils | #38 |
| antibodies animals | #38 |
| innovative tools | #38 |
| cochranmantelhaenszel test | #38 |
| animal models pain | #38 |
| nitrogen species | #38 |
| cldn4 | #38 |
| resultsrats | #39 |
| measurement activity | #39 |
| cell tolerance | #39 |
| autoreactive cells | #39 |
| nzw | #39 |
| ccia | #39 |
| ym1 | #39 |
| allogeneically | #39 |
| clonal expansion cells | #39 |
| oestrogen treatment | #39 |
| wasting syndrome | #39 |
| b6n | #39 |
| data myelin | #39 |
| endoβnacetylglucosaminidase | #39 |
| acpa response | #39 |
| benoist | #39 |
| nfr | #39 |
| isostere | #40 |
| antigens arthritis | #40 |
| polyclonal cell activation | #40 |
| addition impact | #40 |
| peptide cell | #40 |
| disease animal models | #40 |
| positive rheumatoid | #40 |
| adjuvant induced | #40 |
| genetic complexity | #40 |
| rt1c | #40 |
| rats anti | #41 |
| priming phase | #41 |
| genes loci | #41 |
| autoimmune inflammatory diseases | #41 |
| ncii | #41 |
| congenic mapping | #41 |
| severity incidence | #41 |
| aq | #41 |
| rat myelin | #41 |
| mhc haplotype | #41 |
| immunocap isac | #41 |
| effects experiments | #41 |
| autoimmune | #41 |
| antibody isotypes | #42 |
| drb1 shared | #42 |
| species receptors | #42 |
| p38 mapk nfκb | #42 |
| expected onset | #42 |
| spleen weight | #42 |
| ptpn22 locus | #42 |
| cartilage bone destruction | #42 |
| th17 axis | #42 |
| articular collagen | #42 |
| mhc class class | #42 |
| fibroblasts mice | #42 |
| pineal gland melatonin | #42 |
| congeneic | #43 |
| cd11bly6g | #43 |
| crosses genetic | #43 |
| mice autoimmune | #43 |
| immunodominant epitopes | #43 |
| type‐ii | #43 |
| lew rats | #43 |
| arthritis data | #43 |
| rats sex | #43 |
| anticitrullinated | #43 |
| collagen | #43 |
| kgf treatment | #43 |
| spinal glia | #43 |
| treatment autoimmune diseases | #43 |
| anticyclic | #43 |
| pc8 | #43 |
| autoreactive cell | #43 |
| lew lymphocytes | #43 |
| neuritis ean | #44 |
| provocations | #44 |
| inflammation animals | #44 |
| mice adulthood | #44 |
| chloro23 | #44 |
| addition order | #44 |
| c4bbinding protein c4bp | #44 |
| homozygous form | #44 |
| genetic linkage analysis | #44 |
| mathis | #44 |
| peptide induced | #44 |
| epitopes lymphocyte | #44 |
| defensins humans | #44 |
| mice mice autoimmune | #44 |
| outbred rats | #45 |
| relapsing disease | #45 |
| susceptibility arthritis | #45 |
| genetic encoding | #45 |
| chromosome development | #45 |
| nzb | #45 |
| phagotopes | #45 |
| potent suppression | #45 |
| disease histocompatibility | #45 |
| rat2 | #46 |
| carp antibodies | #46 |
| lower severity | #46 |
| neuritis autoimmune | #46 |
| affinity purified | #46 |
| mhc class humans | #46 |
| specific tolerance | #46 |
| isosteres | #46 |
| posttranslationally | #46 |
| c227 | #46 |
| alphachains | #46 |
| locus controlling | #46 |
| cocrystallisation | #46 |
| disease induction | #46 |
| eae mbp | #46 |
| idiotypic antibody | #47 |
| f1 hybrid mice | #47 |
| protective allele | #47 |
| posttranslational rats receptors | #47 |
| association hladrb1 alleles | #47 |
| antibody reactivities | #47 |
| rheumatoid factors | #47 |
| intercrosses | #47 |
| complex mediated | #47 |
| diagnostic accuracy diagnosis | #47 |
| synovial lining layer | #48 |
| cia rats | #48 |
| tlr12 | #48 |
| f1 crosses | #48 |
| peptide recognized | #48 |
| mice nzb | #48 |
| humanized model | #48 |
| γchains | #48 |
| experimental arthritis mice | #48 |
| mice carrying | #48 |
| acetylchitobiose | #48 |
| collagen peptide | #48 |
| antibody specificity | #48 |
| collagen glycosylation | #48 |
| lupus disease | #48 |
| immune nervous | #49 |
| tcell stimulation | #49 |
| experimental crosses | #49 |
| polyvinylcaprolactam | #49 |
| monoclonal autoimmune diseases | #49 |
| class major | #49 |
| histone hdacs | #49 |
| mice caia | #49 |
| comp levels | #49 |
| sex genes | #49 |
| mouse cartilage | #49 |
| bystander activation | #49 |
| mice tolerance | #50 |
| ciiia | #50 |
| loci animals | #50 |
| glutamine uptake | #50 |
| complex region | #50 |
| animal cell culture | #50 |
| antigenantibody | #50 |
| alagly | #50 |
| dependent chronic | #50 |
| disease rats | #50 |
| monoclonal epitopes | #50 |
| inflammation kynurenine | #50 |
| anticarbamylated protein | #50 |
| cytometry analyses | #50 |
| parathyroid cells | #50 |
| glycosylated form | #50 |
| tolerized | #51 |
| rheumatoid factor activity | #51 |
| runting | #51 |
| autoantibodies rheumatoid arthritis | #51 |
| evidence animal models | #51 |
| fewer cells | #51 |
| delayed immunization | #51 |
| antibodies cells | #51 |
| tracheal cartilage | #51 |
| cells ova | #51 |
| derived type | #51 |
| c57bl 6j background | #51 |
| aire mice | #51 |
| lentiviral particles | #51 |
| inbred c57bl autoimmune | #51 |
| xor activity | #52 |
| matrix protein | #52 |
| macrophages skin | #52 |
| antigenpresenting cells | #52 |
| model collagen | #52 |
| ptpn22 | #52 |
| melatonin day | #53 |
| arthritis induction | #53 |
| aged peptides | #53 |
| physiological doses | #53 |
| antibodies epitopes | #53 |
| gastric parietal cell | #53 |
| cartilage erosion | #53 |
| patients rheumatic conditions | #53 |
| lysosomal compartments | #53 |
| carbamylated proteins | #53 |
| protein antibodies | #53 |
| production reactive | #53 |
| triple helical structure | #53 |
| induced autoimmunity | #53 |
| major epitope | #54 |
| yaa | #54 |
| crossbreeding | #54 |
| melatonin animals | #54 |
| carbamylated protein | #54 |
| strain rats | #54 |
| animals autoimmune | #54 |
| predating | #54 |
| imitating | #54 |
| antigens myelomonocytic arthritis | #54 |
| rats social isolation | #54 |
| development individuals | #54 |
| nodes lymphocyte | #54 |
| susceptibility autoimmune disease | #55 |
| macrophage mannose receptor | #55 |
| inflammatory manifestations | #55 |
| arthritis genetic | #55 |
| autoimmune nzb | #55 |
| complex genetic disease | #55 |
| autoimmune reactions | #55 |
| cells salivary | #56 |
| selfreactive cells | #56 |
| animals antibody | #56 |
| labels superoxide | #56 |
| alpha1microglobulin | #56 |
| new animal | #56 |
| mhc | #56 |
| arthritis pathogenesis | #57 |
| antibodies | #57 |
| collagen sequence | #57 |
| cd1 mice | #57 |
| antibodies bind | #57 |
| igg abs | #57 |
| vivo depletion | #57 |
| animals antirheumatic | #57 |
| development autoimmune | #57 |
| oestrogen progesterone | #58 |
| schafer | #58 |
| peptide response | #58 |
| rat type | #58 |
| chronic eae | #58 |
| urokinase activity | #58 |
| resistance eae | #59 |
| anticarp antibodies | #59 |
| genes mhc | #59 |
| hydroxylase diet | #59 |
| encephalitogenicity | #59 |
| oligoclonal igg bands | #59 |
| cartilage matrix protein | #59 |
| anti cell | #59 |
| anti cd8 | #59 |
| articular joints | #59 |
| hpaaxis | #60 |
| alternative activation macrophages | #60 |
| macrophage mannose | #60 |
| protein peptide | #60 |
| dichotomous effects | #60 |
| immunohistopathology | #60 |
| inflammatory cells macrophages | #60 |
| assay epitopes | #60 |
| joint erosions | #60 |
| experimental evoked potentials | #61 |
| serum comp | #61 |
| differentiation myelomonocytic arthritis | #61 |
| cells innate immune | #61 |
| incidence severity | #61 |
| epitope spreading | #61 |
| experimental rats rats | #61 |
| species reactive | #61 |
| major histocompatibility | #61 |
| alpha1m | #61 |
| basic characterization | #62 |
| toxin1 | #62 |
| mice susceptibility | #62 |
| placenta uterus | #62 |
| syngeneically | #62 |
| reduced oxidative | #62 |
| interferon‐β | #62 |
| adaptive immune | #62 |
| cyclic sensitivity | #62 |
| antigens class histocompatibility | #62 |
| fpr2 | #62 |
| autoantibody formation | #62 |
| specificity tumor | #63 |
| delayed interferon | #63 |
| collagen cell | #63 |
| peptide specific | #63 |
| induced experimental | #63 |
| post‐partum | #63 |
| igaproducing cells | #63 |
| mice polyi | #63 |
| duval | #63 |
| specific stages | #63 |
| rats strain | #63 |
| hypersensitivity dth | #63 |
| constant darkness | #63 |
| mog1 | #63 |
| protein disease | #63 |
| glycoprotein myelin | #63 |
| nadph oxidases | #63 |
| transfer animals | #63 |
| lower capacity | #64 |
| maternal origin | #64 |
| tolerance model | #64 |
| secondary immune | #64 |
| freund adjuvant | #64 |
| role apc | #64 |
| flss | #65 |
| induced suppression | #65 |
| histocompatibility complex | #65 |
| autoimmunity humans | #65 |
| major subset | #65 |
| hindpaws | #65 |
| weight variation | #65 |
| model chronic | #65 |
| thy1 antigen | #66 |
| hladr2 | #66 |
| chromosomes mammalian | #66 |
| spontaneous disease | #66 |
| acute arthritis | #66 |
| resemblances | #66 |
| negative rheumatoid | #66 |
| phagocytosis oxidative burst | #66 |
| multispecificity | #66 |
| rheumatoid synovial cells | #66 |
| peripheral joints | #66 |
| experimental lymphocytes | #66 |
| fibrinogen genotype | #67 |
| rheumatoid arthritis susceptibility | #67 |
| development cell | #67 |
| experimental encephalomyelitis | #67 |
| myelomonocytic arthritis | #67 |
| dendritic cells epitopes | #67 |
| strains susceptible | #67 |
| mice cell | #67 |
| mice induced | #67 |
| endos | #67 |
| key interactions | #67 |
| experimental allergic | #67 |
| complex class | #68 |
| individuals positive | #68 |
| anti carp | #68 |
| class region | #68 |
| female sex hormones | #68 |
| rheumatoid chromosomes | #68 |
| frequent infections | #68 |
| sodium diethyldithiocarbamate | #68 |
| helper phenotype | #68 |
| cells mhc class | #68 |
| tolerized mice | #68 |
| severity periodontitis | #68 |
| iggrf | #68 |
| frequency antibodies | #69 |
| vertebrate immune | #69 |
| lymphocytes chronic | #69 |
| rheumatoid disease | #69 |
| cells mouse | #69 |
| relapsing | #69 |
| direct damage | #69 |
| zap‐70 | #69 |
| mrl mice | #70 |
| immunoglobulin interferon | #70 |
| presence rheumatoid factor | #70 |
| response type | #70 |
| role cells | #70 |
| translationally | #70 |
| prolonged graft survival | #70 |
| swr | #71 |
| expression pparγ | #71 |
| susceptibility female | #71 |
| cartilage mice | #71 |
| ztm | #71 |
| human psoriasis | #71 |
| cb10 | #71 |
| isolated rats | #71 |
| naïve mice | #72 |
| delayedtype hypersensitivity dth | #72 |
| antibodies binding | #72 |
| autoimmunity lymphocytes | #72 |
| interphalangeal joints | #72 |
| dark agouti rats | #72 |
| study antibodies | #72 |
| lathyritic | #72 |
| napdh | #72 |
| species ros | #73 |
| oxidase complex | #73 |
| type ifn signature | #73 |
| environmental lighting | #73 |
| mrl lpr | #73 |
| membrane animals | #73 |
| bovine type | #73 |
| treatment stages | #73 |
| knockout protein processing | #73 |
| cartilage explants | #74 |
| pregnancyinduced | #74 |
| peptides sequences | #74 |
| antigens class | #74 |
| hypersensitivity delayed | #74 |
| igarf | #74 |
| genetic disease models | #75 |
| dth mice | #75 |
| diabetes arthritis | #75 |
| effects development | #75 |
| inbred dba receptors | #75 |
| oestradiol | #75 |
| acpapositive | #75 |
| cell reactivity | #75 |
| type collagens | #76 |
| anti carbamylated | #76 |
| rat splenocytes | #76 |
| disease rheumatoid arthritis | #76 |
| peptide mhc | #76 |
| cell deficient | #77 |
| nerve conduction velocity | #77 |
| rt1n | #77 |
| oligomeric | #77 |
| regulatory vaccines | #77 |
| lpr mrl | #77 |
| pain inflammation | #77 |
| development insulitis | #77 |
| inbred mouse strains | #77 |
| cyp7a1 | #77 |
| eae induced | #77 |
| rats eae | #77 |
| new animal model | #77 |
| collagen chains | #77 |
| clinical arthritis | #78 |
| cartilage integrity | #78 |
| rats respiratory | #78 |
| autoantigenic | #78 |
| mhc expression | #78 |
| pythons | #78 |
| pathogenesis rheumatoid arthritis | #78 |
| inflammatory autoimmune | #79 |
| susceptibility disease | #79 |
| autoimmune experimental epitopes | #79 |
| 1ii | #79 |
| mononuclear lung | #79 |
| shared epitope | #79 |
| chromosome study | #80 |
| oxidases | #80 |
| detection autoantibodies | #80 |
| erosive arthritis | #80 |
| arthritis cells | #81 |
| sex linkage | #81 |
| inflammatory phase | #81 |
| expression ll37 | #81 |
| class antigen expression | #81 |
| aspartic acid position | #81 |
| spleen study | #81 |
| hnrnpa2 | #81 |
| type macrophages | #81 |
| mog mbp | #81 |
| estrogen suppression | #81 |
| induced leukocyte | #81 |
| mhcii expression | #81 |
| mrl mp | #81 |
| dr1 antigen | #81 |
| 14weeks | #82 |
| pannus formation | #82 |
| nadphoxidase | #82 |
| expression mhc | #83 |
| bcg infection | #83 |
| tlymphocyte genes | #83 |
| cell independent | #83 |
| drug encephalomyelitis | #83 |
| mice igg | #83 |
| strains animals | #84 |
| arthritis day | #84 |
| multiple sclerosis evidence | #84 |
| epidermal cells | #84 |
| spontaneous development | #84 |
| rat cardiac allografts | #84 |
| naïve cells | #84 |
| reactive cells | #84 |
| antiifngamma | #85 |
| homopentamer | #85 |
| class molecule | #85 |
| inflammation joint | #85 |
| inflammation joints | #85 |
| cells recognize | #85 |
| knockout receptors | #85 |
| preclinical stage | #86 |
| anti cd4 | #86 |
| gfoger | #86 |
| contribution genes | #86 |
| classical humans | #86 |
| severe eae | #86 |
| mutant strains | #86 |
| animal humans | #86 |
| phagocyte nadph | #86 |
| monoclonal antibodies mab | #86 |
| mhc class gene | #87 |
| estrogen induced | #87 |
| alpha1acid glycoprotein | #87 |
| inbred rat strains | #87 |
| smash | #87 |
| copy variation | #88 |
| narac | #88 |
| thps | #88 |
| inguinal lymph nodes | #88 |
| levels anti | #88 |
| fine specificities | #88 |
| arthritic | #89 |
| peptide immunization | #89 |
| depletion cd8 cells | #89 |
| mice antibodies | #89 |
| experimental autoimmune | #89 |
| mabs mab | #89 |
| genetic quantitative | #89 |
| monkeys mice | #90 |
| mediated mechanisms | #90 |
| ilc2 activation | #90 |
| rheumatoid arthritis cells | #90 |
| adjuvant arthritis | #90 |
| genistein treatment | #90 |
| susceptible | #90 |
| autoimmune inbred c57bl | #90 |
| pineal hormone melatonin | #90 |
| arthritis compared | #90 |
| protein induced | #91 |
| cattle collagen | #91 |
| activation cd4 cells | #91 |
| histological sections | #91 |
| synovial fluid serum | #91 |
| backgroundan | #91 |
| cells apc | #91 |
| nod mhc | #92 |
| abdominal region | #92 |
| experimental mouse models | #92 |
| difco | #92 |
| humans immunodominant | #92 |
| anticitrullinated protein | #92 |
| knockout myelin | #93 |
| 290 patients | #93 |
| mice melatonin | #93 |
| natural polymorphisms | #93 |
| cellspecific | #93 |
| animals autoantibodies | #93 |
| xor | #93 |
| fcγrs | #94 |
| macrophages development | #94 |
| endosomal acidification | #94 |
| activated cells cells | #94 |
| galactosylated | #94 |
| autosomal genes | #94 |
| moderateintensity exercise | #95 |
| binding integrins | #95 |
| chronic phase disease | #95 |
| induced sarcoma | #95 |
| cell alpha | #96 |
| data rats | #96 |
| lung emphysema | #96 |
| romani | #96 |
| pregnancy disease | #96 |
| ifnbeta | #96 |
| nonglycosylated | #96 |
| messenger tolllike receptor | #96 |
| macrophages stimulation | #96 |
| fetal rejection | #96 |
| complex mice | #97 |
| macrophages fibroblasts | #97 |
| antiimmunoglobulin | #97 |
| cathelicidins | #97 |
| rheumatoid lymphocytes | #97 |
| il33r | #97 |
| hydroxylysine | #97 |
| citrullinated fibrinogen | #97 |
| genetic female genes | #97 |
| acpa igg | #98 |
| swr mice | #98 |
| rheumatoid cartilage | #98 |
| autoimmune rats | #98 |
| autoimmune experimental | #98 |
| ean | #98 |
| collagen cytokines | #99 |
| rat chromosomes | #99 |
| interleukin‐4 | #99 |
| alternative pathways | #99 |
| inducer animals | #100 |
| cultured crosses | #100 |
| tlymphocyte immunity | #100 |
| protein antibody | #100 |
| ccp anti | #100 |
| invading pathogens | #100 |
| peptides cells | #100 |
| thy1 antigens | #100 |
| tap2 | #100 |
| rats monoclonal antibodies | #100 |
| bone degradation | #101 |
| safety drugs | #101 |
| singlenucleotide polymorphism | #101 |
| diarthrodial | #101 |
| eira | #101 |
| fprs | #101 |
| cell determinants | #101 |
| susceptible strain | #101 |
| brucei infection | #102 |
| mouse monoclonal antibodies | #102 |
| candidate autoantigen | #102 |
| eae animal encephalomyelitis | #102 |
| findings treatment | #102 |
| agalactosyl | #103 |
| ros homeostasis | #103 |
| oxidative burst | #103 |
| hla dr1 | #103 |
| pathogenesis emphysema | #103 |
| drb10401 | #103 |
| mhcii | #104 |
| male mice mice | #104 |
| skg mice | #104 |
| mutation mice | #104 |
| f1 males | #104 |
| synchrotron infrared | #104 |
| thelper cells | #104 |
| arthritic disease | #104 |
| haplotypes histocompatibility | #104 |
| nonarthritic | #104 |
| fcγr | #105 |
| vivo macrophages | #105 |
| osteoclasts mice | #105 |
| dmaam | #105 |
| type 22 | #105 |
| development antibodies | #105 |
| hybridoma cell | #105 |
| autoreactivity | #105 |
| arthritis hla | #106 |
| proteoglycan loss | #106 |
| tcell immunity | #106 |
| disease dose | #106 |
| 273 | #106 |
| primed cells | #106 |
| limited cross | #106 |
| cells synovial | #107 |
| c3h mice | #107 |
| nzb mice | #107 |
| study tolerance | #108 |
| development autoimmune disease | #108 |
| fpr | #108 |
| littermates | #108 |
| structural polymorphism | #109 |
| citrullinated proteins | #109 |
| presentation cells | #109 |
| delayedtype hypersensitivity | #109 |
| autoantibodies autoantigens | #109 |
| reactive cell | #109 |
| enthesophytes | #109 |
| type hypersensitivity | #109 |
| monoclonal igg | #109 |
| carcinoma tumors | #110 |
| autoimmune encephalomyelitis | #110 |
| streptococcal cell wall | #111 |
| inbred dba microscopy | #111 |
| experimental female | #111 |
| backcross | #111 |
| toxic shock syndrome | #111 |
| mog eae | #111 |
| dba 1j mice | #111 |
| female hypersensitivity | #111 |
| cartilage | #111 |
| anti idiotypic antibodies | #112 |
| alphabeta receptors antigen | #112 |
| humoral autoimmunity | #112 |
| amide bond | #112 |
| presymptomatic individuals | #112 |
| extensive literature search | #112 |
| trait loci | #113 |
| xid mice | #113 |
| restricted cell | #113 |
| autoimmune c57bl mice | #113 |
| mice collageninduced arthritis | #113 |
| db1 | #113 |
| adjuvant properties | #113 |
| oligoclonality | #113 |
| tcra | #113 |
| ifngammaproducing cells | #114 |
| adjuvantinduced arthritis | #114 |
| anti mcv | #115 |
| autoantigens autoimmunity | #115 |
| proinflammatory cytokine | #115 |
| mice disease | #115 |
| rats collagen | #115 |
| drb10402 | #115 |
| ccp patients | #116 |
| susceptibility eae | #116 |
| experimental epitopes | #116 |
| transgenic peptides receptors | #116 |
| lutz | #116 |
| pathogenesis autoimmune diseases | #116 |
| immunosorbents | #116 |
| lymphocyte female | #116 |
| glyco | #116 |
| glycopeptides | #116 |
| antibodies reactive | #117 |
| mice type | #117 |
| fluorescence nf | #117 |
| antiarthritic | #117 |
| congenic lines | #117 |
| encephalomyelitis autoimmune | #117 |
| tolerance induced | #117 |
| samples individuals | #118 |
| myelin oligodendrocyte | #118 |
| rats immunized | #118 |
| class expression | #118 |
| psoriasiform dermatitis | #118 |
| pineal hormone | #118 |
| alpha1acid | #118 |
| α enolase | #118 |
| psa rheumatoid arthritis | #119 |
| rheumatoid arthritis review | #119 |
| response cells | #119 |
| radiological damage | #119 |
| 05m | #119 |
| cd4 tcells | #119 |
| neutrophils nets | #120 |
| protein mbp | #120 |
| vivo animal models | #121 |
| experimental animal models | #121 |
| chondrocyte cultures | #121 |
| genes age | #122 |
| immune complex deposition | #122 |
| t‐lymphocyte | #122 |
| transgenic neurons receptors | #122 |
| acpa negative | #122 |
| treatment progesterone | #122 |
| patients acpa | #122 |
| transfer arthritis | #122 |
| pharmacological potential | #122 |
| c5b | #123 |
| type cytokines | #123 |
| symptoms associations | #123 |
| nox2 activation | #123 |
| cell monoclonal | #123 |
| alphabeta cells | #123 |
| cartilage surface | #124 |
| inbred mouse | #124 |
| tlr4 stimulation | #124 |
| preimmunized | #125 |
| oxidases neutrophils | #125 |
| helperinducer | #125 |
| genetic rats | #125 |
| general mechanisms | #125 |
| disease mechanisms | #125 |
| allelic variations | #125 |
| blocking antigens | #125 |
| qtl genes | #125 |
| cryogel | #125 |
| immunodominant peptide | #125 |
| female immunization | #126 |
| nzb nzw | #126 |
| pnipaam | #126 |
| nonobese diabetic | #126 |
| cyclic polymorphism | #126 |
| atp8 | #127 |
| animal enzyme | #127 |
| absence cells | #127 |
| knockout murine | #127 |
| microarray detection | #127 |
| lining layer | #128 |
| anticitrullinated peptide | #128 |
| deiminases | #128 |
| chronic inflammatory disease | #128 |
| dominant epitope | #128 |
| rats patients | #129 |
| bxsb | #129 |
| multiple epitopes | #129 |
| spleen rats | #129 |
| nos2 | #130 |
| vivo absence | #130 |
| disease induced | #130 |
| oestradiol testosterone | #130 |
| cells eae | #130 |
| psd1 | #130 |
| epitope specific | #131 |
| lipomannan | #131 |
| onset arthritis | #131 |
| intercross | #132 |
| induction regulatory cells | #132 |
| disease cgd | #132 |
| mineral oils | #132 |
| kgf | #132 |
| pronociceptive | #132 |
| linomide | #132 |
| reduced severity | #133 |
| rat chromosome | #133 |
| leukosialin | #133 |
| ggaa | #133 |
| myocellular | #134 |
| eae | #134 |
| plasma synovial fluid | #134 |
| interstitial collagens | #134 |
| patients cytokines | #134 |
| accentuate | #134 |
| mice estrogen | #134 |
| knockout receptors antigen | #134 |
| species animals | #134 |
| peptides cyclic | #135 |
| spinal glial | #135 |
| igg immune complexes | #135 |
| intracellular reactive | #136 |
| chronic autoimmune disease | #136 |
| macrophages dendritic | #136 |
| immunizing | #136 |
| stimulated muscle | #137 |
| innate lymphocytes | #137 |
| immunopathological | #137 |
| receptor upregulation | #137 |
| mice deficient | #138 |
| ditiocarb | #138 |
| control development | #139 |
| dmannitol | #139 |
| immunomodulatory drug | #139 |
| autoimmune mice | #139 |
| tcrdelta | #140 |
| thermoresponsive polymer | #141 |
| oligoclonal expansion | #141 |
| producing cell | #141 |
| or113 | #142 |
| single subcutaneous injection | #142 |
| rejection tolerance | #142 |
| smfish | #142 |
| gamma lymphocyte | #142 |
| genetic factors development | #142 |
| interferon‐γ | #142 |
| phadia | #142 |
| tcell alphabeta receptors | #143 |
| mice beta | #143 |
| class haplotypes | #143 |
| cell hybridoma | #143 |
| phosphate isomerase | #143 |
| mhc haplotypes | #144 |
| synovial hyperplasia | #144 |
| rat strains | #144 |
| rheumatoid arthritis | #144 |
| tnf production | #145 |
| inbred buf rats | #145 |
| severe chronic | #145 |
| treatment ici | #145 |
| syngenic | #145 |
| tcr gamma delta | #145 |
| lyme arthritis | #145 |
| rats induced | #146 |
| neonatal growth | #146 |
| function cells | #147 |
| systemic challenge | #147 |
| cellular heterogeneity | #147 |
| pregnancy levels | #147 |
| ccp antibodies | #147 |
| gammainterferon | #147 |
| α2i | #148 |
| redox regulation | #148 |
| interestingly | #148 |
| autoimmune disease | #148 |
| phagocyte nadph oxidase | #148 |
| cell surface antigen | #148 |
| complex diseases | #149 |
| human autoimmune diseases | #149 |
| drb104 | #150 |
| mhc binding | #150 |
| larsen score | #150 |
| humans hybridomas | #151 |
| epicutaneously | #151 |
| mice animals | #151 |
| receptor rats | #151 |
| differential gene expression | #151 |
| levels antibodies | #151 |
| alphabeta receptors | #152 |
| key player | #153 |
| levels pregnancy | #153 |
| arthritic animals | #153 |
| mononuclear cells | #153 |
| pepsin | #153 |
| fcgammar | #154 |
| expression class | #154 |
| daf1 | #154 |
| c4bbinding protein | #154 |
| selfpeptides | #154 |
| critical event | #154 |
| joint inflammation | #154 |
| immune priming | #154 |
| male rats rats | #154 |
| autoantibodies autoimmune | #155 |
| infiltrating cells | #155 |
| f1 mice | #155 |
| arthritis rheumatoid | #155 |
| padi4 | #155 |
| mace acs | #155 |
| serum synovial fluid | #155 |
| suppressive role | #156 |
| mhc region | #156 |
| specificities | #156 |
| stabilin1 | #156 |
| downstream signals | #157 |
| murine keratinocytes | #157 |
| adjuvanticity | #157 |
| genetic diabetes mellitus | #158 |
| analysis structure | #158 |
| hypersensitivity reaction | #158 |
| parentals | #158 |
| arthritis infectious | #159 |
| systemic mice mice | #159 |
| meaib | #159 |
| animals autoimmunity | #159 |
| consensus motif | #159 |
| inbred c3h mice | #159 |
| factors anti | #161 |
| knockout severity | #161 |
| gamma interferon | #161 |
| specific autoimmunity | #161 |
| day onset | #161 |
| nursed | #161 |
| benzylated | #161 |
| epitope | #162 |
| anti ccp | #162 |
| βarrestin recruitment | #162 |
| cd152 | #162 |
| psors1 | #162 |
| arthritis inflammation | #162 |
| rheumatoid autoantigens | #162 |
| binding collagen | #162 |
| onset disease | #163 |
| chains humans | #163 |
| laboratory rats | #163 |
| mouse type | #163 |
| endobetanacetylglucosaminidase | #164 |
| genes qtl | #164 |
| striking similarities | #164 |
| rats induction | #164 |
| agalactosyl igg | #164 |
| autoantibody responses | #164 |
| progesterone effects | #164 |
| mrl | #164 |
| cells macrophages | #165 |
| animal humans immunity | #165 |
| nonimmunized | #166 |
| epitope alleles | #166 |
| tolerance induction | #166 |
| pathogenic pathways | #166 |
| melatonin mice mice | #166 |
| human autoimmunity | #167 |
| tlymphocyte humans | #167 |
| ag7 | #167 |
| class mice | #167 |
| nox2 | #167 |
| seronegative | #167 |
| cd1 | #168 |
| genetic backgrounds | #168 |
| phase disease | #168 |
| mice cd4 cells | #168 |
| denoted | #169 |
| oxazole | #169 |
| acpa levels | #169 |
| p12 | #169 |
| pathogenesis arthritis | #170 |
| joints male | #170 |
| cryogels | #170 |
| inherited disorder | #170 |
| mirp | #170 |
| experimental animal | #170 |
| lymph node cells | #170 |
| oxazolone | #171 |
| encephalomyelitis eae | #171 |
| ros nitric oxide | #171 |
| autoimmune eae | #172 |
| single nucleotide polymorphism | #172 |
| autoimmunity cell | #172 |
| rat placenta | #172 |
| peripheral lymphoid organs | #172 |
| rheumatoid | #172 |
| lst1 | #172 |
| sod3 | #173 |
| monoclonal autoantibodies | #173 |
| inbred dba models | #173 |
| resistant rats | #174 |
| presence autoantibodies | #174 |
| class gene | #174 |
| studies pain | #174 |
| nasal cartilage | #174 |
| ifn signature | #175 |
| understanding pathogenesis | #175 |
| maternal decidua | #175 |
| mice mutation | #175 |
| skin disease | #176 |
| secondary challenge | #176 |
| strains molecular | #176 |
| new mouse model | #176 |
| mammalian crosses | #176 |
| tryptophan catabolism | #176 |
| moab | #176 |
| lymphotoxinα | #177 |
| ctla‐4 | #178 |
| hladrb1 alleles | #178 |
| histocompatibility | #178 |
| protein anti | #179 |
| nod genes | #179 |
| alternative pathway complement | #179 |
| dextran sulphate sodium | #179 |
| mice role | #179 |
| immunized | #179 |
| arthritis methods | #180 |
| cgd patients | #180 |
| complex disease | #180 |
| epitopes female | #180 |
| molecular adaptations | #181 |
| alleles arthritis | #181 |
| autoimmunity disease | #181 |
| genetic influence | #181 |
| hormone melatonin | #182 |
| arginine deiminases | #182 |
| immunoglobulin mice mice | #185 |
| rats reactive | #186 |
| cells lymph nodes | #186 |
| antigen processing presentation | #186 |
| multistep process | #186 |
| drb1 chains | #187 |
| b10 | #187 |
| dba | #187 |
| tcell recognition | #187 |
| substrains | #188 |
| chondritis | #188 |
| molecular peptide | #188 |
| cells disease | #189 |
| mtec | #189 |
| synovial membranes | #190 |
| positionally | #190 |
| inflamed joint | #190 |
| hnrnpa2b1 | #190 |
| oligodendrocyte glycoprotein | #191 |
| autoantibody profiles | #192 |
| ly1 | #192 |
| cross‐reactivity | #192 |
| passive mice mice | #193 |
| fmlf | #193 |
| proteins myelin | #194 |
| glycoprotein peptide | #194 |
| cyclic predictive | #194 |
| perpetuate | #195 |
| mhv | #195 |
| mice mutant | #195 |
| chapter 16 | #195 |
| mhc class expression | #196 |
| tcell response | #196 |
| oophorectomized | #196 |
| lewis rat | #196 |
| myelin glycoprotein | #196 |
| pannus | #197 |
| acutephase response | #197 |
| evidence development | #197 |
| multiplex assay | #197 |
| igmrf | #198 |
| early appearance | #198 |
| swedish patients | #198 |
| genetic links | #198 |
| interleukin17 | #199 |
| dr4 antigen | #199 |
| rat genome | #199 |
| hla association | #200 |
| citrullinated peptide | #200 |
| cell collagen | #200 |
| pathogenesis autoimmune | #201 |
| myelin proteolipid protein | #202 |
| instigation | #202 |
| dendritic cells macrophages | #202 |
| acpa status | #202 |
| myelin proteins myelin | #202 |
| complete elimination | #203 |
| mice cells | #203 |
| 2 complex | #204 |
| spleen staining | #204 |
| class molecules | #204 |
| immunization immunoglobulin | #204 |
| nonparametric tlymphocytes | #205 |
| macrophages mice | #205 |
| dth response | #205 |
| suppresses | #205 |
| ides | #205 |
| native collagen | #205 |
| defb4 | #206 |
| betaestradiol | #206 |
| wild rats | #206 |
| interleukin4 mice mice | #207 |
| desmoglein 3 | #207 |
| noxs | #207 |
| mice peptide | #207 |
| alternative complement pathway | #207 |
| insulitis diabetes | #207 |
| intranasal challenge | #207 |
| parental strains | #207 |
| induced upregulation | #207 |
| immunization mice | #208 |
| vivo patients | #208 |
| naive mice | #208 |
| highest probability | #208 |
| antigen presenting | #208 |
| severity disease | #208 |
| cotwins | #209 |
| immunoglobulin vh | #209 |
| disease rheumatoid | #209 |
| valuable tools | #210 |
| highfatdiet | #210 |
| vav1 | #210 |
| specific antibodies | #210 |
| susceptible strains | #210 |
| citrullinated vimentin | #210 |
| glucose6 phosphate | #211 |
| hla dr4 | #211 |
| diseases genetic | #211 |
| natural antibodies | #211 |
| purified protein derivative | #211 |
| large numbers | #212 |
| association rheumatoid arthritis | #212 |
| cells immobilized | #212 |
| psoriasiform | #213 |
| antibody binding | #213 |
| mice injected | #213 |
| tsst1 | #214 |
| mhc class antigens | #215 |
| antigen induced | #215 |
| central tolerance | #215 |
| cytofluorometric | #215 |
| triethylsilane | #215 |
| inbred rat | #215 |
| training hiit | #216 |
| lower level | #216 |
| dissect | #216 |
| lentiviral vector | #217 |
| rats immunization | #217 |
| joints mice | #217 |
| induced autoimmune | #217 |
| inflammatory infiltrates | #217 |
| resistant strain | #217 |
| cd23 | #217 |
| treatment onset | #218 |
| antigen tcell | #218 |
| granuloma formation | #219 |
| peptide antibodies | #219 |
| k8 | #219 |
| fcrγ | #219 |
| autoimmunity | #219 |
| cells autoimmune | #220 |
| bone erosions | #220 |
| hyl | #220 |
| peptidylarginine deiminases | #220 |
| targeted deletion | #221 |
| redox signaling | #221 |
| pinealectomy | #221 |
| cells dendritic | #221 |
| agouti rats | #221 |
| cyclosporin treatment | #221 |
| fine specificity | #221 |
| rheumatoid factor | #221 |
| wkymvm | #222 |
| thymectomized | #222 |
| monoclonal antigens differentiation | #222 |
| cybb | #222 |
| cartilage damage | #222 |
| carbamylated | #223 |
| igg2a | #223 |
| multiplex | #223 |
| experimental autoimmune neuritis | #223 |
| inflammation vivo | #224 |
| expressing | #224 |
| established disease | #225 |
| cells antigen | #225 |
| interleukin‐10 | #225 |
| lew | #225 |
| clinical scoring | #225 |
| pathogenic antibodies | #226 |
| disease locus | #226 |
| macrophagelike cells | #227 |
| j1 | #227 |
| arthritis objective | #228 |
| delayed type hypersensitivity | #228 |
| presenting cells | #228 |
| cell selection | #229 |
| presence anti | #229 |
| site inflammation | #230 |
| eae rats | #230 |
| human rheumatoid | #231 |
| ls1 | #231 |
| reactive oxygen | #232 |
| monoclonal immunohistochemistry | #232 |
| production ros | #233 |
| ameliorated | #233 |
| synovial joints | #233 |
| lack expression | #233 |
| role eosinophils | #233 |
| centimorgan | #234 |
| lower numbers | #234 |
| staphylococcal infection | #235 |
| chromosome 14 | #235 |
| chronic psychosocial stress | #235 |
| mhc gene | #235 |
| specificity animals | #236 |
| immune complex | #236 |
| control strain | #237 |
| pathological mechanisms | #237 |
| progression arthritis | #238 |
| autoimmune chronic | #238 |
| trait locus | #239 |
| c5 | #239 |
| inbred dba tlymphocytes | #240 |
| study plasma | #241 |
| strong influence | #242 |
| joint pain | #242 |
| positive anti | #243 |
| protected | #243 |
| class genetic | #243 |
| multicomponent | #243 |
| hla drb1 | #243 |
| monoclonal antigen | #243 |
| common denominator | #244 |
| treatment autoimmune | #244 |
| crosses | #244 |
| estrus cycle | #244 |
| cutaneous infection | #244 |
| inflammation cartilage | #244 |
| binding antibodies | #245 |
| allelic differences | #246 |
| rt1l | #246 |
| development emphysema | #246 |
| antibody response | #247 |
| normal cartilage | #247 |
| antibodies anti | #247 |
| inbred strain | #247 |
| new model | #247 |
| florescence | #247 |
| activity assays | #248 |
| efficient expression | #248 |
| induced chronic | #249 |
| oxygen species | #249 |
| fragments rats | #250 |
| picryl | #250 |
| node cells | #250 |
| mouse rat | #250 |
| arthritic joints | #250 |
| inflammation score | #250 |
| hyperinflammation | #251 |
| develops | #251 |
| treatment rats | #251 |
| conditional knockout mice | #251 |
| nadph oxidase | #251 |
| role model | #252 |
| response disease | #252 |
| mice lymphocytes | #252 |
| mice lack | #252 |
| dark agouti | #252 |
| cartilage matrix | #254 |
| lpr mice | #254 |
| proteins glycoproteins | #254 |
| dinitrofluorobenzene | #254 |
| lacking | #254 |
| onset clinical | #254 |
| class mhc | #254 |
| inbred c3h | #255 |
| autoimmune response | #255 |
| specific neutralizing | #256 |
| specific subgroups | #256 |
| inflammatory disorder | #256 |
| anti arthritic | #256 |
| postmenopausal bone | #256 |
| disease cell | #257 |
| additive interaction | #258 |
| class mhc molecules | #259 |
| relationship immunologic | #260 |
| mir144 | #260 |
| chronic granulomatous | #260 |
| denatured | #261 |
| mice expressing | #261 |
| secondary osteoporosis | #261 |
| mediated suppression | #261 |
| autoimmune neuritis | #261 |
| lymphocytes helper | #261 |
| immunologic animals | #262 |
| selfantigen | #263 |
| genetic techniques | #265 |
| crossreactive | #265 |
| primary immunization | #265 |
| pregnancy mice | #265 |
| tolerance mice | #265 |
| mouse strain | #265 |
| cysteine proteases | #267 |
| antigen specific | #267 |
| rats animals | #267 |
| vim2 | #267 |
| lentiviral gene | #268 |
| posttranslational modifications | #268 |
| xid | #268 |
| mann whitney | #269 |
| pathogenic roles | #269 |
| oxpl | #270 |
| complement c5 | #270 |
| castrated | #271 |
| monosodium urate crystals | #271 |
| melatonin effects | #271 |
| selfantigens | #271 |
| amino acid transporters | #273 |
| experimental model | #273 |
| lewis rats | #274 |
| nasally | #275 |
| tcells | #275 |
| inhibitory peptide | #275 |
| hdac1 | #275 |
| synovial lining | #275 |
| fcgr3b | #276 |
| macrophages dendritic cells | #276 |
| producing cells | #277 |
| deiminase type | #277 |
| rheumatoid arthritis association | #277 |
| viral female hepatitis | #277 |
| metabolic properties | #278 |
| recognize | #278 |
| interferongamma | #279 |
| colon length | #279 |
| gp70 | #279 |
| dinucleotide phosphate | #280 |
| induced tolerance | #280 |
| immunological receptors antigen | #281 |
| recipient mice | #281 |
| inflammatory conditions | #281 |
| neonatal mice | #281 |
| passive transfer | #281 |
| hemiacetal | #282 |
| isoflavone genistein | #283 |
| disease susceptibility | #283 |
| factor production | #283 |
| inbred nod | #283 |
| igg2b | #283 |
| aire | #284 |
| increased serum levels | #284 |
| severe colitis | #284 |
| helper inducer | #284 |
| complete protection | #285 |
| endophilin | #285 |
| idiotope | #285 |
| theilovirus | #285 |
| maintained | #285 |
| aureus strain | #285 |
| publication animals antibodies | #285 |
| emulsified | #286 |
| hla dr2 | #287 |
| melatonin release | #288 |
| melatonin mice | #288 |
| antibody production | #288 |
| tlr9 mice | #288 |
| myelin basic protein | #288 |
| cells autoimmunity | #289 |
| mice immunized | #289 |
| disease cells | #291 |
| synovial cells | #291 |
| ctla4 expression | #291 |
| rheumatic conditions | #292 |
| autoimmune mechanisms | #292 |
| increased copy | #293 |
| cytokines disease | #293 |
| induced ros | #293 |
| collagen receptors | #293 |
| mouse genes | #294 |
| unique model | #294 |
| c3h | #295 |
| antigen processing | #295 |
| c57bl 6 mice | #295 |
| gastric parietal | #295 |
| nerve conduction | #296 |
| 6week | #296 |
| tissue‐specific | #296 |
| immunological receptors | #296 |
| murine dendritic cells | #297 |
| helical peptides | #297 |
| dnfb | #297 |
| phosphopyruvate | #297 |
| ppad | #298 |
| vivo imaging | #298 |
| gene selection | #298 |
| cd19 cells | #298 |
| citrullination | #299 |
| transplantation antigens | #299 |
| solidphase synthesis | #299 |
| tcr beta | #300 |
| neutrophil extracellular traps | #301 |
| posttranslational rats | #301 |
| draining lymph | #302 |
| peptide antibody | #302 |
| alphabeta | #302 |
| extraembryonic tissues | #302 |
| epidemiological investigation | #303 |
| pathogeneses | #303 |
| strains mice | #303 |
| animals antibodies | #303 |
| 1 interferon | #303 |
| conditioned disease models | #304 |
| cgd | #304 |
| autoimmune diseases | #304 |
| igg glycosylation | #304 |
| cells tcr | #305 |
| cartilage development | #305 |
| immunological function | #305 |
| mutant strains mice | #305 |
| immunological studies | #306 |
| gammaifn | #306 |
| murine colitis | #306 |
| αgalcer | #306 |
| hcdr3 | #306 |
| class histocompatibility | #307 |
| inpp4b | #307 |
| immunisation | #307 |
| basal metabolic rate | #308 |
| basal metabolic | #309 |
| chromosome 10 | #309 |
| arthritis study | #310 |
| articular cattle cells | #310 |
| multiple sclerosis eae | #311 |
| perpetuation | #311 |
| synthetic peptide | #312 |
| disease symptoms | #312 |
| alleles animals | #312 |
| inflamed joints | #312 |
| exuberant | #313 |
| c3bi | #313 |
| epitopes | #313 |
| induced colitis | #314 |
| activatory | #314 |
| intradermally | #315 |
| mice genes | #315 |
| r620w | #315 |
| trypanosoma brucei brucei | #316 |
| onset rheumatoid | #318 |
| classical risk factors | #318 |
| genetic interactions | #319 |
| galactosyl | #319 |
| tubule cells | #319 |
| spleen bone marrow | #320 |
| genomewide linkage analysis | #320 |
| deiminase | #320 |
| mice subjected | #320 |
| il21r | #323 |
| cells specific | #323 |
| impact disease | #324 |
| ccp1 | #324 |
| expressing human | #324 |
| daf2 | #324 |
| expression cells | #325 |
| rat gene | #325 |
| specific cell | #325 |
| surprisingly | #326 |
| resembles | #327 |
| mgps | #327 |
| c57bl mice | #328 |
| allelic variant | #328 |
| constant light | #329 |
| immunoenzyme | #329 |
| publication adjuvants | #329 |
| complex genes | #330 |
| early arthritis | #331 |
| rheumatoid synovial | #332 |
| fcgammariia | #332 |
| glycoprotein mog | #332 |
| nucleotide polymorphism | #332 |
| mouse hepatitis virus | #333 |
| anticcp | #333 |
| 35ssulfate | #334 |
| susceptibility genes | #335 |
| joint tissues | #335 |
| mrl lpr mice | #335 |
| autoimmune inflammation | #336 |
| cell response | #338 |
| epitope specificity | #340 |
| cells spleen | #340 |
| delayed onset | #340 |
| rat | #341 |
| adjuvants immunologic | #341 |
| erosive | #341 |
| activation macrophages | #341 |
| ros oxygen species | #341 |
| animal enzyme inhibitors | #342 |
| specific autoimmune | #342 |
| 6weeks | #342 |
| incident cardiovascular events | #342 |
| rapid spread | #343 |
| drb1 alleles | #343 |
| diabetic mouse | #343 |
| sequence animals | #343 |
| rats injection | #343 |
| 182780 | #344 |
| monoclonals | #344 |
| acpa positivity | #345 |
| favor | #345 |
| energetic costs | #346 |
| intraperitoneal injection | #347 |
| pemphigus vulgaris pv | #348 |
| reduced capacity | #349 |
| neuritis | #349 |
| complement activity | #349 |
| igg autoantibodies | #350 |
| phenotype rats | #351 |
| thymic selection | #352 |
| methylcholanthrene | #352 |
| c3h hej | #353 |
| immunoregulation | #353 |
| anti cyclic | #353 |
| mice induction | #353 |
| autoantigens autoimmune | #354 |
| arthritis synovial | #354 |
| mice cd4 | #354 |
| splenic macrophages | #355 |
| dsg3 | #357 |
| cells autoantibodies | #358 |
| tbetarii | #358 |
| adjuvant activity | #358 |
| injected | #359 |
| neuritogenic | #359 |
| enos | #359 |
| tcrbeta | #360 |
| tlr3 | #361 |
| pvg | #361 |
| freund | #361 |
| murine lupus | #362 |
| hla transgenic | #362 |
| allergic encephalomyelitis | #363 |
| identification genes | #363 |
| mouse chromosome | #363 |
| generation ros | #363 |
| determines | #363 |
| cells anti | #364 |
| hladr4 | #364 |
| recognized | #364 |
| sex chromosomes | #366 |
| glycoproteins mice | #366 |
| european journal | #366 |
| immune deviation | #366 |
| psychosocial stress | #367 |
| antiidiotypic antibodies | #367 |
| affinity ligand | #368 |
| loci | #368 |
| toxic shock | #368 |
| 100 micrograms | #368 |
| ncf2 | #368 |
| autoimmune responses | #368 |
| histocompatibility antigens | #369 |
| nasal administration | #369 |
| pentameric | #369 |
| immune pathogenesis | #370 |
| increased production | #370 |
| clinical onset | #371 |
| regulate | #371 |
| serum transfer | #371 |
| role mif | #372 |
| newborn antibodies | #372 |
| alternative activation | #373 |
| autoantigens | #375 |
| rheumatoid cell | #375 |
| undifferentiated arthritis | #376 |
| acutephase proteins | #376 |
| glucose6 | #377 |
| gia | #379 |
| reparixin | #380 |
| mouse monoclonal antibody | #381 |
| oxidase deficiency | #381 |
| induced lupus | #381 |
| fragments immunoglobulin | #382 |
| fia | #382 |
| granulomatous | #383 |
| granulomatous disease | #384 |
| specific loci | #384 |
| naive rats | #384 |
| c1a | #384 |
| postmenopausal bone loss | #385 |
| shock syndrome | #385 |
| pc4 | #386 |
| cell specificity | #386 |
| antioxid | #387 |
| ptpn22 gene | #387 |
| filaggrin | #387 |
| backcrosses | #387 |
| phase response | #388 |
| inbred nod receptors | #388 |
| downregulating | #389 |
| deficient | #390 |
| ovulation rate | #390 |
| greater 50 | #390 |
| anaphylatoxin c5a | #391 |
| peptidylarginine | #391 |
| radiological progression | #391 |
| finetune | #392 |
| rf1 | #394 |
| il4 il10 | #394 |
| ameliorating | #395 |
| draining | #397 |
| induced metabolic | #397 |
| autoantibody levels | #397 |
| juvenile chronic arthritis | #398 |
| immunized mice | #399 |
| protein myelin | #399 |
| regulation animals | #399 |
| inflammatory reactions | #400 |
| reactive oxygen species | #400 |
| antibody formation | #401 |
| genes cells | #401 |
| biacore | #403 |
| inflammation demyelination | #403 |
| immunopeptidome | #403 |
| beta chain | #404 |
| fcγriib | #404 |
| experimental | #405 |
| basic protein | #405 |
| effects models | #407 |
| rheumatoid case | #407 |
| n31 | #407 |
| pam3csk4 | #408 |
| major locus | #409 |
| immunogenetics | #409 |
| intracellular processing | #410 |
| 3hproline | #410 |
| diabetes loci | #410 |
| cd43 | #412 |
| cell phenotypes | #412 |
| hladrb1 | #412 |
| titres | #413 |
| susceptibility loci | #413 |
| characteristic feature | #414 |
| reproductive performance | #414 |
| cultured collagen | #415 |
| igk | #415 |
| levels autoantibodies | #416 |
| female mice | #416 |
| synovial inflammation | #417 |
| spontaneous mutation | #417 |
| lupus mice | #417 |
| genetically modified mice | #418 |
| wtccc | #419 |
| induced pain | #419 |
| class hdacs | #419 |
| molecular interactions | #419 |
| hiit | #420 |
| ameliorate | #420 |
| tcell | #421 |
| dr4 | #422 |
| lower affinity | #422 |
| lipidomic | #423 |
| restricted | #424 |
| subsets animals | #424 |
| hyaline cartilage | #425 |
| inflammatory cells | #426 |
| regulatory animals | #426 |
| congenic strain | #426 |
| carbohydrate moiety | #429 |
| epitopes humans | #430 |
| nod mouse | #430 |
| nonimmunogenic | #430 |
| postimmunization | #430 |
| immunoregulatory | #431 |
| il10 mice | #433 |
| patients healthy individuals | #433 |
| cells antibodies | #434 |
| spontaneous autoimmune | #435 |
| factor 5 | #435 |
| cells beta | #436 |
| reactivities | #436 |
| chromosomes chromosome | #437 |
| decalcified | #437 |
| crystallizable | #437 |
| mass spectrometric analysis | #437 |
| immunised | #438 |
| specific antigens | #438 |
| mice effects | #438 |
| helperinducer tlymphocytes | #438 |
| joint swelling | #439 |
| cells | #439 |
| wildtype mice | #440 |
| nod | #440 |
| female immunoglobulin | #441 |
| normal rats rats | #441 |
| vitro techniques leukocytes | #441 |
| effector functions | #441 |
| complete adjuvant | #442 |
| mice activation | #442 |
| patients population | #442 |
| methylβcyclodextrin | #443 |
| mhc class molecules | #443 |
| myelin basic | #444 |
| tlr2 expression | #444 |
| genomewide scan | #445 |
| systemic mice | #445 |
| mice humans | #445 |
| mouse models | #445 |
| skeletal muscle function | #445 |
| ros production | #447 |
| inbred strains receptors | #448 |
| control mice | #448 |
| pain model | #448 |
| induced mice | #448 |
| synovial tissue | #449 |
| tcell responses | #449 |
| complement factor | #449 |
| innate adaptive | #450 |
| apcs | #451 |
| igg anti | #451 |
| heterologous | #452 |
| hybridoma cells | #452 |
| reduced production | #452 |
| differs | #454 |
| lglutamine | #456 |
| cells chronic | #456 |
| inbred c57bl tlymphocytes | #457 |
| raloxifene | #457 |
| eae cns | #459 |
| rheumatoid cells | #459 |
| resembling | #459 |
| priming | #459 |
| lung macrophages | #459 |
| antibodies monoclonal | #460 |
| neutrophil functions | #462 |
| 256 | #462 |
| autoantigen | #462 |
| gilt | #463 |
| fab fragments | #464 |
| autoantibody production | #465 |
| receptor tcr | #466 |
| salivary glands | #466 |
| cells lymph | #467 |
| earlier onset | #469 |
| titers | #469 |
| anticyclic citrullinated peptide | #474 |
| disease mice | #474 |
| antibody mediated | #474 |
| arthritic rats | #474 |
| cartilage cells | #475 |
| human autoimmune | #476 |
| cluster genes | #477 |
| mice exhibited | #477 |
| therapeutic vaccination | #478 |
| mediated inflammation | #478 |
| female hla | #479 |
| apoptosis arthritis | #479 |
| laboratory rat | #479 |
| aggravated | #480 |
| deacetylase 1 | #480 |
| quantitative trait loci | #480 |
| anti idiotypic | #482 |
| polymorphonuclear cells | #482 |
| immune reactions | #484 |
| immunologists | #485 |
| immunoglobulin male | #486 |
| tcralpha | #487 |
| jca | #487 |
| controlling | #487 |
| oxyntic | #487 |
| specific immune | #488 |
| invariant natural | #488 |
| insulitis | #488 |
| gland animals | #489 |
| normal mice | #490 |
| cytoplasmic calcium | #494 |
| nacetylglucosaminidase | #495 |
| h2b | #496 |
| early rheumatoid | #496 |
| reactive nitrogen | #496 |
| gammadelta cells | #496 |
| conclude | #496 |
| mbp | #498 |
| small effects | #498 |
| receptor 9 | #499 |
| biologicals | #500 |
| autoreactive cd4 | #503 |
| immunoenzyme techniques | #503 |
| nadph | #503 |
| pathogenic | #506 |
| immunofluorescence analysis | #507 |
| chondrocytes collagen | #507 |
| isopropyl | #508 |
| persistent pain | #508 |
| mab mabs | #508 |
| mineral oil | #508 |
| gingipain | #509 |
| immunization passive | #509 |
| orosomucoid | #509 |
| mhc class | #510 |
| mice knockout mice | #510 |
| 812 | #511 |
| systemic spread | #511 |
| differential gene | #511 |
| c3h hej mice | #511 |
| deficient mice | #511 |
| blymphocytes | #512 |
| mrp8 | #515 |
| hydroxyquinolines | #517 |
| behavioral alterations | #517 |
| antibody complex | #518 |
| u1 | #518 |
| chronic granulomatous disease | #519 |
| suggestive linkage | #519 |
| inflammation | #519 |
| tcr recognition | #520 |
| modified form | #521 |
| dextran sulfate sodium | #522 |
| ttg | #522 |
| pcorr | #522 |
| data peptide | #523 |
| inflammation role | #523 |
| encephalitogenic | #524 |
| litter size | #524 |
| p47phox | #524 |
| neutrophil granulocytes | #525 |
| mechanical hypersensitivity | #526 |
| tconv | #526 |
| mnc | #526 |
| maternal antibodies | #527 |
| disease acute | #527 |
| spleen cells | #527 |
| tolonium | #528 |
| primed | #528 |
| vaccinates | #528 |
| larsen | #528 |
| displayed | #529 |
| tolllike receptor tlr4 | #529 |
| ifa | #529 |
| rat rats | #529 |
| antigen presentation | #530 |
| pathogenesis sle | #530 |
| cell antibodies | #530 |
| isac | #530 |
| autoantibody | #530 |
| ratg | #531 |
| bred | #532 |
| epistatic | #532 |
| lyt2 | #533 |
| complex role | #533 |
| posttranslational receptors | #534 |
| translational modification | #536 |
| resorptions | #536 |
| spleen lymphocytes | #536 |
| urokinase | #537 |
| synovial | #537 |
| animals | #538 |
| experimental rats | #538 |
| cells inflammatory | #538 |
| antigen recognition | #540 |
| suppressive | #540 |
| joints | #540 |
| fibroblast synoviocytes | #540 |
| membrane attack complex | #541 |
| rheumatoid humans | #543 |
| specific autoantibodies | #544 |
| regulating | #545 |
| protein tyrosine phosphatase | #545 |
| hypomorphic | #546 |
| animal gene | #547 |
| shortcut | #547 |
| tlymphocytes | #547 |
| formyl peptide receptors | #548 |
| entheses | #548 |
| immunohistochemical methods | #548 |
| mog | #550 |
| immunoglobulin fab | #552 |
| mixed lymphocyte reaction | #553 |
| nox activity | #554 |
| breeder | #555 |
| beta animals | #557 |
| stronger association | #557 |
| cell epitopes | #557 |
| cells control | #558 |
| early onset | #559 |
| healthy mice | #560 |
| elispot assay | #561 |
| transgenic molecular | #562 |
| ptdins3p | #563 |
| negative selection | #563 |
| inbred strains | #563 |
| neutrophil depletion | #564 |
| deeper layers | #565 |
| therapeutic treatment | #565 |
| immunoglobulin heavy chains | #566 |
| target tissue | #566 |
| earlier | #566 |
| darkness | #566 |
| crucial | #567 |
| outbred | #568 |
| interferon signature | #568 |
| disease loci | #568 |
| cells pathogenesis | #569 |
| mycobacteria | #569 |
| neutrophilia | #569 |
| concomitantly | #570 |
| mice compared | #571 |
| transgenic mouse models | #572 |
| btla | #572 |
| keratin8 | #573 |
| col2 | #574 |
| presenting | #576 |
| pepstatins | #576 |
| estrogen treatment | #577 |
| terpenes | #577 |
| keratinocyte growth factor | #578 |
| prolactin prl | #578 |
| ptm | #579 |
| sera patients | #579 |
| triple helix | #580 |
| methotrexate mice | #581 |
| f1 hybrids | #581 |
| inflammatory joint | #583 |
| production ifngamma | #583 |
| hybridoma | #583 |
| lymphocyte antigens | #584 |
| time onset | #584 |
| exaggerated | #584 |
| antibody reactions | #585 |
| traps nets | #590 |
| environmental triggers | #591 |
| antigen antibody | #591 |
| immunological tolerance | #592 |
| lxrα | #592 |
| oligoclonal | #592 |
| transgenic models | #593 |
| noncollagenous | #593 |
| macrophages | #594 |
| adaptive immunity | #594 |
| autoimmune disorders | #594 |
| multiplexing | #595 |
| th1 cytokines | #595 |
| clonal expansion | #595 |
| xanthine oxidoreductase | #596 |
| cells study | #599 |
| tcell activation | #599 |
| develop | #600 |
| augmented | #602 |
| th2 cytokines | #602 |
| n85 | #602 |
| spite | #602 |
| mouse monoclonal | #603 |
| pemphigus vulgaris | #603 |
| common diseases | #603 |
| cells male | #604 |
| phagosomal | #604 |
| cells involved | #604 |
| oxa | #606 |
| mice inbred | #606 |
| animal rats | #606 |
| class humans | #607 |
| genotype hla | #608 |
| frozen sections | #608 |
| spleen animals | #609 |
| inefficiently | #610 |
| regulatory role | #610 |
| production ifn | #611 |
| naive | #611 |
| positive individuals | #612 |
| quantitative trait locus | #615 |
| mutant strains receptors | #616 |
| alpha chains | #616 |
| exponential phase | #616 |
| acetophenones | #616 |
| class antigens | #616 |
| autoantibodies | #616 |
| idiotypic | #616 |
| th1 type | #616 |
| oral immunization | #617 |
| nonobese | #617 |
| beta type | #618 |
| day mice | #619 |
| wistar restraint | #620 |
| promiscuous | #620 |
| consequent | #621 |
| receptor 3 | #621 |
| inflammatory role | #621 |
| nicotinamide adenine | #622 |
| fluorine18 | #624 |
| receptors antigen | #624 |
| loci identified | #625 |
| chronic stage | #625 |
| animal mice | #628 |
| cytoplasmic ca2 | #628 |
| local injection | #629 |
| cross reactions | #630 |
| inflammatory disease | #630 |
| reactive antibodies | #632 |
| healthy rats | #632 |
| development eae | #633 |
| highintensity interval training | #634 |
| fibromodulin | #634 |
| langerhans cells | #635 |
| vivo binding | #635 |
| nabs | #637 |
| ifn beta | #637 |
| cells inhibition | #638 |
| class genes | #638 |
| inflammation autoimmunity | #640 |
| estrogens female | #640 |
| biotinylated | #643 |
| mouse lung | #644 |
| cell binding | #645 |
| immune serum | #646 |
| haplotype | #649 |
| antigen specificity | #650 |
| patients sera | #650 |
| genetic disease | #652 |
| idiotypic antibodies | #654 |
| hexadecane | #654 |
| interphalangeal | #655 |
| antibody titres | #655 |
| new pathway | #658 |
| genetic linkage | #658 |
| axotomized | #659 |
| sialoprotein | #660 |
| cyba | #660 |
| inbred cba mice | #661 |
| peptide binding | #661 |
| acute inflammation | #661 |
| mutated | #662 |
| cartilage destruction | #663 |
| ifng | #664 |
| animal ear | #665 |
| delayed hypersensitivity | #665 |
| reactive | #666 |
| lymphoid organs | #666 |
| receptors igg | #666 |
| 264 | #666 |
| superantigens | #666 |
| activation mice | #669 |
| apeced | #670 |
| drb1 | #670 |
| disease autoimmune | #671 |
| purified proteins | #673 |
| treatment protocol | #674 |
| cells induce | #674 |
| desmoglein | #675 |
| pyramidal neurons | #675 |
| genetic epistasis | #675 |
| strikingly | #676 |
| idiotypes | #677 |
| adherent cells | #677 |
| germinal center | #677 |
| china cohort | #678 |
| il12p70 | #679 |
| igg response | #679 |
| major genes | #679 |
| thelper | #680 |
| lymphocytes mice | #682 |
| cells role | #682 |
| puzzle | #683 |
| normal animals | #683 |
| inbred c57bl mice | #683 |
| helper cell | #684 |
| specific antibody | #684 |
| intradermal injection | #686 |
| transgenic receptors | #687 |
| βarrestin | #688 |
| subsets | #689 |
| foot joints | #689 |
| delayed | #689 |
| rendered | #690 |
| early rheumatoid arthritis | #690 |
| production autoantibodies | #691 |
| disease genes | #692 |
| muscle glucose | #695 |
| knockout polymorphism | #695 |
| paam | #696 |
| igg antibodies | #696 |
| anas | #697 |
| luminex | #697 |
| disease hla | #698 |
| mice model | #698 |
| uterus | #700 |
| heavy chain genes | #701 |
| microspectroscopy | #703 |
| inbred | #704 |
| quantitative trait | #704 |
| complete freund | #706 |
| histopathological analysis | #707 |
| fibroblastlike synoviocytes | #707 |
| extracellular trap | #708 |
| specific cells | #710 |
| estradiol female | #710 |
| igl | #712 |
| posttranslational | #713 |
| spleens | #716 |
| predetermined | #716 |
| mice lacking | #717 |
| acute bout | #718 |
| antibodies patients | #718 |
| lymphocyte depletion | #719 |
| proliferative response | #720 |
| regulatory function | #720 |
| deficiency syndromes | #721 |
| buf | #721 |
| surrounding tissues | #722 |
| th1 th17 | #723 |
| macrophages mice mice | #725 |
| human hand | #725 |
| cd1d | #728 |
| dmaema | #728 |
| mhc molecules | #729 |
| ccps | #729 |
| th2 cytokine | #729 |
| cdk6 | #730 |
| cns inflammation | #732 |
| animals antigens antigens | #732 |
| cholesterol metabolism | #732 |
| administrated | #732 |
| excessive inflammation | #734 |
| finding | #735 |
| rats treatment | #736 |
| net formation | #736 |
| locus | #737 |
| cheeks | #739 |
| operates | #740 |
| c57bl | #740 |
| species specificity | #741 |
| cd5 cells | #741 |
| nkt | #742 |
| tissue destruction | #742 |
| vivo mice | #743 |
| immunologic deficiency | #743 |
| cell responses | #743 |
| treatment anti | #744 |
| role disease | #746 |
| mycobacterial infections | #747 |
| autoantibodies autoimmunity | #749 |
| keratinocyte | #749 |
| nonobese diabetic mice | #749 |
| intensity interval | #749 |
| preclinical phase | #751 |
| transferred | #751 |
| control disease | #753 |
| metabolomic | #755 |
| hapten | #755 |
| tlr activation | #755 |
| ere | #755 |
| mice anti | #757 |
| autoantibodies type | #758 |
| phenotypic differences | #758 |
| disease protection | #758 |
| reacted | #759 |
| hyperinflammatory | #759 |
| linkage region | #760 |
| knockout tlymphocytes | #760 |
| ifngamma production | #761 |
| ccp | #761 |
| polycytidylic | #762 |
| immunocap | #763 |
| gamma ifn | #765 |
| glut4 translocation | #767 |
| periarticular | #772 |
| redox signal | #773 |
| hkexchanging | #773 |
| cells apcs | #773 |
| peripheral tolerance | #774 |
| afflicted | #777 |
| diseases cell | #778 |
| fab fragment | #778 |
| interacted | #779 |
| inbred nzb | #780 |
| acid transporters | #781 |
| arthritis osteoarthritis | #782 |
| development autoimmunity | #782 |
| nox1 | #782 |
| pathogenic role | #782 |
| arthritis psa | #783 |
| chronic colitis | #784 |
| clinical scores | #786 |
| transgenic mutation | #789 |
| reduced incidence | #790 |
| inflammatory lesions | #790 |
| transgenic receptors antigen | #790 |
| peptide fragments | #790 |
| pineal gland | #791 |
| polyarthritis | #792 |
| cell gamma | #793 |
| cell humans | #794 |
| antibodies directed | #794 |
| neutrophil function | #796 |
| interval training | #796 |
| neutrophil extracellular | #796 |
| pathogen free | #797 |
| lymphocyte proliferation | #798 |
| genes immunoglobulin | #798 |
| carbohydrate moieties | #800 |
| polyi | #801 |
| matrix proteins | #801 |
| innate adaptive immunity | #802 |
| blymphocyte chain genes | #802 |
| thy1 | #802 |
| monoclonal binding | #802 |
| redox control | #805 |
| induces | #805 |
| count male | #805 |
| helper cells | #805 |
| multinucleated giant cells | #808 |
| backcrossing | #809 |
| bone erosion | #810 |
| catabolism | #811 |
| function mutation | #811 |
| strains receptors | #812 |
| resident cells | #812 |
| acc1 | #812 |
| febuxostat | #813 |
| nonreceptor type | #815 |
| ctb | #817 |
| arginines | #817 |
| auricle | #820 |
| leads | #820 |
| cd8 antigens | #821 |
| collagen cross | #821 |
| leukocyte infiltration | #822 |
| piece | #823 |
| colocalizes | #824 |
| humoral immune response | #824 |
| electroporated | #824 |
| prominently | #825 |
| genetic environmental | #825 |
| psoriasis psoriatic arthritis | #825 |
| response animals | #826 |
| muscle training | #826 |
| chondroid | #827 |
| growth factor beta | #829 |
| class antigen | #829 |
| producing | #830 |
| effects immune | #830 |
| cross reactivity | #834 |
| inbred c57bl | #841 |
| lpr | #841 |
| immunoglobulin mice | #842 |
| peyers patches | #842 |
| diabetic nod | #844 |
| therapeutic approaches | #844 |
| chronic active | #845 |
| il25 | #845 |
| mice transgenic | #846 |
| inflammatory arthritis | #846 |
| induce | #848 |
| intermingled | #850 |
| macroscopically | #851 |
| antigen cell | #852 |
| lymphocyte | #852 |
| new possibilities | #854 |
| leukocyte migration | #854 |
| ms275 | #855 |
| tcell receptors antigen | #855 |
| alveolar mice mice | #856 |
| importantly | #856 |
| strongest association | #856 |
| mcv | #858 |
| post translational | #861 |
| immune defence | #862 |
| treatment reduced | #865 |
| lyme | #866 |
| mediated inflammatory | #867 |
| knockin mice | #867 |
| factor anti | #867 |
| mice reduced | #867 |
| cross reactive | #868 |
| strongest | #868 |
| lentiviral | #869 |
| parietal cells | #869 |
| hinge region | #869 |
| lnc | #872 |
| immune tolerance | #873 |
| dextran sulfate | #873 |
| lower expression | #874 |
| parasitemia | #874 |
| elisas | #875 |
| cells expressing | #876 |
| granulomas | #877 |
| fcγri | #878 |
| synovial fluid patients | #878 |
| arthritis inflammatory | #879 |
| adoptive | #881 |
| antigen4 | #881 |
| pregnancy animal | #882 |
| systemic autoimmune diseases | #882 |
| testosterone treatment | #883 |
| fluid synovial | #884 |
| cartilaginous | #888 |
| standard therapies | #890 |
| genetic dissection | #891 |
| psoriasis vulgaris | #891 |
| basic | #893 |
| regulator | #895 |
| completely | #896 |
| intranasal administration | #897 |
| inflammation mediators | #897 |
| ctla4 antigen | #898 |
| interleukin1alpha | #898 |
| phosphatase receptor | #902 |
| partly | #904 |
| granulocytes | #904 |
| inception cohort | #905 |
| γδ cells | #906 |
| infiltrations | #906 |
| rats inbred | #907 |
| lipocalins | #908 |
| extracellular traps | #909 |
| immunohistochemical analyses | #910 |
| single injection | #911 |
| immunoglobulin levels | #911 |
| liu | #911 |
| chromosome 16 | #912 |
| mitochondrial ros | #913 |
| lectin pathway | #913 |
| ciita | #914 |
| pneumonitis | #914 |
| proliferate | #915 |
| allelic variation | #915 |
| enolase | #915 |
| immunemediated diseases | #916 |
| cytokine response | #923 |
| psoriatic arthritis psa | #924 |
| neutrophil chemotaxis | #924 |
| antibodies antibody | #924 |
| chromosome mapping | #925 |
| fluorobenzene | #925 |
| cd200 | #925 |
| phenotypic analysis | #926 |
| nkt cells | #926 |
| repertoires | #929 |
| burst | #930 |
| tissue transglutaminase | #931 |
| data role | #932 |
| hydratase | #933 |
| citrulline | #933 |
| alpha animals | #935 |
| macropinocytosis | #936 |
| alters | #937 |
| arthritides | #938 |
| lymphocyte activation | #938 |
| 1040 | #939 |
| synovia | #939 |
| rns | #940 |
| immune reactivity | #940 |
| analysed | #940 |
| vitro stimulation | #941 |
| collagen structure | #941 |
| genetic analysis | #941 |
| disease model | #941 |
| mediated autoimmune | #944 |
| association hla | #945 |
| sciatic nerves | #945 |
| mice mice | #947 |
| inflammatory pathways | #948 |
| clinical observations | #948 |
| fluid patients | #948 |
| humanized mice | #949 |
| riii | #950 |
| vivo | #950 |
| l3t4 | #954 |
| environmental determinants | #955 |
| nos1 | #957 |
| carrying | #958 |
| differentiation tlymphocyte antigens | #959 |
| levels ros | #962 |
| mhc peptide | #962 |
| chronic disease | #963 |
| cellular immunization | #965 |
| cytotoxic tlymphocytes | #967 |
| cells lymphocytes | #967 |
| animals cytokines | #967 |
| monoclonal antigens | #967 |
| cell transfer | #969 |
| lower frequency | #969 |
| chromosome 15 | #971 |
| draining lymph nodes | #972 |
| secreting cells | #973 |
| susceptibility locus | #978 |
| cartilage articular | #979 |
| synovial membrane | #981 |
| w5 | #982 |
| genes chromosome | #982 |
| lymphocytes | #982 |
| binding peptides | #983 |
| pain behavior | #984 |
| tbb | #987 |
| tallele | #988 |
| microspectrophotometry | #990 |
| macrophages cells | #991 |
| knockout models | #991 |
| allergic contact dermatitis | #992 |
| immunodominance | #992 |
| cells reactive | #993 |
| patients rp | #994 |
| transgenic expression | #994 |
| 510 | #994 |
| cartilage bone | #995 |
| hej | #995 |
| spontaneously | #997 |
| formyl peptide | #997 |
| knee joints | #997 |
| laminin fibronectin | #998 |
| antigen expression | #999 |
| immunoglobulin fragments | #1000 |
| lymphocyte subpopulations | #1002 |
| multiple loci | #1003 |
| expands | #1004 |
| processing presentation | #1004 |
| aggravate | #1004 |
| protective role | #1007 |
| igg subclasses | #1011 |
| nrc | #1012 |
| cyclic peptides | #1012 |
| 95 stroke | #1013 |
| interleukin21 | #1013 |
| model multiple | #1015 |
| igg | #1015 |
| direct comparison | #1015 |
| nerve roots | #1016 |
| cells mast | #1016 |
| cellular composition | #1016 |
| aged arthritis | #1017 |
| patients early | #1019 |
| melatonin levels | #1019 |
| cd4 antigens | #1020 |
| immunoglobulin variable | #1022 |
| cysteine protease | #1025 |
| diseases animals | #1026 |
| genetic humans | #1027 |
| innate killer cells | #1028 |
| il4 | #1029 |
| dr1 | #1031 |
| baseline 24 months | #1031 |
| mice treated | #1032 |
| oxidase | #1034 |
| major regulator | #1036 |
| species production | #1039 |
| tramp | #1040 |
| arthritis psoriatic | #1041 |
| expression mrna | #1042 |
| complementary genes | #1043 |
| das28 | #1045 |
| myelin proteins | #1050 |
| parental strain | #1050 |
| patients rheumatoid | #1051 |
| chromosome 5 | #1052 |
| inflammatory macrophages | #1055 |
| gamma delta | #1055 |
| antigens differentiation | #1056 |
| immune defense | #1056 |
| mannans | #1057 |
| rat cells | #1060 |
| sterile inflammation | #1062 |
| morula | #1062 |
| lymphocytes cells | #1062 |
| transgenic | #1063 |
| tarsus | #1066 |
| role immune | #1069 |
| decidua | #1069 |
| disease humans polymorphism | #1069 |
| oxazoles | #1069 |
| synovial fluids | #1071 |
| transgenic cells | #1075 |
| fcγ | #1076 |
| radiological | #1077 |
| peptidylarginine deiminase | #1078 |
| epistasis | #1079 |
| key steps | #1080 |
| adjuvant cfa | #1080 |
| reestablishment | #1082 |
| lymphoid cells | #1082 |
| irf1 | #1086 |
| dependent regulation | #1087 |
| al2 | #1088 |
| uppsala | #1089 |
| haplotypes | #1089 |
| enlarged | #1091 |
| inflamed | #1092 |
| osteoclast formation | #1093 |
| 7 weeks | #1096 |
| oligodendrocyte | #1098 |
| inkt cells | #1102 |
| igs | #1103 |
| effector mechanisms | #1104 |
| cells increased | #1105 |
| arginine deiminase | #1114 |
| molecular mimicry | #1115 |
| fibril | #1115 |
| subdominant | #1115 |
| sclerosis myelin | #1116 |
| clinical disease | #1116 |
| cd5 | #1117 |
| genetic factors | #1117 |
| deamidation | #1117 |
| animal immunity | #1117 |
| antitoxin | #1117 |
| disulfide | #1117 |
| antigenic peptides | #1118 |
| pil | #1121 |
| lymphocytes regulatory | #1123 |
| recognizing | #1126 |
| primary immunodeficiency | #1127 |
| cells ifn | #1128 |
| predisposing | #1128 |
| foreign antigens | #1128 |
| humans lymphocyte | #1128 |
| isomerase | #1128 |
| dissected | #1130 |
| treatment day | #1132 |
| skeletal muscle fibers | #1132 |
| superantigen | #1134 |
| cryosections | #1135 |
| immune response | #1135 |
| vivo administration | #1136 |
| glucosyl | #1136 |
| overlapped | #1136 |
| c57 | #1137 |
| underline | #1138 |
| peptide sequence | #1138 |
| editorial | #1139 |
| anticardiolipin antibodies | #1139 |
| cd4foxp3 | #1142 |
| mice rats | #1146 |
| syntenic | #1147 |
| treatment animals | #1149 |
| helpers | #1149 |
| agonist | #1150 |
| cd4 cells | #1151 |
| subcloned | #1155 |
| disease onset | #1157 |
| antibody affinity | #1160 |
| inactivating | #1161 |
| lxr | #1161 |
| respiratory burst | #1163 |
| prolactin rats | #1164 |
| demonstrating | #1168 |
| stainings | #1168 |
| increased severity | #1170 |
| activated cells | #1171 |
| transduction toll | #1174 |
| gp91phox | #1175 |
| nadph oxidoreductases | #1176 |
| inflamed tissues | #1178 |
| models disease | #1178 |
| 10b | #1179 |
| preponderance | #1180 |
| recombinant interferon | #1180 |
| genetic background | #1181 |
| chemiluminescent | #1182 |
| destructive | #1182 |
| arginine residues | #1184 |
| objective investigate | #1186 |
| disease haplotypes humans | #1186 |
| lymphocytes cell | #1188 |
| synovial fibroblasts | #1188 |
| human type | #1190 |
| ileitis | #1191 |
| splenic cells | #1192 |
| rat human | #1192 |
| antiphospholipid | #1193 |
| infiltrates | #1195 |
| primary sjögrens syndrome | #1195 |
| cells rheumatoid | #1199 |
| antibodies mabs | #1200 |
| basic mechanisms | #1200 |
| antibody | #1200 |
| susceptibility | #1200 |
| somatically | #1201 |
| lung mice mice | #1204 |
| protein arginine | #1208 |
| identified loci | #1210 |
| h2k | #1211 |
| predisposition disease | #1212 |
| onset progression | #1212 |
| c5a | #1213 |
| rationales | #1214 |
| singlecell | #1214 |
| hdacs | #1217 |
| critical issues | #1218 |
| chronic inflammation | #1218 |
| igg subclass | #1220 |
| ilc2 | #1221 |
| adaptive immune response | #1223 |
| mononuclear | #1223 |
| compared wt | #1223 |
| subcellular fractionation | #1224 |
| adaptive immune responses | #1225 |
| tlymphocyte antigens | #1226 |
| chromosome 4 | #1227 |
| linkage analysis | #1229 |
| antimicrobial peptides amps | #1229 |
| analyse | #1230 |
| experimental models | #1231 |
| therapeutically | #1232 |
| subsets lymphocytes | #1233 |
| aps | #1233 |
| host defense | #1238 |
| immunological mechanisms | #1240 |
| human cd4 | #1241 |
| cell lymphocytes | #1244 |
| indel | #1247 |
| mouse | #1250 |
| immune inflammatory | #1251 |
| lining | #1252 |
| animal | #1253 |
| ltb | #1253 |
| dead cells | #1254 |
| animal doseresponse relationship | #1259 |
| mesenteric lymph nodes | #1263 |
| differentiation lymphocyte | #1263 |
| antigen presenting cells | #1264 |
| synovium | #1265 |
| pathogenic mechanisms | #1266 |
| adenine dinucleotide | #1269 |
| suppress | #1269 |
| suppressive function | #1270 |
| molecular pathogenesis | #1270 |
| rheumatoid arthritis patients | #1270 |
| synovial fluid | #1271 |
| rat mouse | #1273 |
| eae model | #1274 |
| claudin4 | #1274 |
| rats mice | #1275 |
| chromosomal regions | #1275 |
| inducer | #1279 |
| rattus norvegicus | #1282 |
| becn1 | #1282 |
| hla molecules | #1283 |
| staphylococcal | #1283 |
| c4a | #1283 |
| rodent models | #1284 |
| spreading | #1286 |
| joint destruction | #1287 |
| attacked | #1288 |
| disease response | #1290 |
| pathological processes | #1294 |
| immunochip | #1295 |
| suppressor cells | #1296 |
| serm | #1297 |
| day pregnancy | #1297 |
| peripheral cells | #1297 |
| nadph oxidase activity | #1299 |
| production anti | #1299 |
| data protein | #1300 |
| publication animals antigens | #1300 |
| restimulation | #1305 |
| hdac3 | #1307 |
| model experimental | #1307 |
| peptide library | #1309 |
| ali | #1310 |
| social isolation | #1310 |
| fab2 | #1312 |
| phagocytic cells | #1313 |
| generated | #1313 |
| introgressed | #1314 |
| lymphoproliferation | #1315 |
| permissive | #1315 |
| increased susceptibility | #1316 |
| detailed characterization | #1316 |
| immune | #1316 |
| protects | #1319 |
| estradiol treatment | #1320 |
| hydrolyzes | #1321 |
| immunoglobulin isotypes | #1321 |
| phagocytes | #1322 |
| intrathymic | #1322 |
| healthy human subjects | #1322 |
| submandibular | #1323 |
| collagen types | #1323 |
| aureus infections | #1325 |
| acute phase proteins | #1327 |
| valuable tool | #1327 |
| therapeutic antibodies | #1328 |
| dietary nitrate | #1329 |
| receptor 2 | #1330 |
| human igg | #1330 |
| immunological memory | #1332 |
| pockets | #1333 |
| identically | #1335 |
| thymectomy | #1335 |
| rats rats | #1336 |
| new therapies | #1336 |
| acute phase response | #1338 |
| induction phase | #1341 |
| cells mice | #1341 |
| adjuvants | #1344 |
| increasing evidence | #1348 |
| knockout mutation | #1349 |
| promiscuity | #1350 |
| galactosylceramides | #1356 |
| allergic contact | #1359 |
| position | #1361 |
| alp | #1361 |
| elimination | #1361 |
| regulatory genes | #1362 |
| disease activity score | #1364 |
| believed | #1364 |
| n44 | #1366 |
| hypersensitivity | #1367 |
| 590 | #1368 |
| bacterial arthritis | #1372 |
| ameliorates | #1374 |
| membrane glycoproteins | #1375 |
| trait | #1375 |
| betad | #1375 |
| shared | #1375 |
| rat spinal cord | #1379 |
| il1r | #1381 |
| abrogates | #1383 |
| immunogen | #1383 |
| surface cells | #1384 |
| rats humans | #1388 |
| exacerbation | #1388 |
| variable region | #1389 |
| suffer | #1389 |
| regulatory treg | #1390 |
| clinical signs | #1390 |
| cd2 | #1390 |
| squalene | #1392 |
| human patients | #1392 |
| phage display | #1393 |
| feto | #1393 |
| cd4cd8 | #1394 |
| effects rats | #1396 |
| inbred mice | #1397 |
| disease outcomes | #1397 |
| positional | #1399 |
| submandibular glands | #1400 |
| joint disease | #1403 |
| early patients | #1403 |
| mononuclear phagocytes | #1406 |
| linkage genetic | #1409 |
| disease phenotypes | #1412 |
| animals disease | #1413 |
| antigens humans | #1415 |
| enzymelinked immunosorbent | #1416 |
| activation neutrophils | #1417 |
| humans immune | #1417 |
| cytokine profile | #1424 |
| class switching | #1425 |
| bacterial infections | #1431 |
| genetic heterogeneity | #1436 |
| gene usage | #1438 |
| stages disease | #1439 |
| cells type | #1440 |
| peptide | #1441 |
| guillainbarré syndrome | #1451 |
| arthritis systemic | #1453 |
| inbred strains mice | #1454 |
| cell activation | #1458 |
| alpha1 | #1458 |
| monoclonal | #1460 |
| knockout rats | #1461 |
| proinflammatory responses | #1461 |
| expression genetic | #1462 |
| lupus | #1464 |
| salt concentrations | #1465 |
| ccr6 | #1467 |
| pfp | #1467 |
| opens | #1467 |
| cell origin | #1468 |
| inflammatory properties | #1469 |
| cells pregnancy | #1472 |
| activation status | #1473 |
| immune deficiency | #1474 |
| cartilage cell | #1474 |
| muscle muscle | #1476 |
| cells activated | #1478 |
| allelic variants | #1479 |
| allotype | #1480 |
| specific gene | #1482 |
| responses animals | #1482 |
| markers genetic | #1483 |
| blisters | #1483 |
| initiate | #1486 |
| cells lung | #1486 |
| inflammatory diseases | #1486 |
| genetic regulation | #1486 |
| stroke 95 | #1487 |
| host defence | #1489 |
| hormone release | #1489 |
| donated | #1490 |
| human cartilage | #1491 |
| mice day | #1491 |
| inbred rats | #1491 |
| humoral immune | #1497 |
| myelin | #1499 |
| emphysematous | #1499 |
| treatment inflammatory | #1504 |
| regulatory effects | #1504 |
| monocytes neutrophils | #1504 |
| specific monoclonal | #1505 |
| vivo vitro | #1505 |
| joint arthritis | #1507 |
| eluate | #1507 |
| mimicking | #1507 |
| fls | #1508 |
| mapped | #1509 |
| inflammatory cell | #1510 |
| hindlimbs | #1511 |
| chromosome 6 | #1512 |
| stimulates | #1515 |
| egfp | #1516 |
| induced ali | #1520 |
| human leukocyte antigen | #1524 |
| earlier studies | #1525 |
| lia | #1525 |
| genes dominant | #1528 |
| knockout mitochondria | #1530 |
| sex steroids | #1531 |
| streptococcus pyogenes | #1533 |
| glutamic acid | #1535 |
| malaise | #1536 |
| lysines | #1537 |
| downregulate | #1540 |
| net release | #1545 |
| protein rna | #1546 |
| unexpectedly | #1547 |
| production macrophages | #1547 |
| increased numbers | #1548 |
| acetylglucosaminidase | #1549 |
| chronic phase | #1554 |
| higher level | #1555 |
| mediated diseases | #1559 |
| intraperitoneally | #1560 |
| copy variations | #1563 |
| 4 humans | #1563 |
| neuroimmunomodulation | #1563 |
| activate | #1564 |
| intradermal | #1565 |
| vsg | #1566 |
| matrix components | #1567 |
| guerin | #1567 |
| mammalian embryo | #1568 |
| immunoglobulin humans | #1568 |
| formyl | #1569 |
| sufficient | #1573 |
| cytotoxic lymphocyte | #1574 |
| pineal | #1574 |
| independent | #1577 |
| cochran | #1577 |
| cathelicidin | #1578 |
| glycolipid | #1580 |
| collagens | #1585 |
| fab | #1592 |
| mac1 | #1593 |
| factor beta | #1597 |
| conserved | #1597 |
| directed | #1597 |
| defines | #1598 |
| cell mediated | #1600 |
| twins | #1600 |
| f1 | #1600 |
| adoptive transfer | #1600 |
| reactive nitrogen species | #1603 |
| autoantibodies biomarkers | #1604 |
| cell receptor | #1605 |
| estriol | #1607 |
| cells th17 | #1607 |
| helical | #1611 |
| stromal cells | #1615 |
| chondrocyte | #1616 |
| immunity animals | #1617 |
| chronic inflammatory diseases | #1617 |
| isosteric | #1619 |
| autoimmune diabetes | #1621 |
| anaphylatoxin | #1622 |
| c57bl 6 | #1622 |
| humans immunoglobulin | #1622 |
| differently | #1625 |
| unreactive | #1626 |
| antigen | #1626 |
| rat spinal | #1629 |
| iggs | #1630 |
| complement component | #1632 |
| c3b | #1635 |
| immunohistology | #1635 |
| lund | #1639 |
| collagen fibers | #1639 |
| type interferon | #1641 |
| mice increased | #1642 |
| abrogated | #1644 |
| p6 | #1644 |
| c4b | #1645 |
| aspartic acid | #1647 |
| intracellular ros | #1651 |
| sjl | #1652 |
| opsonization | #1653 |
| complement activation | #1657 |
| linked | #1658 |
| defence | #1658 |
| complement receptors | #1660 |
| commonly | #1660 |
| staphylococcal enterotoxin | #1661 |
| transporter type | #1661 |
| immune complexes | #1661 |
| enterotoxins | #1662 |
| mice knockout | #1664 |
| tcell receptors | #1665 |
| salt intake | #1668 |
| tumor vasculature | #1669 |
| coincided | #1670 |
| primary sjögren | #1671 |
| isopropylacrylamide | #1672 |
| pathogenic cells | #1673 |
| immunologic epitopes | #1673 |
| gamma production | #1678 |
| single nucleotide | #1683 |
| cd206 | #1686 |
| complement c5a | #1686 |
| auto | #1689 |
| cocktail | #1689 |
| igm antibodies | #1691 |
| method analysis | #1693 |
| agouti | #1694 |
| ido1 | #1694 |
| classical pathway | #1696 |
| transgenic mice | #1696 |
| severity | #1701 |
| triple | #1704 |
| animals autoantigens | #1704 |
| 5 months | #1704 |
| precede | #1704 |
| suppressors | #1706 |
| encoded | #1707 |
| disulfiram | #1711 |
| treg cells | #1711 |
| beta chains | #1712 |
| erosions | #1712 |
| mice neutrophils | #1714 |
| sjögrens syndrome | #1719 |
| ankylosis | #1719 |
| evoke | #1720 |
| pulmonary aspergillosis | #1721 |
| tolerance | #1721 |
| skewing | #1725 |
| oophorectomy | #1727 |
| showing | #1728 |
| mutant mice | #1729 |
| myelin proteolipid | #1729 |
| drug targets | #1732 |
| analysis protein | #1734 |
| immune responses | #1734 |
| 369 | #1734 |
| staphylococcal infections | #1736 |
| sicca | #1737 |
| phagocytic | #1737 |
| fmoc | #1739 |
| intranasally | #1740 |
| arthritis patients | #1742 |
| affinity binding | #1743 |
| 626 | #1744 |
| prophylactic treatment | #1744 |
| cd11 | #1745 |
| osteoclasts | #1746 |
| strain mice | #1748 |
| alternative pathway | #1748 |
| zap70 | #1748 |
| new loci | #1749 |
| responded | #1750 |
| neoplastic disease models | #1753 |
| peroxide | #1758 |
| infiltrating | #1762 |
| endoglycosidase | #1764 |
| dr2 | #1766 |
| inhibitory receptors | #1766 |
| multiple genes | #1770 |
| higher frequency | #1770 |
| triggering | #1770 |
| glycosylation | #1774 |
| peptide antigens | #1775 |
| operate | #1776 |
| blocking | #1781 |
| adoptively | #1782 |
| cnbr | #1783 |
| ll37 | #1784 |
| articular cell | #1784 |
| local administration | #1788 |
| immunohistological | #1789 |
| compartmentalized | #1791 |
| carbohydrates | #1792 |
| pathogenesis | #1793 |
| render | #1794 |
| dogma | #1794 |
| competed | #1797 |
| immune recognition | #1800 |
| polymorphism genetic | #1801 |
| disease pathogenesis | #1801 |
| rat models | #1802 |
| rechallenge | #1803 |
| cd19 antigens | #1803 |
| peyer | #1804 |
| obese diabetic | #1805 |
| aureus infection | #1808 |
| predisposed | #1810 |
| immunogenic | #1810 |
| complement pathway | #1811 |
| activated lymphocytes | #1811 |
| elucidation | #1811 |
| psoriatic | #1813 |
| recovery phase | #1814 |
| pregnancy rats | #1817 |
| nonfunctional | #1817 |
| promoting | #1818 |
| ossification | #1818 |
| il2r | #1818 |
| blymphocyte | #1819 |
| intravenously | #1819 |
| crossed | #1823 |
| katpase | #1824 |
| hydroxylated | #1825 |
| myelin sheath | #1825 |
| neurodegenerative diseases | #1827 |
| deplete | #1830 |
| female sex | #1833 |
| genetic susceptibility | #1836 |
| new treatments | #1839 |
| pathogenesis disease | #1841 |
| trif | #1843 |
| resolution inflammation | #1844 |
| clinical score | #1846 |
| subsequently | #1846 |
| inflammation macrophages | #1847 |
| estrogen | #1848 |
| cultured disease | #1849 |
| pyogenes | #1852 |
| specific immunity | #1854 |
| genetic variance | #1854 |
| cd8 lymphocytes | #1856 |
| macrophages neutrophils | #1856 |
| humoral | #1857 |
| rac2 | #1858 |
| barre | #1858 |
| cocktails | #1860 |
| haenszel | #1862 |
| secreting | #1863 |
| structural basis | #1864 |
| aggravation | #1864 |
| lacrimal apparatus | #1865 |
| silastic | #1871 |
| rats groups | #1871 |
| immunoadsorption | #1873 |
| inkt | #1874 |
| carries | #1875 |
| major | #1876 |
| cartilages | #1879 |
| subsequent development | #1879 |
| candidate | #1883 |
| antigen humans | #1890 |
| inflammation lung | #1892 |
| polyclonal | #1893 |
| bacterial clearance | #1894 |
| ovalbumin | #1897 |
| cyanogen | #1900 |
| striking | #1902 |
| tcr repertoire | #1903 |
| lymphatics | #1903 |
| indicating | #1905 |
| complexity | #1905 |
| proteins rats | #1907 |
| model rats | #1908 |
| gammadelta | #1910 |
| mediated | #1910 |
| enzyme linked | #1911 |
| cell maturation | #1912 |
| cells neutrophils | #1912 |
| interferon gamma | #1914 |
| erythematosus sle | #1916 |
| chromosome | #1916 |
| totally | #1918 |
| 6 hours | #1920 |
| cartilage tissue | #1923 |
| anti | #1924 |
| 721 | #1924 |
| gαq | #1926 |
| pronounced | #1927 |
| ears | #1929 |
| isoantigens | #1931 |
| bcell receptors | #1933 |
| expression cytokines | #1934 |
| animals lymphocytes | #1937 |
| trypanosoma brucei | #1937 |
| sialyltransferases | #1939 |
| mice receptors | #1940 |
| antigen tcell receptors | #1944 |
| type plasminogen | #1945 |
| predisposition | #1949 |
| subclasses | #1950 |
| prevented | #1950 |
| constituting | #1955 |
| cardiac allografts | #1956 |
| perforin | #1957 |
| snakes | #1957 |
| agp | #1959 |
| mmc | #1962 |
| edition | #1967 |
| pinocytosis | #1967 |
| iga igg | #1967 |
| levels serum | #1967 |
| possibilities | #1969 |
| fcγ receptor | #1969 |
| strong | #1971 |
| intravenous injection | #1972 |
| react | #1975 |
| mip | #1977 |
| stimulations | #1978 |
| synovial tissues | #1979 |
| carp | #1979 |
| ova | #1980 |
| inbred cba | #1980 |
| cd154 | #1982 |
| pregnant rats | #1983 |
| disease pathology | #1985 |
| cell clone | #1985 |
| milder | #1988 |
| spans | #1997 |
| mast cell | #1999 |
| cd18 | #2000 |
| transgenic rats | #2001 |
| microglia activation | #2002 |
| presenting cell | #2006 |
| heteroplasmy | #2007 |
| contact dermatitis | #2008 |
| reverted | #2008 |
| rats effects | #2008 |
| prototypic | #2011 |
| response infection | #2016 |
| abca1 | #2016 |
| barré syndrome | #2018 |
| knockout | #2020 |
| tissue inflammation | #2021 |
| immunoglobulin | #2023 |
| genes | #2025 |
| cell | #2027 |
| mabs | #2028 |
| cytokine secretion | #2028 |
| demyelination | #2030 |
| chord | #2031 |
| tetramers | #2032 |
| c5ar | #2033 |
| conformational epitopes | #2035 |
| mesenteric lymph | #2035 |
| beta gene | #2035 |
| factor mif | #2041 |
| 4 tlr4 | #2041 |
| mab | #2042 |
| diethyldithiocarbamate | #2043 |
| immunomodulatory properties | #2044 |
| sex chromosome | #2045 |
| cell immunity | #2047 |
| hypergammaglobulinemia | #2050 |
| oestrogens | #2050 |
| species signal | #2053 |
| castration | #2053 |
| cell function | #2053 |
| coinciding | #2055 |
| emphysema | #2056 |
| glycosylation humans | #2057 |
| increased frequency | #2058 |
| innate inflammation | #2058 |
| dramatically | #2059 |
| vitro vivo | #2061 |
| activation complement | #2061 |
| accompanied | #2067 |
| genetic differences | #2068 |
| dominant | #2070 |
| contributors | #2071 |
| proteomics analysis | #2072 |
| hyaluronoglucosaminidase | #2072 |
| mdsc | #2076 |
| mature cells | #2077 |
| polyradiculoneuropathy | #2077 |
| respiratory tract | #2079 |
| lysine residues | #2080 |
| antiphospholipid syndrome | #2081 |
| cell depletion | #2082 |
| mice pregnancy | #2083 |
| methotrexate mtx | #2094 |
| complement | #2094 |
| conditional deletion | #2095 |
| lysine | #2096 |
| addressed | #2097 |
| αβ | #2100 |
| bioreactor | #2100 |
| suggested | #2102 |
| evokes | #2103 |
| led | #2103 |
| antigens hla | #2104 |
| patients rheumatoid arthritis | #2105 |
| human chondrocytes | #2110 |
| nose | #2117 |
| lentiviral vectors | #2120 |
| pulmonary inflammation | #2122 |
| glycan | #2122 |
| immune functions | #2126 |
| pad4 | #2127 |
| oxidants | #2129 |
| total igg | #2130 |
| secondary receptors | #2133 |
| inducing | #2136 |
| occurring | #2139 |
| histopathological | #2140 |
| target tissues | #2141 |
| selective estrogen | #2141 |
| dissection | #2142 |
| plasminogen | #2143 |
| transduction lymphocytes | #2145 |
| extracellular calcium | #2146 |
| subphenotypes | #2146 |
| bound | #2147 |
| h2d | #2147 |
| circulating monocytes | #2149 |
| immunohistochemical analysis | #2151 |
| 129 strain mice | #2151 |
| reality | #2153 |
| clinical aspects | #2157 |
| periphery | #2161 |
| major histocompatibility complex | #2162 |
| late stages | #2165 |
| moabs | #2165 |
| rheumatoid biomarkers | #2165 |
| prone | #2169 |
| entire | #2174 |
| syringes | #2176 |
| mimics | #2177 |
| animal model | #2179 |
| immune regulation | #2180 |
| human leukocytes | #2181 |
| psoriatic arthritis | #2184 |
| dynorphins | #2184 |
| dnp | #2185 |
| native | #2188 |
| injury ali | #2200 |
| dss | #2203 |
| lps stimulation | #2204 |
| structural requirements | #2211 |
| molecular pathways | #2213 |
| confirming | #2214 |
| 12th | #2215 |
| therapeutic effects | #2216 |
| interleukin2 | #2216 |
| activation cells | #2217 |
| animal mice mice | #2217 |
| naïve | #2219 |
| regulates | #2220 |
| galactose | #2220 |
| suggesting | #2221 |
| wt mice | #2224 |
| immunoreactivity | #2225 |
| shrna | #2232 |
| mammalian | #2232 |
| governs | #2233 |
| neutralized | #2233 |
| presentation | #2234 |
| accelerates | #2236 |
| ctla4 | #2239 |
| autoimmune conditions | #2239 |
| reduced susceptibility | #2239 |
| lacked | #2240 |
| graft rejection | #2244 |
| inflammatory phenotype | #2248 |
| cholera toxin | #2248 |
| cell priming | #2252 |
| exacerbated | #2253 |
| monoclonal antibodies | #2254 |
| cell receptors | #2256 |
| tcell proliferation | #2261 |
| sjögren | #2263 |
| regulation immune | #2265 |
| involved pathogenesis | #2267 |
| hla | #2269 |
| mph | #2274 |
| progeny | #2274 |
| immunospot | #2278 |
| murine | #2279 |
| antigenic | #2279 |
| neutrophil apoptosis | #2280 |
| mice treatment | #2280 |
| lymph nodes | #2281 |
| dependent | #2284 |
| inflammatory | #2288 |
| immunizations | #2289 |
| homologous | #2292 |
| plasmatic | #2293 |
| histological evaluation | #2296 |
| determining | #2296 |
| modified proteins | #2296 |
| cba mice | #2297 |
| regulatory mechanisms | #2299 |
| knockout mice | #2300 |
| apocynin | #2302 |
| segregating | #2308 |
| infiltrating macrophages | #2309 |
| presentation antigens | #2310 |
| wounding | #2312 |
| drastically | #2315 |
| genetic basis | #2315 |
| il10 | #2317 |
| healthy donors | #2318 |
| hydroxylation | #2320 |
| barré | #2320 |
| inflammatory mechanisms | #2321 |
| sera | #2325 |
| throughput nucleotide | #2325 |
| p00002 | #2326 |
| antigens histocompatibility | #2328 |
| wild | #2329 |
| cells induced | #2331 |
| demyelinating disease | #2336 |
| n24 | #2338 |
| lewis | #2345 |
| gk | #2347 |
| receptor α | #2353 |
| reciprocal | #2353 |
| specific igg | #2358 |
| ethylenes | #2358 |
| illness stress | #2361 |
| monosaccharide | #2363 |
| hyaline | #2364 |
| biological agents | #2365 |
| lectins type | #2366 |
| acrylamides | #2366 |
| sex hormone | #2366 |
| degradative | #2367 |
| phosphoproteins | #2369 |
| eliminated | #2374 |
| wf | #2374 |
| lymphotoxin | #2375 |
| immunogens | #2375 |
| peptides derived | #2375 |
| treatment rheumatoid arthritis | #2376 |
| genetic selection | #2376 |
| cxcl1 | #2382 |
| amps | #2382 |
| antinociceptive | #2383 |
| nonalcoholic steatohepatitis | #2384 |
| mouse model | #2386 |
| contaminating | #2386 |
| sidechain | #2391 |
| phenotypes | #2391 |
| receptor transforming | #2392 |
| knock | #2394 |
| syngeneic | #2394 |
| septic arthritis | #2396 |
| systemic lupus erythematosus | #2397 |
| hla genes | #2398 |
| p38 mapk | #2400 |
| inflammatory reaction | #2400 |
| serum autoantibodies | #2408 |
| increased incidence | #2409 |
| mice models | #2411 |
| equina | #2413 |
| intraperitoneal injections | #2418 |
| genetic receptors | #2420 |
| genetic studies | #2420 |
| structure analysis | #2423 |
| realtime pcr | #2424 |
| mice expression | #2426 |
| tlr2 tlr4 | #2429 |
| lentivirus | #2430 |
| acute phase | #2430 |
| suggestive evidence | #2430 |
| unmodified | #2431 |
| cko | #2432 |
| cytokines chemokines | #2432 |
| collagen fibrils | #2432 |
| lymphocytes cd4 | #2432 |
| cells antigens | #2434 |
| early phases | #2440 |
| agents arthritis | #2440 |
| inflammatory activity | #2442 |
| mice multiple | #2446 |
| genetic predisposition | #2449 |
| receptors complement | #2450 |
| b6 | #2450 |
| 551 | #2451 |
| lipoxin | #2458 |
| inflammatory demyelinating | #2459 |
| animal disease models | #2463 |
| exemplified | #2466 |
| idiotype | #2468 |
| antibody responses | #2469 |
| strains | #2471 |
| animals cd4 | #2473 |
| administration intranasal | #2473 |
| translational modifications | #2477 |
| additively | #2477 |
| axotomy | #2477 |
| class | #2480 |
| quantitative | #2480 |
| regulatory | #2487 |
| animal experiments | #2492 |
| specific | #2493 |
| organ specific | #2497 |
| transforming growth factor | #2498 |
| negative feedback | #2501 |
| alleviated | #2502 |
| albeit | #2502 |
| cystatin | #2504 |
| mhc class genes | #2505 |
| multiparous | #2511 |
| transgenic microscopy | #2512 |
| bystander | #2515 |
| il17a | #2516 |
| ppd | #2518 |
| chemokines cytokines | #2519 |
| dichotomous | #2519 |
| contribute | #2522 |
| naturally | #2523 |
| treatment rheumatoid | #2524 |
| hyperostosis | #2525 |
| amiloride | #2526 |
| nod mice | #2527 |
| pathogenicity | #2534 |
| microsatellite markers | #2534 |
| infiltration | #2541 |
| resemblance | #2542 |
| undertaken | #2545 |
| postmenopausal osteoporosis | #2546 |
| proteolipid | #2552 |
| dapsone | #2560 |
| similarities | #2561 |
| igm iga | #2562 |
| plp | #2563 |
| kynurenine | #2563 |
| deprotection | #2564 |
| nox | #2566 |
| succeeded | #2567 |
| fine | #2573 |
| transferring | #2573 |
| passive | #2574 |
| rp patients | #2575 |
| dying cells | #2575 |
| tumor models | #2576 |
| quantitative traits | #2577 |
| incomplete | #2577 |
| complementarity | #2580 |
| peptides | #2585 |
| chick | #2589 |
| calgranulin | #2590 |
| antibody levels | #2591 |
| peritoneal macrophages | #2591 |
| misinterpretation | #2593 |
| interferon type | #2595 |
| sex hormones | #2597 |
| fibrinolysin | #2598 |
| antiinflammatory properties | #2603 |
| onset | #2603 |
| unlinked | #2605 |
| zymosan | #2610 |
| induction | #2611 |
| postulated | #2614 |
| exert | #2615 |
| antimicrobial peptides | #2618 |
| surprising | #2621 |
| interferon beta | #2623 |
| proteolipid protein | #2632 |
| ifn α | #2634 |
| single chain | #2639 |
| sialoglycoproteins | #2643 |
| plasmin | #2647 |
| unable | #2649 |
| asparagine | #2651 |
| tlr9 | #2653 |
| antigens | #2656 |
| disease genotype | #2658 |
| hla antigens | #2659 |
| functional impact | #2663 |
| antinuclear | #2663 |
| submandibular gland | #2663 |
| eluted | #2666 |
| osteonectin | #2667 |
| brucei | #2670 |
| invading | #2670 |
| n22 | #2670 |
| microliters | #2671 |
| biological pathways | #2673 |
| bordetella | #2680 |
| ease | #2683 |
| new therapeutic strategies | #2683 |
| leukocyte antigen | #2688 |
| th1 | #2690 |
| acd | #2696 |
| day treatment | #2697 |
| allelic | #2697 |
| genetic variations | #2698 |
| igg3 | #2698 |
| animal encephalomyelitis | #2702 |
| neutrophils macrophages | #2703 |
| gamma mice | #2711 |
| peptides protein | #2714 |
| γδ | #2716 |
| treatment mice | #2717 |
| rat model | #2718 |
| human complement | #2725 |
| patients anti | #2727 |
| polymorphic | #2729 |
| biased | #2730 |
| lymphocyte subsets | #2730 |
| ifngamma | #2730 |
| post partum | #2731 |
| fumigatus | #2735 |
| lamina propria | #2735 |
| serum anti | #2738 |
| fragment | #2743 |
| vav | #2743 |
| mice exposed | #2750 |
| leucocyte | #2754 |
| resemble | #2762 |
| bromocriptine | #2768 |
| transgenic mouse | #2772 |
| depleting | #2773 |
| human leukocyte | #2774 |
| tyrosine phosphatase | #2774 |
| strong evidence | #2777 |
| cytolysis | #2777 |
| qtls | #2777 |
| detectable | #2780 |
| enigmatic | #2780 |
| iga igm | #2780 |
| genetically | #2782 |
| finemapping | #2785 |
| explanation | #2785 |
| treated rats | #2786 |
| alcoholic steatohepatitis | #2786 |
| intraperitoneal | #2787 |
| tolerogenic | #2789 |
| bone cartilage | #2790 |
| sjogren syndrome | #2791 |
| inbred mrl | #2798 |
| current review | #2798 |
| animal encephalomyelitis autoimmune | #2799 |
| hk | #2801 |
| callithrix | #2804 |
| spleen | #2812 |
| 261 | #2813 |
| neuropathology | #2817 |
| genistein | #2819 |
| alpha | #2821 |
| lack | #2822 |
| activated macrophages | #2825 |
| hyaluronidase | #2830 |
| conventionally | #2831 |
| narrowed | #2832 |
| prl | #2835 |
| olive oil | #2838 |
| demyelinating diseases | #2841 |
| resistant | #2842 |
| hallmark | #2843 |
| glucose uptake | #2846 |
| beta receptor | #2847 |
| beta tgf | #2848 |
| bind | #2848 |
| th1 response | #2852 |
| demyelinating | #2852 |
| polymorphonuclear leukocytes | #2856 |
| phases | #2858 |
| dependent cell | #2859 |
| treg cell | #2859 |
| antibodies antinuclear | #2864 |
| polymorphonuclear | #2864 |
| interleukin receptors | #2864 |
| splenocytes | #2865 |
| characterising | #2865 |
| interleukin33 | #2869 |
| rats inbred strains | #2869 |
| cyanogen bromide | #2874 |
| disease characterized | #2875 |
| guillain | #2875 |
| cells cd8 | #2881 |
| periodontitis | #2882 |
| parvalbumin | #2884 |
| reveals | #2885 |
| clone cells | #2885 |
| exacerbate | #2888 |
| igg iga | #2891 |
| migration inhibitory | #2892 |
| costimulatory molecules | #2895 |
| tgfbeta | #2895 |
| innate immune responses | #2896 |
| dce | #2896 |
| antigens class humans | #2898 |
| dq | #2905 |
| antigen hla | #2907 |
| atp synthase | #2909 |
| enhancement | #2911 |
| linked immunosorbent | #2911 |
| studying | #2918 |
| diseases disease | #2920 |
| shortly | #2920 |
| allogenic | #2921 |
| ergometry | #2921 |
| steadily | #2925 |
| vaccine development | #2925 |
| type lectin | #2926 |
| obvious | #2927 |
| ifn γ | #2931 |
| autoimmune disorder | #2935 |
| dextran | #2939 |
| female flow | #2943 |
| expression macrophages | #2944 |
| injections | #2944 |
| ifn gamma | #2945 |
| proteins peptides | #2946 |
| cd68 | #2947 |
| patients antibodies | #2949 |
| interleukin4 | #2950 |
| cells immune | #2955 |
| eventually | #2956 |
| toll receptor | #2961 |
| cell infiltration | #2962 |
| expressions | #2963 |
| calcium ions | #2964 |
| qtl | #2965 |
| histocytochemistry | #2967 |
| suppressed | #2967 |
| hnrnp | #2980 |
| genetics | #2982 |
| ifn response | #2985 |
| cepacia | #2988 |
| antirheumatic agents | #2993 |
| elusive | #2994 |
| hdac | #2995 |
| thymus gland | #2997 |
| swedish | #2998 |
| respective | #3000 |
| lineage commitment | #3003 |
| indoleamine | #3009 |
| time points | #3009 |
| cells female | #3010 |
| therapeutic strategies | #3014 |
| innate | #3014 |
| illustrating | #3017 |
| anthrax | #3019 |
| interferon ifn | #3020 |
| wild type mice | #3026 |
| defensins | #3027 |
| vdr | #3031 |
| accelerating | #3033 |
| lung inflammation | #3033 |
| macrophage migration | #3036 |
| t‐cell | #3039 |
| endo | #3039 |
| synthetic peptides | #3040 |
| appearance | #3045 |
| quinoxalines | #3047 |
| cd8 | #3048 |
| immunomodulator | #3050 |
| model mice | #3051 |
| longterm treatment | #3052 |
| twin studies | #3053 |
| complex traits | #3055 |
| ppt | #3058 |
| interleukin23 | #3061 |
| profound | #3067 |
| sjögren syndrome | #3069 |
| prevailing | #3073 |
| salivary | #3076 |
| mediated immune | #3077 |
| role cell | #3078 |
| beta | #3080 |
| destruction | #3082 |
| irrespective | #3083 |
| model human | #3083 |
| gene expression profiling | #3086 |
| impairing | #3087 |
| nodes | #3091 |
| glutamic | #3092 |
| inhibitory factors | #3092 |
| parvalbumins | #3093 |
| inbred balb mice | #3098 |
| receptor 4 | #3098 |
| genetic deletion | #3100 |
| detailed description | #3101 |
| postpartum period | #3107 |
| germinal | #3108 |
| antirheumatic | #3109 |
| staphylococcus | #3114 |
| type wt | #3120 |
| neuronal cell | #3123 |
| effects treatment | #3124 |
| suspect | #3127 |
| igm igg | #3130 |
| specificity | #3131 |
| glycans | #3136 |
| monoclonal antibody | #3137 |
| receptors tlrs | #3142 |
| psoriasis | #3142 |
| logarithm | #3146 |
| cd4 cd8 | #3147 |
| preformed | #3151 |
| immune systems | #3152 |
| possibility | #3153 |
| cell activity | #3154 |
| molecule | #3155 |
| propria | #3155 |
| cba | #3164 |
| posttranslational modification | #3167 |
| sjogren | #3171 |
| massively | #3172 |
| accumulated | #3180 |
| cell specific | #3185 |
| precedes | #3185 |
| blockage | #3187 |
| tissue specific | #3191 |
| dynorphin | #3191 |
| pertussis toxin | #3192 |
| cells rats | #3193 |
| adult mice | #3193 |
| keratinocytes | #3194 |
| unravel | #3199 |
| reactivity | #3202 |
| helper | #3204 |
| modified | #3205 |
| ovx | #3208 |
| serum levels | #3210 |
| erbeta | #3211 |
| antiinflammatory | #3211 |
| phagosomes | #3212 |
| nitroarginine | #3212 |
| abs | #3216 |
| publication arthritis | #3224 |
| cells animals | #3224 |
| gpi | #3226 |
| chromosome 1 | #3237 |
| class iii | #3239 |
| clarified | #3242 |
| permitting | #3246 |
| collagenous | #3247 |
| macrophage | #3247 |
| lod score | #3252 |
| bacterial antibodies | #3254 |
| backbone | #3257 |
| nonalcoholic steatohepatitis nash | #3260 |
| female gonadal | #3263 |
| treated animals | #3264 |
| acrylic | #3265 |
| chronic inflammatory | #3267 |
| meps | #3270 |
| immunosorbent assay | #3272 |
| implicate | #3274 |
| inflammation interferon | #3278 |
| proteoglycans | #3278 |
| sch | #3280 |
| arthralgia | #3283 |
| nephritis | #3283 |
| gonadal steroid | #3284 |
| normal rats | #3287 |
| abundantly | #3289 |
| igg1 | #3298 |
| models genetic | #3298 |
| immunoglobulin heavy | #3303 |
| erythematosus | #3305 |
| proteins mice | #3309 |
| adaptations | #3309 |
| characterise | #3314 |
| elicits | #3314 |
| blastocyst | #3315 |
| nociception | #3316 |
| absence | #3318 |
| diseases autoimmune | #3321 |
| beta receptors | #3325 |
| publication animals | #3325 |
| mice protein | #3327 |
| anticardiolipin | #3328 |
| confirmed | #3329 |
| gc cells | #3331 |
| serologically | #3332 |
| suppression | #3338 |
| regional lymph nodes | #3341 |
| macromolecular | #3343 |
| clinical phenotypes | #3345 |
| cd62l | #3353 |
| influenced | #3355 |
| trypanosoma | #3358 |
| akr | #3371 |
| vitamin d3 | #3373 |
| editor | #3377 |
| antinuclear antibodies | #3382 |
| sle | #3384 |
| genetic polymorphisms | #3385 |
| ovariectomy | #3386 |
| levels inflammatory | #3395 |
| macroporous | #3395 |
| mechanistic studies | #3395 |
| explains | #3396 |
| mount | #3397 |
| tubercle | #3402 |
| somatic mutations | #3406 |
| receptors transforming | #3410 |
| haptens | #3413 |
| early phase | #3413 |
| positions | #3418 |
| nk cells | #3419 |
| erythematosus systemic | #3419 |
| neutrophil activation | #3421 |
| reacts | #3421 |
| penetrant | #3425 |
| reply | #3432 |
| proving | #3434 |
| receptor type | #3434 |
| dendritic cells | #3436 |
| serum igg | #3437 |
| alleles | #3440 |
| permitted | #3441 |
| cauda | #3443 |
| 4 months | #3444 |
| injection | #3445 |
| superoxide production | #3446 |
| protein tyrosine | #3447 |
| obscure | #3448 |
| humans immunization | #3448 |
| increased sensitivity | #3449 |
| antimicrobial peptide | #3451 |
| diffusely | #3459 |
| characterised | #3469 |
| patients sle | #3470 |
| h5n1 | #3470 |
| flow cytometry | #3476 |
| modifying | #3477 |
| inflammatory mediators | #3491 |
| multimers | #3491 |
| proteoglycan | #3496 |
| successes | #3497 |
| il21 | #3500 |
| ly | #3501 |
| elucidate | #3503 |
| classical | #3505 |
| developed | #3505 |
| protein processing | #3506 |
| salivary gland | #3507 |
| publication animals animals | #3509 |
| neutrophilic | #3510 |
| pathobiology | #3511 |
| pathological features | #3517 |
| specific cd4 | #3519 |
| globulins | #3526 |
| 267 | #3528 |
| deoxyguanosine | #3528 |
| phenotypically | #3529 |
| germline | #3529 |
| predispose | #3532 |
| micrometer | #3534 |
| lacrimal | #3534 |
| transglutaminases | #3535 |
| radiolabelled | #3539 |
| cyclosporins | #3540 |
| regulatory cells tregs | #3540 |
| mbq | #3541 |
| dominantly | #3548 |
| histological examination | #3554 |
| investigate | #3559 |
| infections staphylococcus | #3561 |
| mast cells | #3563 |
| cultured disease models | #3568 |
| socs1 | #3570 |
| humans interferon | #3571 |
| histological | #3574 |
| homogenate | #3576 |
| gamma | #3580 |
| interesting | #3580 |
| negative patients | #3583 |
| artificially | #3584 |
| role development | #3585 |
| cytolytic | #3589 |
| hindlimb | #3590 |
| il33 | #3593 |
| triggered | #3597 |
| compared wild | #3597 |
| usage | #3601 |
| immunohistochemical staining | #3608 |
| upregulation | #3612 |
| previous findings | #3617 |
| intranasal | #3619 |
| tcr | #3622 |
| potential roles | #3624 |
| cleave | #3624 |
| genetic association | #3629 |
| attenuate | #3633 |
| rp | #3633 |
| mapping chromosomes | #3634 |
| valuable | #3637 |
| genetic | #3637 |
| adhere | #3638 |
| today | #3645 |
| cultured culture media | #3651 |
| allele | #3655 |
| gene deletion | #3657 |
| enhances | #3657 |
| cd4 positive | #3659 |
| exerts | #3663 |
| clinical severity | #3665 |
| tolllike receptor | #3665 |
| luminol | #3667 |
| 95 association | #3671 |
| cd44 | #3678 |
| il23 | #3690 |
| tgf beta | #3691 |
| female genes | #3694 |
| fibronectins | #3697 |
| toll receptors | #3700 |
| igg igm | #3702 |
| heavy chain | #3705 |
| synovitis | #3708 |
| publication animals humans | #3708 |
| cyclohexanecarboxylic | #3709 |
| aggregated | #3717 |
| inbred nod mice | #3730 |
| systemic male | #3735 |
| sequence deletion | #3740 |
| dh | #3742 |
| 378 | #3746 |
| cells produce | #3750 |
| therapeutic benefit | #3752 |
| macrophage cell | #3753 |
| mediate | #3754 |
| contributing | #3754 |
| complement c4 | #3758 |
| immunochemistry | #3759 |
| biomedicine | #3763 |
| type 4 | #3763 |
| lymphocytes tumor | #3766 |
| epitope mapping | #3767 |
| identification | #3771 |
| partum | #3772 |
| mtdna | #3773 |
| d3 | #3775 |
| jakob | #3786 |
| th17 | #3786 |
| reduced expression | #3787 |
| diphtheria | #3803 |
| immunohistochemical | #3805 |
| hind | #3808 |
| skewed | #3820 |
| superoxide | #3822 |
| integrins | #3822 |
| ribonucleoprotein | #3823 |
| new opportunities | #3831 |
| models immunological | #3834 |
| encompassing | #3838 |
| mmp9 expression | #3839 |
| puerperal | #3839 |
| noncoding rna | #3840 |
| unclear | #3847 |
| amelioration | #3854 |
| postulate | #3858 |
| il17 | #3858 |
| identical | #3859 |
| housed | #3861 |
| genetic dna | #3867 |
| cells treg | #3873 |
| genetic promoter regions | #3880 |
| prominent | #3887 |
| glycoside | #3887 |
| kinase2 | #3887 |
| reacting | #3888 |
| dinucleotide | #3894 |
| decreased levels | #3896 |
| synoviocytes | #3900 |
| microsatellite repeats | #3903 |
| superoxides | #3904 |
| dominate | #3907 |
| recognition | #3912 |
| endogenous | #3918 |
| established | #3919 |
| animal studies | #3926 |
| rats messenger | #3931 |
| hladr | #3934 |
| immunophenotyping | #3941 |
| manifestations | #3942 |
| nerves | #3944 |
| toes | #3946 |
| affect | #3947 |
| neutrophils | #3947 |
| polymorphism | #3949 |
| gingivalis | #3957 |
| nets | #3958 |
| mechanisms involved | #3961 |
| involvement | #3973 |
| disrupted | #3975 |
| associate | #3975 |
| 297 | #3982 |
| adult arthritis | #3988 |
| stimulate | #3992 |
| heavy chains | #3992 |
| question | #3999 |
| ifn β | #3999 |
| broader | #4001 |
| patients osteoarthritis | #4009 |
| elevated levels | #4012 |
| sinuses | #4016 |
| superoxide dismutase | #4018 |
| chondrocytes | #4018 |
| individual patients | #4028 |
| ags | #4029 |
| inflammatory processes | #4033 |
| influences | #4034 |
| higher expression | #4034 |
| efficiently | #4050 |
| glycoproteins | #4054 |
| hla alleles | #4059 |
| expression cell | #4063 |
| conferred | #4065 |
| c1q | #4069 |
| produce | #4072 |
| fragments | #4072 |
| hinge | #4074 |
| eliciting | #4075 |
| stat4 | #4076 |
| requirement | #4076 |
| plethora | #4077 |
| glycoprotein | #4077 |
| contrast | #4085 |
| llc | #4089 |
| upregulated | #4090 |
| systemic lupus | #4092 |
| expression type | #4098 |
| fine mapping | #4102 |
| atpases | #4103 |
| leukocyte | #4105 |
| glands | #4107 |
| conferring | #4108 |
| neutrophil | #4113 |
| creutzfeldt | #4115 |
| current concepts | #4116 |
| gelatin | #4120 |
| absent | #4121 |
| therapy genetic | #4122 |
| sclerosis animals | #4124 |
| drives | #4126 |
| regulatory cells | #4126 |
| protect | #4131 |
| mycobacterial | #4133 |
| promoter polymorphism | #4137 |
| stat1 | #4144 |
| functionally | #4147 |
| articular cartilage | #4161 |
| lupus erythematosus | #4162 |
| hla dq | #4165 |
| motor neurons | #4166 |
| polygenic | #4169 |
| placenta pregnancy | #4173 |
| tumour necrosis factor | #4177 |
| stimulatory | #4178 |
| early pregnancy | #4180 |
| immunology | #4183 |
| effector | #4184 |
| systemic disease | #4187 |
| superoxide anion | #4191 |
| infiltrating lymphocytes | #4192 |
| spe | #4193 |
| monocyte | #4201 |
| breeders | #4203 |
| enterotoxin | #4206 |
| ici | #4207 |
| porphyromonas gingivalis | #4207 |
| beads | #4213 |
| antigens cd8 | #4214 |
| animal drug | #4222 |
| depletion | #4223 |
| cytometric analysis | #4224 |
| parathyroid | #4225 |
| long noncoding | #4227 |
| mutant | #4232 |
| inbred balb | #4239 |
| treated mice | #4242 |
| kidneys | #4244 |
| macrophage infiltration | #4244 |
| granulocytic | #4249 |
| continuously | #4250 |
| chondrosarcoma | #4250 |
| witnessed | #4252 |
| conjunction | #4256 |
| immunological | #4257 |
| immunity innate | #4258 |
| bout | #4260 |
| igh | #4262 |
| lymphoid | #4264 |
| cell repertoire | #4268 |
| day1 | #4270 |
| denominator | #4270 |
| complex | #4272 |
| suggestive | #4276 |
| dermatitis | #4285 |
| experimental mice | #4285 |
| clues | #4286 |
| gene targeting | #4290 |
| cd4 | #4291 |
| balb | #4292 |
| disease genetic | #4294 |
| repertoire | #4302 |
| molecular modeling | #4303 |
| provocation | #4303 |
| shares | #4307 |
| sciatic | #4307 |
| tuberculin | #4308 |
| positive cells | #4309 |
| functional role | #4310 |
| cell populations | #4317 |
| receptors interleukin2 | #4317 |
| suppressive effects | #4320 |
| hydroxy2deoxyguanosine | #4331 |
| pparγ | #4350 |
| new insight | #4353 |
| trypanosomiasis | #4358 |
| fungal infection | #4364 |
| glutamine | #4364 |
| peritonitis | #4365 |
| wildtype | #4370 |
| immunoassays | #4373 |
| swelling | #4375 |
| penetrance | #4381 |
| caused | #4381 |
| cell clones | #4396 |
| disease chronic | #4402 |
| mucous | #4402 |
| prevents | #4414 |
| restored | #4417 |
| joint | #4420 |
| modulating | #4426 |
| receptor beta | #4434 |
| closer | #4434 |
| disturbed | #4434 |
| buprenorphine | #4435 |
| model systems | #4443 |
| early | #4453 |
| acute chronic | #4454 |
| aspartic | #4458 |
| parathyroid glands | #4470 |
| confers | #4473 |
| inflammatory pain | #4477 |
| disease duration | #4480 |
| thymocytes | #4481 |
| calmette | #4488 |
| strains rats | #4489 |
| synthase type | #4490 |
| treg | #4493 |
| neutralizing antibodies | #4503 |
| thickened | #4503 |
| human cell | #4505 |
| genetic loci | #4510 |
| extensively | #4516 |
| colitis | #4526 |
| derived cells | #4532 |
| therapeutic implications | #4534 |
| immunotoxins | #4535 |
| beta cells | #4539 |
| cells th2 | #4541 |
| challenged | #4542 |
| lymphocytes cd8 | #4545 |
| 101 | #4546 |
| cytotoxic lymphocytes | #4547 |
| articular chondrocytes | #4553 |
| interleukin5 | #4558 |
| messenger rats rats | #4564 |
| beta cell | #4566 |
| homing | #4576 |
| extracellular ca2 | #4576 |
| hydrolases | #4577 |
| fasl | #4578 |
| cell separation | #4580 |
| proliferative | #4581 |
| neurosecretory | #4585 |
| immunologic | #4592 |
| production inflammatory | #4593 |
| suggests | #4596 |
| inbred shr rats | #4607 |
| modulatory | #4608 |
| ros levels | #4613 |
| igg antibody | #4613 |
| interact | #4613 |
| confer | #4616 |
| depleted | #4639 |
| conditioned medium | #4642 |
| environmental factors | #4643 |
| positive selection | #4658 |
| fashion | #4658 |
| porphyromonas | #4666 |
| visualized | #4667 |
| endorphins | #4669 |
| implicated | #4670 |
| determinant | #4675 |
| causing | #4678 |
| langerhans | #4681 |
| chains | #4681 |
| monocytes macrophages | #4683 |
| animals antigens | #4693 |
| 259 | #4696 |
| female rats | #4699 |
| lymph | #4707 |
| protecting | #4707 |
| inherited | #4709 |
| defined | #4710 |
| destabilization | #4716 |
| facs | #4718 |
| human studies | #4720 |
| orthomyxoviridae infections | #4725 |
| humans inflammation | #4729 |
| cell population | #4734 |
| positive patients | #4736 |
| α1 | #4739 |
| clone | #4741 |
| mediating | #4744 |
| factor 88 | #4750 |
| panel | #4753 |
| gout | #4757 |
| new drugs | #4764 |
| histopathology | #4767 |
| orchiectomy | #4773 |
| cellular localization | #4775 |
| alveolar macrophages | #4776 |
| e4 | #4776 |
| purified | #4778 |
| differing | #4793 |
| eralpha | #4798 |
| male membrane | #4800 |
| rodents | #4801 |
| displaying | #4809 |
| osteoclastogenesis | #4809 |
| hydrolyzed | #4815 |
| tumor antigens | #4816 |
| effector cells | #4819 |
| cd4 cd8 cells | #4821 |
| paw | #4821 |
| cytokines | #4821 |
| cholera | #4822 |
| distinct | #4831 |
| coincides | #4833 |
| litters | #4843 |
| stress rats | #4846 |
| tissue injury | #4847 |
| rats receptors | #4850 |
| interferon γ | #4852 |
| matrix ecm | #4852 |
| stemness | #4860 |
| articular | #4861 |
| venules | #4863 |
| infiltrate | #4868 |
| th17 cells | #4872 |
| tlr2 | #4880 |
| hpa axis | #4882 |
| ifn | #4885 |
| exocrine | #4888 |
| multifactorial | #4889 |
| 116 | #4891 |
| lod | #4892 |
| specific binding | #4893 |
| ige | #4896 |
| humoral immunity | #4897 |
| induced lung | #4899 |
| preimplantation | #4905 |
| essential roles | #4915 |
| discuss | #4916 |
| immunosorbent | #4917 |
| correlating | #4923 |
| interleukins | #4927 |
| deacetylases | #4928 |
| closely | #4932 |
| timepoints | #4940 |
| humans multiple | #4945 |
| deficiency | #4946 |
| disease process | #4962 |
| naturally occurring | #4962 |
| monitored | #4964 |
| elicit | #4966 |
| forelimb | #4967 |
| contradictory | #4975 |
| point mutation | #4976 |
| cell antigen | #4990 |
| understand | #4995 |
| male rats | #4998 |
| kupffer cells | #5001 |
| thymic | #5003 |
| eosinophilia | #5004 |
| innate immune | #5004 |
| modulates | #5011 |
| wt | #5012 |
| isotype | #5012 |
| upa | #5014 |
| opened | #5018 |
| sh3 | #5019 |
| granuloma | #5021 |
| gland | #5024 |
| enhancing | #5026 |
| vimentin | #5026 |
| expand | #5026 |
| poliomyelitis | #5041 |
| explaining | #5042 |
| il5 | #5044 |
| diamines | #5048 |
| heterozygous | #5049 |
| coculture techniques | #5051 |
| cd8 cells | #5055 |
| caveolin | #5065 |
| th1 cells | #5067 |
| linkage | #5067 |
| phospholipid | #5071 |
| arthritis juvenile | #5072 |
| sitedirected mutagenesis | #5076 |
| molecular basis | #5084 |
| cells blood | #5085 |
| bcg | #5086 |
| alum | #5087 |
| autologous | #5087 |
| olive | #5088 |
| new treatment | #5089 |
| multiple sclerosis | #5098 |
| master regulator | #5100 |
| osteopontin | #5109 |
| aged anti | #5110 |
| occurs | #5112 |
| elispot | #5112 |
| sulfasalazine | #5115 |
| isoantibodies | #5120 |
| dq antigens | #5134 |
| contributes | #5139 |
| lesser | #5145 |
| traditionally | #5148 |
| cytosolic | #5152 |
| epidermis | #5158 |
| connection | #5165 |
| cytokines female | #5170 |
| titrated | #5171 |
| preceded | #5175 |
| antigen receptor | #5178 |
| lymphocytes cytotoxic | #5179 |
| binding | #5185 |
| sex characteristics | #5186 |
| transfer | #5187 |
| polymorphism single | #5188 |
| phenotypic | #5191 |
| complement proteins | #5192 |
| molecular level | #5196 |
| ovariectomized | #5210 |
| popliteal | #5224 |
| ers | #5235 |
| serves | #5238 |
| beta2 | #5238 |
| chimeric | #5241 |
| immunosuppressive | #5246 |
| epidermal | #5250 |
| cognate | #5258 |
| mucus | #5258 |
| cd86 | #5261 |
| tested | #5262 |
| deleterious effects | #5266 |
| progenitors | #5270 |
| costimulation | #5275 |
| detects | #5277 |
| osteoclast | #5277 |
| erosion | #5278 |
| prolactin | #5280 |
| therapeutic intervention | #5280 |
| maternally | #5289 |
| gels | #5292 |
| leu | #5294 |
| plasmapheresis | #5298 |
| clinical findings | #5299 |
| key component | #5301 |
| drug humans | #5301 |
| neutralization | #5301 |
| amino | #5310 |
| suggestion | #5312 |
| staphylococcus aureus | #5312 |
| anhydrases | #5315 |
| manner | #5320 |
| c57bl 6j | #5320 |
| spontaneous | #5321 |
| lipopolysaccharides macrophages | #5345 |
| genetic mapping | #5348 |
| ketoglutarate | #5350 |
| opposing | #5352 |
| proinflammatory | #5365 |
| clathrin | #5369 |
| multiplexed | #5371 |
| glomerulonephritis | #5377 |
| modifies | #5379 |
| cultured human | #5386 |
| expansion | #5387 |
| il1α | #5391 |
| tolllike receptors | #5397 |
| oxidation reduction | #5398 |
| new strategies | #5401 |
| mice molecular | #5402 |
| positive lymphocytes | #5402 |
| tnf α | #5411 |
| epigenetic mechanisms | #5417 |
| antiinflammatory agents | #5417 |
| adversely | #5418 |
| fulvestrant | #5420 |
| activation | #5420 |
| dendritic | #5428 |
| compartments | #5429 |
| antigens surface | #5429 |
| signaling molecules | #5432 |
| mif | #5457 |
| cell culture | #5458 |
| wide spectrum | #5473 |
| sideeffects | #5478 |
| multitude | #5482 |
| located | #5499 |
| immunoglobulins | #5500 |
| reproduced | #5507 |
| histological analysis | #5507 |
| lactating | #5515 |
| cytotoxic | #5519 |
| cytokines humans | #5525 |
| balb mice | #5542 |
| therapeutic | #5547 |
| thymus | #5551 |
| immunosuppressive agents | #5559 |
| pv | #5560 |
| sexual dimorphism | #5560 |
| nociceptive | #5565 |
| redox | #5572 |
| cell expansion | #5578 |
| acute lung | #5583 |
| t1d | #5585 |
| percentage | #5588 |
| allergic reactions | #5592 |
| typed | #5596 |
| lipopolysaccharide lps | #5598 |
| potently | #5600 |
| acute lung injury | #5603 |
| oxidase activity | #5613 |
| control animals | #5614 |
| structural homology | #5616 |
| sequence amino | #5621 |
| synthases | #5633 |
| biotinylation | #5642 |
| bead | #5645 |
| pemphigus | #5649 |
| urgent | #5650 |
| type ifn | #5655 |
| proliferative responses | #5658 |
| explants | #5660 |
| abolished | #5660 |
| regarded | #5663 |
| 198 | #5671 |
| directing | #5676 |
| lung mice | #5677 |
| heterotrimeric | #5684 |
| antioxidant defense | #5685 |
| numbers | #5685 |
| aetiology | #5687 |
| triggers | #5689 |
| keratins | #5695 |
| progression disease | #5697 |
| cytokine expression | #5697 |
| skeletal muscle | #5698 |
| experimental animals | #5700 |
| immune mediated | #5710 |
| avenues | #5715 |
| effective treatments | #5735 |
| altogether | #5737 |
| variable | #5759 |
| integrases | #5760 |
| hfd | #5762 |
| ecm | #5776 |
| mechanisms | #5794 |
| mast | #5802 |
| b16 | #5808 |
| frozen | #5808 |
| linking | #5808 |
| inflammatory disorders | #5809 |
| diabetes t1d | #5814 |
| allergic | #5820 |
| splenic | #5829 |
| bal | #5830 |
| hampered | #5832 |
| toxoid | #5835 |
| earliest | #5837 |
| key regulators | #5844 |
| gabapentin | #5847 |
| type receptors | #5850 |
| large proportion | #5851 |
| proteinases | #5862 |
| cfa | #5868 |
| stronger | #5871 |
| disease genotype humans | #5872 |
| deleted | #5875 |
| hyaluronan receptors | #5875 |
| vitro experiments | #5880 |
| microtomography | #5882 |
| single cells | #5896 |
| evidence role | #5898 |
| modulation | #5900 |
| ace2 | #5917 |
| standardization | #5918 |
| abp | #5919 |
| synthetic | #5920 |
| bronchoalveolar lavage fluid | #5925 |
| low doses | #5925 |
| ics | #5932 |
| subclass | #5941 |
| identifying | #5941 |
| depend | #5947 |
| genomic regions | #5947 |
| explain | #5951 |
| interfere | #5953 |
| biobank | #5960 |
| cytokine production | #5962 |
| expression humans | #5965 |
| nerve regeneration | #5966 |
| factor 1 | #5968 |
| avidin | #5970 |
| foxp3 | #5975 |
| costimulatory | #5977 |
| clarify | #5980 |
| symptom onset | #5983 |
| denaturation | #5986 |
| inability | #5988 |
| knee joint | #5990 |
| eosinophils | #5991 |
| cell subset | #6000 |
| immunity | #6010 |
| glyburide | #6010 |
| 88 | #6014 |
| tetanus | #6019 |
| stress induced | #6022 |
| consisting | #6023 |
| fluorescent dyes | #6044 |
| cnvs | #6045 |
| stimulated | #6056 |
| nih | #6065 |
| igm | #6073 |
| tumor infiltrating | #6074 |
| cleared | #6074 |
| laminin | #6075 |
| genetic therapy | #6077 |
| relapsing remitting | #6083 |
| sle patients | #6089 |
| responsible | #6091 |
| undertook | #6097 |
| messengers | #6100 |
| cages | #6103 |
| stat6 | #6105 |
| ligated | #6107 |
| uncoupling | #6115 |
| bone diseases | #6115 |
| telomeric | #6122 |
| infection mice | #6127 |
| unique | #6140 |
| replacing | #6149 |
| plasma cells | #6150 |
| lowers | #6156 |
| inguinal | #6166 |
| responses | #6171 |
| susceptibility gene | #6171 |
| prophylactic | #6183 |
| genomewide association studies | #6193 |
| instances | #6210 |
| cell functions | #6210 |
| models human | #6217 |
| interferon | #6220 |
| translation | #6222 |
| humans lupus | #6235 |
| characterized | #6236 |
| progesterone | #6253 |
| introduction | #6260 |
| cell type | #6265 |
| exclusively | #6269 |
| protective | #6270 |
| microarray | #6272 |
| serum concentration | #6278 |
| sexes | #6280 |
| immune cell | #6285 |
| myelomonocytic | #6286 |
| histone | #6287 |
| biological evaluation | #6290 |
| difficult | #6298 |
| dermis | #6313 |
| sheath | #6316 |
| monolithic | #6318 |
| minor | #6320 |
| allowed | #6320 |
| tracheal | #6322 |
| estrus | #6336 |
| immunomodulatory | #6337 |
| lymphocyte count | #6339 |
| localize | #6347 |
| tumor immune | #6348 |
| borrelia burgdorferi | #6355 |
| cell biology | #6355 |
| remitting | #6355 |
| virgin | #6356 |
| microsatellite | #6356 |
| signs | #6360 |
| tears | #6363 |
| tryptic | #6370 |
| pertussis | #6372 |
| unresolved | #6378 |
| ros generation | #6379 |
| cells cell | #6381 |
| metalloproteinase | #6392 |
| human subjects | #6394 |
| nicotinamide | #6408 |
| registers | #6410 |
| prodromal | #6450 |
| gonadal | #6451 |
| neuropathological | #6454 |
| models molecular | #6455 |
| peritoneum | #6460 |
| express | #6470 |
| biologic | #6473 |
| transgenes | #6474 |
| c4 | #6475 |
| immunity mucosal | #6476 |
| genetic variants | #6477 |
| inoculation | #6477 |
| severe | #6501 |
| gene function | #6502 |
| demonstrates | #6508 |
| organ specificity | #6511 |
| cell numbers | #6513 |
| stages | #6515 |
| chronic | #6523 |
| nitrite | #6523 |
| synergy | #6523 |
| share | #6539 |
| played | #6540 |
| proteins animals | #6559 |
| apc | #6559 |
| antibody titers | #6572 |
| cytotoxicity immunologic | #6575 |
| pace | #6583 |
| proteases | #6588 |
| rheumatic | #6588 |
| toll | #6603 |
| expression genes | #6603 |
| stain | #6604 |
| major source | #6614 |
| translocating | #6615 |
| parturition | #6635 |
| hpa | #6636 |
| whitney | #6639 |
| solid phase | #6644 |
| affinity | #6645 |
| parenchyma | #6650 |
| regulation | #6650 |
| presently | #6651 |
| sclerosis | #6655 |
| memory cell | #6657 |
| cystine | #6658 |
| cells cd4 | #6665 |
| subfamily | #6672 |
| animals antioxidants | #6683 |
| melatonin | #6683 |
| current understanding | #6687 |
| burgdorferi | #6696 |
| macrophages alveolar | #6701 |
| long noncoding rnas | #6715 |
| histone deacetylases | #6742 |
| normal levels | #6747 |
| pups | #6747 |
| estrogens | #6749 |
| demonstration | #6755 |
| relevant | #6761 |
| comparative genomics | #6768 |
| elastase | #6774 |
| cd8 positive | #6776 |
| interleukin18 | #6782 |
| helpful | #6782 |
| cytometric | #6804 |
| demonstrate | #6812 |
| study role | #6813 |
| glucose transport | #6814 |
| crystal structure | #6819 |
| induced acute | #6825 |
| intra articular | #6825 |
| eosinophil | #6829 |
| cterminal | #6829 |
| cd19 | #6829 |
| conflicting | #6830 |
| lname | #6833 |
| antilymphocyte | #6836 |
| molecules | #6840 |
| aspergillosis | #6852 |
| case control | #6852 |
| lymphoid tissues | #6854 |
| participates | #6855 |
| periodontal disease | #6855 |
| vascular endothelium | #6862 |
| sciatic nerve | #6863 |
| alter | #6865 |
| bioreactors | #6867 |
| activating | #6871 |
| facial nerve | #6873 |
| cell communication | #6882 |
| tool | #6883 |
| cytokine release | #6887 |
| lethality | #6889 |
| inflammatory responses | #6893 |
| lung injury | #6900 |
| ankle joint | #6907 |
| harboring | #6908 |
| gastritis | #6915 |
| tumour necrosis | #6921 |
| recessive | #6922 |
| acetaldehyde | #6925 |
| induced pulmonary | #6931 |
| alternative | #6934 |
| microarray analysis | #6937 |
| cyclic | #6951 |
| inflammatory response | #6953 |
| sulfones | #6960 |
| player | #6974 |
| likewise | #6976 |
| exacerbations | #6984 |
| cdr | #6993 |
| equally | #7001 |
| rac1 | #7013 |
| biological function | #7014 |
| mapping | #7016 |
| translational | #7020 |
| degrade | #7020 |
| mimic | #7025 |
| assay elisa | #7033 |
| fewer | #7033 |
| suppressing | #7047 |
| th1 th2 | #7048 |
| histology | #7056 |
| nucleotide | #7060 |
| genome wide | #7063 |
| target cells | #7063 |
| heterogeneous | #7071 |
| aureus | #7072 |
| subjected | #7072 |
| immune cells | #7075 |
| serine proteases | #7082 |
| proportion | #7083 |
| reduced | #7086 |
| glomeruli | #7088 |
| finally | #7092 |
| atherosclerotic lesions | #7094 |
| orthomyxoviridae | #7108 |
| lyme disease | #7115 |
| thp1 cells | #7121 |
| apoptotic cells | #7124 |
| dividing | #7134 |
| mounted | #7137 |
| autophagy | #7144 |
| extracellular | #7153 |
| immunity cellular | #7161 |
| genetic markers | #7162 |
| messenger rats | #7166 |
| cascades | #7175 |
| synteny | #7188 |
| moiety | #7194 |
| promoted | #7198 |
| higher incidence | #7202 |
| lymphoid tissue | #7205 |
| bovine serum albumin | #7219 |
| dependency | #7223 |
| amino acid | #7225 |
| relevance | #7233 |
| mtx | #7237 |
| recognised | #7238 |
| polysaccharides | #7242 |
| sirt1 | #7251 |
| participate | #7253 |
| prevalent | #7262 |
| immuno | #7265 |
| role pathogenesis | #7272 |
| breeding | #7286 |
| inheritance | #7292 |
| rolling | #7300 |
| prime | #7313 |
| dissecting | #7326 |
| avidity | #7332 |
| expressed genes | #7334 |
| adhesins | #7335 |
| inflammasome | #7342 |
| potential targets | #7343 |
| secreted | #7347 |
| disease specific | #7350 |
| uncontrolled | #7353 |
| metalloendopeptidases | #7355 |
| microglobulin | #7363 |
| adulthood | #7369 |
| transduction animals | #7370 |
| oxide nitric | #7377 |
| array | #7387 |
| analyses | #7391 |
| nervous | #7406 |
| transglutaminase | #7410 |
| chemokines | #7411 |
| interleukin6 | #7411 |
| proven | #7418 |
| supernatants | #7428 |
| genotyping | #7446 |
| immunocytochemistry | #7453 |
| fusion protein | #7456 |
| cells peripheral | #7461 |
| β2 | #7467 |
| airways | #7489 |
| adjuvant | #7493 |
| inhibitory factor | #7500 |
| cytotoxic cells | #7518 |
| disease incidence | #7535 |
| anchor | #7536 |
| eliminate | #7540 |
| early disease | #7541 |
| il1 beta | #7545 |
| lesser extent | #7547 |
| interleukin1beta | #7549 |
| necrotic | #7550 |
| activity relationship | #7553 |
| responder | #7562 |
| elevations | #7589 |
| interacting | #7594 |
| micrograms | #7596 |
| appeared | #7610 |
| hydrocarbon | #7610 |
| arginine | #7621 |
| evident | #7628 |
| cytometry | #7630 |
| unexplained | #7632 |
| allogeneic | #7640 |
| peripheral nervous | #7645 |
| sustain | #7654 |
| receptors immunologic | #7659 |
| component | #7661 |
| graft survival | #7661 |
| murine model | #7665 |
| considerable | #7704 |
| histone deacetylase | #7707 |
| placental | #7712 |
| differentially expressed | #7721 |
| chromosomes | #7722 |
| activators | #7728 |
| motifs | #7730 |
| critical roles | #7731 |
| bacterial toxins | #7735 |
| diagnostics | #7735 |
| initiation | #7745 |
| 325 | #7749 |
| rodent | #7751 |
| chain | #7753 |
| granulocyte | #7754 |
| leukocytes mononuclear | #7766 |
| candidate genes | #7769 |
| activates | #7772 |
| mer | #7772 |
| 37°c | #7773 |
| manuscript | #7780 |
| resolving | #7797 |
| carbonic | #7798 |
| cells tregs | #7800 |
| cell surface receptors | #7807 |
| diet fat | #7810 |
| tgf beta1 | #7831 |
| lipopolysaccharides | #7836 |
| patients levels | #7843 |
| strain | #7844 |
| cells pbmcs | #7853 |
| sirtuin | #7854 |
| retinoid | #7862 |
| interleukin1 | #7866 |
| ifnγ | #7872 |
| gene therapy | #7878 |
| amenable | #7895 |
| analyze | #7897 |
| illness | #7901 |
| lymphopenia | #7909 |
| 2nd | #7917 |
| th2 | #7918 |
| fact | #7925 |
| mann | #7929 |
| myocarditis | #7932 |
| discoveries | #7955 |
| cellular immune | #7957 |
| immunodiffusion | #7959 |
| transform infrared | #7960 |
| positive | #7982 |
| nitrites | #7983 |
| candidate gene | #7987 |
| scoring | #7989 |
| tregs | #7991 |
| direct effects | #7991 |
| unknown | #7993 |
| immune function | #7994 |
| oxidative | #7996 |
| fertilized | #8002 |
| identifies | #8007 |
| haplotypes humans | #8011 |
| polymorphisms | #8012 |
| psa | #8015 |
| essential | #8017 |
| hydroxy | #8030 |
| capacity | #8031 |
| raised | #8040 |
| lncrna | #8047 |
| macroscopic | #8049 |
| myeloid differentiation | #8054 |
| respiratory distress | #8063 |
| address | #8064 |
| drive | #8066 |
| evaluation preclinical | #8067 |
| ascertained | #8077 |
| factor signal | #8077 |
| spanning | #8085 |
| hypophyseal | #8087 |
| tetramer | #8088 |
| appearing | #8088 |
| clinical evaluation | #8089 |
| suboptimal | #8101 |
| physiological | #8105 |
| homozygosity | #8108 |
| prolongation | #8108 |
| considerably | #8109 |
| intronic | #8113 |
| prerequisite | #8120 |
| reasons | #8130 |
| nash | #8133 |
| bovine | #8133 |
| latest | #8134 |
| definition | #8141 |
| macrophages peritoneal | #8141 |
| dying | #8148 |
| trachea | #8156 |
| peripheral nerve | #8160 |
| relapses | #8166 |
| conditioned | #8167 |
| elevated | #8167 |
| harbor | #8170 |
| characterize | #8170 |
| bacterial infection | #8176 |
| expression | #8180 |
| member | #8181 |
| induced inflammation | #8186 |
| rescue | #8192 |
| sacrificed | #8197 |
| cassette | #8198 |
| analysing | #8209 |
| underlying | #8214 |
| preferential | #8216 |
| sulphate | #8225 |
| genetic associations | #8225 |
| defective | #8238 |
| ors | #8241 |
| marginal zone | #8244 |
| foster | #8245 |
| wide | #8261 |
| cultured cytokines | #8268 |
| ppar | #8274 |
| fibrinogen | #8275 |
| bone resorption | #8290 |
| clinical manifestations | #8294 |
| disease genome | #8295 |
| differ | #8295 |
| subcutaneous injection | #8300 |
| streptococcal | #8302 |
| oxygen | #8304 |
| combined treatment | #8309 |
| monoester | #8310 |
| remodeling | #8311 |
| peptide1 | #8316 |
| 11 | #8316 |
| aspergillus fumigatus | #8316 |
| genetically modified | #8320 |
| tlr | #8339 |
| cov2 infection | #8349 |
| boronic | #8363 |
| vh | #8363 |
| frequency | #8364 |
| parietal | #8367 |
| firstly | #8379 |
| fibrils | #8388 |
| migrate | #8391 |
| expressed | #8400 |
| residue | #8401 |
| poly | #8401 |
| p001 | #8404 |
| cd11b | #8408 |
| unaffected | #8411 |
| hydrophilicity | #8420 |
| advancement | #8424 |
| notion | #8424 |
| macrophage activation | #8429 |
| highlights | #8433 |
| defense | #8436 |
| viable | #8460 |
| 14 | #8468 |
| lamina | #8472 |
| manifestation | #8482 |
| protein conformation | #8485 |
| damaging | #8500 |
| promotes | #8502 |
| booster | #8512 |
| inflammatory process | #8516 |
| involves | #8520 |
| cells express | #8525 |
| mildly | #8527 |
| phenotype | #8539 |
| drug development | #8539 |
| burkholderia | #8540 |
| forkhead transcription | #8544 |
| human neutrophils | #8545 |
| estradiol | #8546 |
| copy | #8554 |
| tubule | #8558 |
| adaptive | #8568 |
| inflammatory cytokines | #8576 |
| responsive | #8580 |
| cellular functions | #8582 |
| marginal | #8600 |
| productive | #8609 |
| region | #8618 |
| stress reactive | #8622 |
| chickens | #8638 |
| xanthine | #8641 |
| positivity | #8659 |
| uncovered | #8689 |
| inducers | #8705 |
| outline | #8708 |
| experimental mice mice | #8716 |
| constitutive expression | #8717 |
| vigorous | #8717 |
| ccaat | #8720 |
| staphylococci | #8725 |
| regulatory cell | #8734 |
| cytokine | #8750 |
| recovered | #8751 |
| resorption | #8757 |
| rejection | #8759 |
| larynx | #8761 |
| subset | #8775 |
| chemokine receptor | #8777 |
| impaired | #8781 |
| highlight | #8782 |
| promoter | #8789 |
| cells human | #8790 |
| 4 weeks | #8792 |
| homozygous | #8792 |
| generate | #8799 |
| fungal infections | #8807 |
| human serum | #8808 |
| occasionally | #8808 |
| parotid | #8809 |
| chemically | #8809 |
| generates | #8811 |
| female male | #8812 |
| cytokine levels | #8825 |
| correlated | #8830 |
| kupffer | #8836 |
| cell phenotype | #8866 |
| pathway | #8867 |
| precisely | #8877 |
| bovis | #8882 |
| pathways | #8883 |
| unidentified | #8885 |
| frequencies | #8890 |
| deletion | #8893 |
| key regulator | #8903 |
| endopeptidases | #8922 |
| flow cytometric | #8932 |
| strengthen | #8941 |
| hypothalamo | #8941 |
| and or | #8942 |
| staining | #8944 |
| chemiluminescence | #8945 |
| modulate | #8948 |
| pge2 | #8966 |
| subpopulation | #8967 |
| pitfalls | #8967 |
| attack | #8975 |
| neonatal | #8981 |
| gene | #8983 |
| endosomal | #8987 |
| 129 | #8990 |
| vasculature | #9008 |
| rna long | #9017 |
| adrenocorticotropic | #9019 |
| chemoattractant | #9019 |
| discriminate | #9043 |
| thp1 | #9068 |
| leading | #9074 |
| positioned | #9075 |
| specific role | #9081 |
| glut4 | #9084 |
| hl60 | #9115 |
| cd4 cell | #9129 |
| human | #9131 |
| differentially | #9131 |
| cell surface | #9135 |
| pad | #9136 |
| ongoing | #9160 |
| reconstitution | #9166 |
| negative | #9175 |
| causative | #9182 |
| preincubation | #9186 |
| secrete | #9196 |
| tnf | #9198 |
| lethal | #9205 |
| serologic | #9213 |
| respiratory syndrome | #9222 |
| innate immunity | #9233 |
| started | #9233 |
| sequence | #9238 |
| cells isolated | #9241 |
| glomerulus | #9242 |
| immortalized | #9244 |
| severely | #9250 |
| orphan | #9255 |
| offer | #9255 |
| millions | #9268 |
| ubiquitous | #9272 |
| matrix | #9273 |
| killer | #9278 |
| crystal structures | #9313 |
| clear | #9315 |
| smoking status | #9329 |
| sdspage | #9335 |
| copolymers | #9346 |
| carbohydrate | #9368 |
| neutralizing | #9381 |
| immunoblot | #9395 |
| sweden | #9420 |
| functionality | #9425 |
| cysteine | #9458 |
| ifnα | #9459 |
| lacks | #9460 |
| treatment strategies | #9463 |
| immunomodulation | #9473 |
| luminescent | #9474 |
| molecular | #9484 |
| endotoxins | #9487 |
| tlr4 | #9501 |
| immobilized | #9505 |
| cyclosporin | #9519 |
| immunofluorescence | #9519 |
| hormonal | #9519 |
| sensitized | #9523 |
| detrimental | #9524 |
| heritable | #9530 |
| preexisting | #9543 |
| neuroinflammation | #9558 |
| factor beta1 | #9560 |
| interferon regulatory | #9572 |
| regulated | #9576 |
| culture techniques | #9577 |
| analogous | #9593 |
| entering | #9608 |
| affinities | #9614 |
| steroid hormones | #9615 |
| pretreated | #9624 |
| vaccinated | #9638 |
| gestation | #9639 |
| mammalian cells | #9643 |
| attached | #9647 |
| genetic models | #9655 |
| basement membrane | #9657 |
| key | #9658 |
| vehicle | #9670 |
| cell adhesion | #9678 |
| slight | #9694 |
| dramatic | #9694 |
| accessible | #9708 |
| snp | #9709 |
| azathioprine | #9721 |
| ear | #9723 |
| environment interaction | #9730 |
| livers | #9753 |
| humanized | #9753 |
| maintenance | #9756 |
| metabolic syndrome mets | #9758 |
| functional analysis | #9772 |
| blocked | #9776 |
| cleavage | #9781 |
| microscopic | #9784 |
| adhesion cell | #9784 |
| nasal | #9786 |
| plasminogen activator | #9788 |
| structure activity | #9789 |
| lowered | #9804 |
| infectious | #9804 |
| sterile | #9810 |
| driven | #9836 |
| fibronectin | #9846 |
| delineation | #9856 |
| rheumatology | #9870 |
| phage | #9872 |
| memory cells | #9874 |
| nonhuman primates | #9876 |
| pathogens | #9902 |
| serological | #9907 |
| coculture | #9927 |
| interleukin8 | #9936 |
| healthy control | #9938 |
| reactions | #9953 |
| monkeys | #9973 |
| anticipated | #9993 |
| nucleic acids | #10007 |
| flare | #10014 |
| inflammatory cytokine | #10023 |
| genotype | #10053 |
| serum | #10061 |
| leukocytes | #10067 |
| administered | #10070 |
| differentiation factor | #10076 |
| inflammation male | #10091 |
| generating | #10093 |
| surface receptors | #10102 |
| fibrin | #10105 |
| cells patients | #10110 |
| virulence factors | #10110 |
| activated | #10122 |
| ccl4 | #10125 |
| il1beta | #10131 |
| edge | #10132 |
| new strategy | #10136 |
| host cells | #10139 |
| mitogens | #10140 |
| cell signaling | #10143 |
| kappa | #10143 |
| th2 cells | #10147 |
| retroviridae | #10157 |
| postmenopausal | #10172 |
| traps | #10177 |
| hydrogen peroxide | #10184 |
| placenta | #10185 |
| named | #10188 |
| tlrs | #10207 |
| delta | #10218 |
| summarize | #10236 |
| day | #10244 |
| molecular biology | #10259 |
| rats spraguedawley receptors | #10277 |
| arg | #10279 |
| reproducible | #10283 |
| animals anti | #10304 |
| germ | #10305 |
| gene environment | #10307 |
| tendency | #10317 |
| scid | #10324 |
| lectins | #10329 |
| dismutase | #10332 |
| avian influenza | #10343 |
| reductive | #10347 |
| complete | #10365 |
| mediators | #10378 |
| nterminal | #10392 |
| partially | #10400 |
| lasting | #10406 |
| promote | #10424 |
| determine | #10429 |
| cterminus | #10432 |
| refined | #10437 |
| kill | #10441 |
| cattle | #10446 |
| assays | #10447 |
| indirectly | #10460 |
| mediates | #10474 |
| thioredoxin | #10475 |
| occur | #10477 |
| motif | #10479 |
| redundant | #10502 |
| receptor binding | #10504 |
| developing | #10513 |
| behavior animal | #10515 |
| promoter regions | #10545 |
| phosphate | #10548 |
| produced | #10552 |
| exception | #10554 |
| dysregulated | #10557 |
| critical | #10564 |
| influence | #10568 |
| understood | #10572 |
| converting enzyme | #10584 |
| progressive | #10597 |
| rise | #10608 |
| female | #10609 |
| shortened | #10612 |
| small molecule | #10616 |
| nf kappa | #10617 |
| extracellular matrix | #10620 |
| paralysis | #10632 |
| primers | #10636 |
| collectively | #10637 |
| underlie | #10642 |
| testosterone | #10659 |
| macrophage colony | #10664 |
| selective inhibitor | #10667 |
| aged osteoarthritis | #10675 |
| summary | #10684 |
| repeats | #10685 |
| pbs | #10702 |
| respond | #10705 |
| cerebrospinal fluid | #10708 |
| 17 | #10713 |
| disruption | #10729 |
| issue | #10762 |
| conformation | #10767 |
| il18 | #10770 |
| generation | #10781 |
| cleaved | #10800 |
| 103 | #10811 |
| conditional | #10821 |
| capture | #10822 |
| operated | #10824 |
| seropositive | #10826 |
| cellular mechanisms | #10838 |
| belonging | #10857 |
| saline | #10857 |
| restraint | #10864 |
| phosphatase | #10866 |
| immunoblotting | #10872 |
| factor1 | #10880 |
| base | #10885 |
| connective tissue | #10896 |
| multifunctional | #10904 |
| phagocytosis | #10904 |
| avoid | #10909 |
| ineffective | #10909 |
| luciferase | #10915 |
| bronchoalveolar | #10916 |
| promise | #10920 |
| secondary | #10926 |
| pivotal | #10926 |
| mulatta | #10929 |
| mannose | #10934 |
| persisted | #10939 |
| concluded | #10955 |
| methotrexate | #10967 |
| myeloid cells | #10978 |
| airway inflammation | #10982 |
| degrading | #10983 |
| subcutaneously | #10984 |
| immunoassay | #10984 |
| characterization | #10986 |
| governing | #10998 |
| ethanol | #11000 |
| septic | #11000 |
| tnfα | #11003 |
| mpo | #11010 |
| cell subsets | #11012 |
| originally | #11016 |
| 263 | #11027 |
| immunohistochemistry | #11028 |
| scid mice | #11030 |
| occurrence | #11030 |
| messenger | #11037 |
| hyper | #11040 |
| optical imaging | #11045 |
| skin | #11056 |
| establish | #11066 |
| calcitriol | #11067 |
| tumor progression | #11088 |
| paternal | #11094 |
| add | #11096 |
| freezing | #11102 |
| systemic | #11112 |
| infection animals | #11117 |
| focusing | #11144 |
| genetic polymorphism | #11161 |
| innate immune response | #11167 |
| male | #11167 |
| osteoarthritis | #11176 |
| influx | #11177 |
| receptors | #11177 |
| subsequent | #11177 |
| affinity chromatography | #11186 |
| genes involved | #11187 |
| ankylosing spondylitis | #11197 |
| article | #11201 |
| directly | #11208 |
| bsa | #11210 |
| limited | #11223 |
| sorting | #11229 |
| elicited | #11230 |
| interleukin10 | #11232 |
| disulfides | #11233 |
| contributed | #11248 |
| peptidase | #11251 |
| human blood | #11281 |
| ability | #11284 |
| extensive | #11297 |
| humans influenza | #11314 |
| genotyped | #11318 |
| compared controls | #11322 |
| depends | #11323 |
| oxidant | #11344 |
| caution | #11347 |
| addressing | #11351 |
| tissue damage | #11352 |
| correlate | #11354 |
| extra | #11356 |
| histopathologic | #11376 |
| neuroglia | #11384 |
| modifications | #11385 |
| experimental evidence | #11409 |
| increased expression | #11410 |
| pharmacology | #11413 |
| oxidative phosphorylation | #11428 |
| eosinophilic | #11432 |
| interleukin12 | #11437 |
| quantified | #11438 |
| receptor | #11445 |
| hla class | #11447 |
| cell death | #11460 |
| enhance | #11461 |
| reduces | #11466 |
| governed | #11476 |
| initiating | #11479 |
| contrasting | #11480 |
| melanoma cells | #11488 |
| compared healthy | #11489 |
| cd8 cell | #11498 |
| ankle | #11508 |
| serine | #11525 |
| cytosol | #11542 |
| recipient | #11546 |
| ca2 | #11559 |
| therapeutic interventions | #11561 |
| mets | #11566 |
| jurkat | #11569 |
| backgrounds | #11570 |
| inflammatory effects | #11595 |
| culture medium | #11599 |
| differential expression | #11606 |
| frequently | #11627 |
| alteration | #11627 |
| chicken | #11649 |
| swiss | #11652 |
| enhanced | #11661 |
| exerted | #11663 |
| immunologic memory | #11672 |
| transforming growth | #11678 |
| relief | #11691 |
| synergism | #11703 |
| psychotic | #11730 |
| controls | #11730 |
| toxin | #11735 |
| aiming | #11737 |
| innovative | #11751 |
| amyotrophic | #11769 |
| cell lineage | #11773 |
| constitutes | #11774 |
| inoculated | #11781 |
| commentary | #11785 |
| multiple | #11805 |
| selective | #11814 |
| display | #11817 |
| moderately | #11819 |
| altered | #11829 |
| insufficient | #11830 |
| sequence homology | #11840 |
| 9 | #11857 |
| graft | #11866 |
| analogues | #11871 |
| forkhead | #11888 |
| stained | #11890 |
| enzyme | #11942 |
| augmentation | #11943 |
| classic | #11944 |
| supplied | #11946 |
| gastrointestinal tract | #11958 |
| reveal | #11966 |
| animals bone | #11966 |
| maternal fetal | #11968 |
| adherent | #11980 |
| stress response | #11991 |
| contribution | #11998 |
| tgf | #12005 |
| biomarker | #12016 |
| antiserum | #12017 |
| cricetulus | #12021 |
| deacetylase | #12050 |
| encoding | #12051 |
| plasma cell | #12059 |
| aethiops | #12067 |
| propose | #12072 |
| fat diet | #12104 |
| immunologic factors | #12106 |
| protection | #12107 |
| downstream | #12107 |
| il2 | #12111 |
| tyrosine | #12113 |
| lung | #12116 |
| effectively | #12118 |
| replaced | #12144 |
| induced cell | #12147 |
| bromide | #12152 |
| humans | #12155 |
| quiescent | #12181 |
| switched | #12181 |
| genetic vectors | #12203 |
| oligodeoxyribonucleotides | #12204 |
| histologic | #12222 |
| myd88 | #12222 |
| lectin | #12223 |
| therapeutics | #12230 |
| mesenteric | #12231 |
| toxic | #12231 |
| represents | #12233 |
| receptors estrogen | #12236 |
| corticosterone | #12242 |
| noncoding | #12244 |
| diabetic mice | #12257 |
| fibroblasts humans | #12268 |
| recombinant | #12270 |
| splice | #12271 |
| involving | #12273 |
| fluorescent antibody | #12276 |
| mineral | #12297 |
| tnf alpha | #12300 |
| streptococcus | #12310 |
| harmful | #12319 |
| depending | #12361 |
| acid | #12363 |
| leukocyte count | #12369 |
| syndromes | #12371 |
| tradeoff | #12389 |
| interplay | #12412 |
| origin | #12416 |
| clonal | #12420 |
| microfilament | #12423 |
| reversed | #12439 |
| publication adaptor proteins | #12462 |
| weaker | #12464 |
| protein expression | #12503 |
| pain | #12532 |
| hydrochloride | #12535 |
| drug design | #12567 |
| functional | #12573 |
| rats treated | #12596 |
| suppressor | #12596 |
| binding site | #12597 |
| monomeric | #12605 |
| cells natural | #12637 |
| medullary | #12637 |
| explained | #12643 |
| macaca | #12645 |
| notably | #12664 |
| chronic diseases | #12665 |
| fetuses | #12665 |
| adenine | #12679 |
| cdnas | #12679 |
| 6 weeks | #12681 |
| p38 mitogen | #12681 |
| investigation | #12697 |
| instance | #12709 |
| alveolar | #12729 |
| persistent | #12729 |
| receptor alpha | #12743 |
| modulators | #12770 |
| interactions | #12785 |
| aimed | #12791 |
| nature | #12795 |
| influencing | #12800 |
| diminished | #12804 |
| tibia | #12813 |
| initiated | #12813 |
| sole | #12814 |
| metalloproteinases | #12819 |
| thought | #12823 |
| twin | #12854 |
| isolated | #12871 |
| solely | #12882 |
| disadvantages | #12886 |
| sulfhydryl | #12921 |
| sustained | #12922 |
| assay | #12926 |
| breakdown | #12984 |
| cell division | #13004 |
| embryonic development | #13020 |
| damage | #13056 |
| removing | #13067 |
| tryptophan | #13079 |
| tightly | #13087 |
| crystallography | #13101 |
| hyaluronic | #13102 |
| enabling | #13133 |
| time pcr | #13141 |
| publications | #13143 |
| receptors cell | #13145 |
| stereoisomerism | #13158 |
| distress syndrome | #13175 |
| ancestral | #13179 |
| retained | #13203 |
| valine | #13205 |
| division | #13213 |
| suffering | #13215 |
| single nucleotide polymorphisms | #13234 |
| opportunity | #13243 |
| opportunities | #13258 |
| 1 protein | #13270 |
| chemotaxis | #13279 |
| modulator | #13283 |
| lavage fluid | #13293 |
| transgene | #13297 |
| ascending | #13302 |
| regulators | #13320 |
| elucidated | #13323 |
| purity | #13330 |
| bronchoalveolar lavage | #13334 |
| nk | #13353 |
| fisher | #13357 |
| inhibitory effects | #13362 |
| lymphoproliferative | #13372 |
| amyotrophic lateral | #13377 |
| facilitating | #13380 |
| overexpressed | #13383 |
| scattered | #13389 |
| borrelia | #13393 |
| intact | #13410 |
| independently | #13433 |
| thiol | #13434 |
| fibroblast | #13447 |
| oocytes | #13463 |
| embryos | #13465 |
| marrow derived | #13484 |
| spraguedawley receptors | #13488 |
| overcome | #13489 |
| endopeptidase | #13500 |
| aspect | #13523 |
| lateral sclerosis | #13577 |
| tail | #13589 |
| selectively | #13591 |
| lipopolysaccharide | #13598 |
| elisa | #13612 |
| heritability | #13616 |
| vertebrates | #13627 |
| renal disease | #13634 |
| cure | #13674 |
| peripheral | #13689 |
| reproductive | #13755 |
| clones | #13757 |
| requires | #13783 |
| profiling gene | #13808 |
| lavage | #13811 |
| exon | #13822 |
| arising | #13831 |
| secretory | #13835 |
| techniques | #13873 |
| 6 | #13879 |
| killer cells | #13891 |
| exposed | #13917 |
| cloned | #13927 |
| iga | #13936 |
| hepatocytes | #13938 |
| tolerant | #13992 |
| lncrnas | #14002 |
| anti inflammatory | #14010 |
| killed | #14033 |
| selectin | #14034 |
| sensitization | #14035 |
| environmental | #14057 |
| insertion | #14063 |
| recombinant proteins | #14070 |
| neighboring | #14098 |
| reflects | #14102 |
| great | #14120 |
| preclinical | #14123 |
| highlighting | #14145 |
| preventing | #14148 |
| healthy individuals | #14159 |
| administration | #14164 |
| vaccination | #14176 |
| potent | #14183 |
| retroviral | #14208 |
| multigene | #14246 |
| advances | #14275 |
| amino acids | #14298 |
| ester | #14310 |
| oxidative stress | #14315 |
| cord | #14319 |
| incidence | #14322 |
| impairs | #14323 |
| domain | #14325 |
| psychosis | #14326 |
| p38 | #14329 |
| bovine serum | #14329 |
| isolation | #14334 |
| differentiation | #14342 |
| multiprotein | #14366 |
| mineral density | #14406 |
| differentiation cells | #14414 |
| #14414 | |
| resolve | #14420 |
| colony stimulating | #14421 |
| consistently | #14448 |
| kinases animals | #14452 |
| paracrine | #14452 |
| adenoviridae | #14472 |
| chlorocebus | #14481 |
| marrow transplantation | #14485 |
| targeted | #14490 |
| pathology | #14492 |
| il1 | #14500 |
| integrative | #14510 |
| cells vitro | #14537 |
| monocytes | #14540 |
| bone density | #14589 |
| infectious diseases | #14593 |
| biomedical | #14605 |
| nitrate | #14616 |
| nf kappab | #14627 |
| recombinant human | #14632 |
| divergent | #14638 |
| pathological | #14640 |
| enzyme activation | #14658 |
| lupus nephritis | #14661 |
| smoking | #14673 |
| transforming | #14675 |
| gfp | #14681 |
| inborn | #14696 |
| hand | #14698 |
| green fluorescent | #14703 |
| scarce | #14718 |
| substances | #14724 |
| risk developing | #14724 |
| nitrates | #14728 |
| oxide synthase | #14731 |
| p005 | #14732 |
| particulate | #14751 |
| oxidoreductases | #14753 |
| protein binding | #14757 |
| blood vessels | #14759 |
| human cells | #14768 |
| interferon alpha | #14780 |
| il1β | #14800 |
| degenerative | #14815 |
| proteinase | #14817 |
| originating | #14824 |
| vitro | #14829 |
| overlapping | #14835 |
| biocompatible | #14851 |
| prostaglandins | #14881 |
| controlled | #14895 |
| interaction | #14916 |
| chronically | #14923 |
| genomic dna | #14929 |
| potential therapeutic | #14939 |
| colleagues | #14950 |
| plays | #15011 |
| cross | #15041 |
| implications | #15063 |
| escape | #15078 |
| granule | #15079 |
| receptor gene | #15089 |
| phosphoric | #15090 |
| converting | #15126 |
| acute respiratory | #15173 |
| spinal cord | #15185 |
| seroepidemiologic | #15205 |
| bmd | #15213 |
| proliferation cells | #15219 |
| covalently | #15234 |
| preferentially | #15252 |
| adhesion | #15299 |
| fetus | #15300 |
| processed | #15329 |
| allografts | #15337 |
| synthase | #15339 |
| bone mineral density | #15340 |
| accelerate | #15346 |
| neurodegenerative | #15377 |
| pretreatment | #15379 |
| blood mononuclear | #15414 |
| interleukin6 il6 | #15440 |
| comparative | #15474 |
| selected | #15486 |
| antigens bacterial | #15511 |
| cells dcs | #15513 |
| locally | #15521 |
| transcriptase polymerase | #15530 |
| influenza human | #15537 |
| basis | #15540 |
| hormone | #15542 |
| central nervous | #15566 |
| estrogen receptor | #15572 |
| transduction | #15579 |
| vaccines | #15623 |
| responsiveness | #15647 |
| rna interference | #15649 |
| binds | #15651 |
| accelerator | #15673 |
| limitation | #15675 |
| pyruvate | #15682 |
| sequenced | #15696 |
| conformational | #15701 |
| cd28 | #15708 |
| connective | #15748 |
| gastric | #15775 |
| single | #15789 |
| fluorescent | #15793 |
| bone loss | #15832 |
| induced expression | #15835 |
| protein structure | #15849 |
| spinal | #15861 |
| vasculitis | #15884 |
| treating | #15887 |
| kappab | #15894 |
| gcsf | #15908 |
| competitive | #15910 |
| positron emission | #15913 |
| downregulation | #15914 |
| systemic inflammation | #15944 |
| methylated | #15945 |
| neurodegeneration | #15945 |
| involve | #15980 |
| ap1 | #15985 |
| plasmon resonance | #15986 |
| reflected | #15993 |
| chromatographic | #16019 |
| cnv | #16065 |
| oligonucleotide array | #16092 |
| 106 | #16097 |
| responding | #16105 |
| pluripotent | #16135 |
| bone mineral | #16141 |
| undetectable | #16148 |
| skeletal | #16151 |
| neurons | #16154 |
| tissue distribution | #16155 |
| disequilibrium | #16156 |
| beta1 | #16172 |
| exhibited | #16189 |
| response treatment | #16236 |
| grafted | #16238 |
| array sequence | #16239 |
| glandular | #16252 |
| functional studies | #16273 |
| responders | #16278 |
| new class | #16282 |
| subunit | #16293 |
| required | #16309 |
| animals base | #16310 |
| subclinical | #16311 |
| linkage disequilibrium | #16342 |
| receptor signaling | #16351 |
| difference | #16367 |
| remarkably | #16382 |
| molecular structure | #16391 |
| form | #16409 |
| signalling | #16414 |
| molecular mechanism | #16419 |
| publication antibodies | #16433 |
| cd40 | #16468 |
| shr | #16471 |
| capable | #16496 |
| grouped | #16512 |
| subcutaneous | #16522 |
| fibroblasts | #16525 |
| revealing | #16544 |
| targeting | #16552 |
| node | #16585 |
| respiratory | #16585 |
| organs | #16586 |
| tumor cells | #16600 |
| antibodies bacterial | #16603 |
| subunits | #16626 |
| profiling | #16651 |
| necrosis | #16655 |
| establishing | #16709 |
| negatively | #16709 |
| uric | #16743 |
| irradiated | #16757 |
| nick | #16765 |
| intramolecular | #16795 |
| deeper | #16801 |
| instrumental | #16812 |
| detected | #16851 |
| clinically | #16859 |
| immunoreactive | #16859 |
| serve | #16878 |
| inhibitory | #16881 |
| documented | #16904 |
| greatly | #16907 |
| colony | #16928 |
| turn | #16941 |
| immunosuppression | #16942 |
| mmps | #16957 |
| inhibition | #16959 |
| receptor 1 | #16964 |
| additionally | #16970 |
| humans hydrogen | #16982 |
| structurally | #16985 |
| prior | #16994 |
| additional | #17005 |
| binding protein | #17006 |
| recombinant fusion | #17013 |
| sulfate | #17069 |
| b7 | #17077 |
| count | #17083 |
| il12 | #17096 |
| sex factors | #17111 |
| consist | #17113 |
| minimal | #17116 |
| alpha subunit | #17119 |
| lysosomal | #17126 |
| unexpected | #17137 |
| tissue | #17148 |
| pluripotent stem | #17151 |
| receptors tumor | #17172 |
| csf | #17185 |
| activator | #17202 |
| lymph node | #17208 |
| underlying mechanisms | #17217 |
| stimulation | #17249 |
| starting | #17298 |
| peritoneal | #17299 |
| cell proliferation | #17318 |
| fluid | #17330 |
| propensity | #17345 |
| generations | #17377 |
| humans immunity | #17410 |
| constitute | #17425 |
| demonstrated | #17444 |
| membrane | #17466 |
| muscle skeletal | #17479 |
| types | #17505 |
| allowing | #17505 |
| fibrous | #17515 |
| transcriptase | #17515 |
| type iii | #17546 |
| localization | #17547 |
| constitutive | #17559 |
| cytometry humans | #17570 |
| discovery | #17583 |
| treatments | #17596 |
| peripheral blood | #17615 |
| variation | #17616 |
| packed | #17678 |
| differed | #17683 |
| expanded | #17687 |
| proved | #17691 |
| plasmon | #17698 |
| longitudinally | #17713 |
| pbmcs | #17728 |
| stimulating factor | #17743 |
| somatic | #17805 |
| inflammatory bowel disease | #17815 |
| dcs | #17827 |
| relating | #17861 |
| alpha tnf | #17880 |
| neuroendocrine | #17920 |
| oligonucleotide | #17954 |
| homology | #17962 |
| surface plasmon | #17971 |
| pregnancy | #17985 |
| chromosomal | #17994 |
| post | #17998 |
| inhibit | #18002 |
| labelled | #18004 |
| damaged | #18064 |
| osmolar | #18107 |
| 2 4 | #18130 |
| creating | #18142 |
| cytoplasm | #18155 |
| released | #18157 |
| trigger | #18161 |
| corticosteroids | #18164 |
| species | #18168 |
| endocrine | #18192 |
| vertebrate | #18206 |
| labeled | #18208 |
| subcellular | #18231 |
| rna messenger | #18235 |
| protein serine | #18279 |
| limiting | #18281 |
| reverse transcriptase | #18325 |
| evidenced | #18329 |
| truncated | #18336 |
| avian | #18345 |
| net | #18345 |
| males | #18375 |
| critically | #18389 |
| assumed | #18433 |
| modulated | #18444 |
| rats wistar | #18448 |
| pathogen | #18464 |
| immunogenicity | #18486 |
| acids | #18490 |
| reaching | #18494 |
| nonparametric | #18512 |
| constitutively | #18518 |
| hyaluronan | #18609 |
| processing | #18609 |
| sulfonamides | #18643 |
| investigating | #18651 |
| 15 | #18656 |
| 22 | #18658 |
| verify | #18669 |
| signal transduction | #18682 |
| agents steroidal | #18685 |
| remaining | #18721 |
| aim | #18788 |
| cerebrospinal | #18788 |
| created | #18803 |
| balanced | #18823 |
| cultured | #18823 |
| carry | #18829 |
| pathophysiological | #18830 |
| production | #18927 |
| nerve | #18943 |
| nested | #18957 |
| nfκb | #18987 |
| failed | #18988 |
| sequence analysis | #19002 |
| specific antigen | #19050 |
| observations | #19062 |
| provided | #19067 |
| bone marrow | #19084 |
| lungs | #19111 |
| stimulating | #19136 |
| protein | #19164 |
| bearing | #19167 |
| publication administration | #19185 |
| gained | #19200 |
| mitochondrial | #19260 |
| symptoms | #19288 |
| lost | #19298 |
| majority | #19304 |
| intra | #19311 |
| interacts | #19344 |
| hormones | #19441 |
| fatal | #19464 |
| interferons | #19489 |
| analyzing | #19515 |
| exogenous | #19526 |
| cytoskeletal | #19553 |
| adrenal | #19553 |
| rapidly | #19574 |
| inducible | #19616 |
| etiology | #19652 |
| environment | #19668 |
| implanted | #19680 |
| lps | #19681 |
| mice scid | #19683 |
| vesicular | #19701 |
| lineage | #19719 |
| markers | #19789 |
| histologically | #19817 |
| offers | #19826 |
| cutaneous | #19834 |
| precise | #19836 |
| pharmacological | #19854 |
| fetal | #19862 |
| shifted | #19875 |
| newly | #19892 |
| supporting | #19915 |
| vitro techniques | #19945 |
| yielded | #19948 |
| 8 | #19978 |
| cns | #19979 |
| 28 | #19979 |
| response relationship | #20014 |
| transient | #20038 |
| modify | #20055 |
| designated | #20056 |
| reverse | #20057 |
| casecontrol study | #20088 |
| mutagenesis | #20118 |
| illustrated | #20126 |
| downregulated | #20133 |
| ultimately | #20202 |
| κb | #20256 |
| 1 diabetes | #20263 |
| hypothalamic | #20285 |
| primary | #20303 |
| entered | #20310 |
| nitric | #20316 |
| gene expression | #20364 |
| markedly | #20453 |
| genotype humans | #20460 |
| mature | #20491 |
| microglia | #20561 |
| circulating | #20574 |
| overexpressing | #20593 |
| human pair | #20604 |
| polyacrylamide | #20612 |
| marrow | #20651 |
| defining | #20660 |
| pregnant | #20665 |
| equal | #20678 |
| resting | #20729 |
| injured | #20739 |
| mild | #20819 |
| local | #20825 |
| discovered | #20835 |
| cricetinae | #20839 |
| reduction | #20847 |
| illustrate | #20874 |
| lactic | #20908 |
| hypothesized | #20913 |
| tended | #20919 |
| 10 | #20952 |
| successful | #20952 |
| cell derived | #20955 |
| aberrant | #20961 |
| animals biomarkers | #21033 |
| 2 | #21085 |
| attractive | #21228 |
| acute | #21279 |
| produces | #21297 |
| transfected | #21316 |
| marked | #21340 |
| decreased | #21383 |
| maternal | #21389 |
| emerged | #21445 |
| survived | #21524 |
| confirms | #21558 |
| membrane proteins | #21585 |
| forming | #21593 |
| preserved | #21732 |
| contained | #21802 |
| previous | #21805 |
| 16 | #21813 |
| doses | #21835 |
| immunodeficiency | #21852 |
| electrophoresis | #21867 |
| mellitus type | #21871 |
| natural killer | #21877 |
| cell count | #21898 |
| prolonged | #21903 |
| heavy | #21965 |
| increasing | #21979 |
| polymeric | #22042 |
| gradually | #22067 |
| glial | #22202 |
| selecting | #22242 |
| extremely | #22248 |
| 4 | #22274 |
| opportunistic | #22307 |
| accepted | #22356 |
| emission tomography | #22395 |
| enable | #22402 |
| humans models | #22445 |
| initially | #22458 |
| microscopy confocal | #22466 |
| physiologic | #22470 |
| appears | #22488 |
| releasing | #22497 |
| suitable | #22522 |
| humans immunosuppressive | #22529 |
| confirm | #22553 |
| chemokine | #22558 |
| metabolic | #22585 |
| actins | #22597 |
| loss | #22611 |
| nf | #22756 |
| reactive protein | #22834 |
| utilizing | #22899 |
| transformed | #22917 |
| progression female | #22918 |
| detailed | #23005 |
| natural | #23089 |
| cell types | #23132 |
| sex | #23234 |
| null | #23277 |
| untranslated | #23305 |
| signaling | #23324 |
| syndrome | #23335 |
| bone | #23397 |
| necrosis factor | #23407 |
| rich | #23430 |
| cells tumor | #23467 |
| nucleic | #23501 |
| continued | #23663 |
| cellular | #23667 |
| expression gene | #23728 |
| attenuated | #23757 |
| mitogen | #23814 |
| serine threonine | #23835 |
| examine | #23864 |
| fusion proteins | #23968 |
| organ | #23990 |
| remained | #23998 |
| prevent | #24026 |
| confined | #24245 |
| oxidized | #24325 |
| called | #24330 |
| discussed | #24334 |
| genomic | #24394 |
| covering | #24485 |
| embryonic | #24490 |
| interleukin | #24583 |
| varying | #24640 |
| weeks | #24698 |
| mechanistic | #24796 |
| putative | #24897 |
| detect | #24963 |
| sarcoidosis | #24963 |
| remains | #25082 |
| controversial | #25175 |
| implies | #25192 |
| stromal | #25269 |
| type 1 diabetes | #25410 |
| enriched | #25470 |
| relation | #25543 |
| attributed | #25618 |
| 7 | #25632 |
| proteins | #25644 |
| tumor necrosis | #25683 |
| dysregulation | #25711 |
| cytoplasmic | #25732 |
| inflammatory agents | #25735 |
| energetic | #25813 |
| healthy | #25887 |
| representing | #25917 |
| challenging | #25976 |
| threonine | #25988 |
| mechanisms underlying | #26094 |
| signal | #26163 |
| tnfalpha | #26432 |
| frequent | #26487 |
| individuals | #26568 |
| antibodies viral | #26579 |
| growth factor | #26602 |
| validated | #26686 |
| lower | #26708 |
| treat | #26713 |
| 3 | #26751 |
| tolerated | #26780 |
| pathophysiology | #26782 |
| explored | #26850 |
| tumor necrosis factor | #26925 |
| comparable | #26955 |
| normal | #27016 |
| define | #27055 |
| exist | #27121 |
| presented | #27123 |
| consists | #27152 |
| intracellular | #27233 |
| invariant | #27331 |
| animals cells | #27339 |
| adaptor proteins | #27447 |
| chromosomes human | #27524 |
| associations | #27560 |
| kda | #27648 |
| tract | #27680 |
| possess | #27765 |
| exclude | #27824 |
| cell tumor | #27826 |
| attributable | #28018 |
| proteins humans | #28150 |
| heterozygote | #28266 |
| treated | #28436 |
| observe | #28472 |
| remain | #28560 |
| regulation humans | #28667 |
| threonine kinases | #28809 |
| hypothesis | #28819 |
| require | #28838 |
| examined | #29041 |
| infection | #29082 |
| 5 | #29247 |
| animals apoptosis | #29491 |
| intracellular signaling | #29517 |
| easily | #29557 |
| effective | #29656 |
| 005 | #29706 |
| fully | #29936 |
| exhibit | #29947 |
| gtp binding | #29997 |
| intravenous | #30185 |
| cell movement | #30520 |
| oxide | #30546 |
| reached | #30655 |
| active | #30908 |
| versus | #30963 |
| 1 | #31228 |
| cell differentiation | #31374 |
| vary | #31548 |
| blotting western | #31843 |
| free | #32409 |
| expression regulation | #32516 |
| needed | #32543 |
| objectives | #32805 |
| generally | #33368 |
| inhibited | #33394 |
| clinical | #33439 |
| sought | #34008 |
| reduce | #34128 |
| biological | #34247 |
| reflect | #34701 |
| separately | #34818 |
| agents | #34868 |
| assess | #34935 |
| polymerase | #35201 |
| nuclear | #35715 |
| polymerase chain | #36180 |
| formed | #36819 |
| chain reaction | #36949 |
| 001 | #36954 |
| measured | #42007 |
Kjør rapport | |
Prominent publications by Rikard Holmdahl
KOL-Index: 15284
The purpose of the study was to map the dominant T cell epitope of the CB11 sequence of CII in RTlu haplotype rats and to determine if, when used as a synthetic peptide, it would induce tolerance to protect against CIA. A dominant epitope corresponding to residues 184-198 included in the sequence of the CB11 fragment of bovine CII was identified in proliferation assay using peptides in an epitope scanning system using synthetic peptides of 15 amino acids, overlapping by 12 amino acids. ...
| Kjent for Mucosal Tolerance | Synthetic Peptide | Cell Epitope | Cia Cii | Collagen‐induced Arthritis |
KOL-Index: 14658
An antibody response to defined epitopes located on the triple helical portion of type II collagen (CII) is associated with the development of collagen-induced arthritis (CIA) and rheumatoid arthritis (RA). Monoclonal antibodies to epitopes associated with arthritis, but not antibodies specific for epitopes not associated with arthritis, induce arthritis in mice, the so-called collagen antibody induced arthritis (CAIA) model. We have selected monoclonal IgG antibodies specific for four ...
| Kjent for Collagen Antibody | Induced Arthritis | Monoclonal Antibodies | Mice Inbred | Specific Epitopes |
KOL-Index: 13984
The Aq major histocompatibility complex (MHC) class II molecule is associated with susceptibility to murine collagen-induced arthritis (CIA), whereas the closely related H-2Ap molecule is not. To understand the molecular basis for this difference, we have analyzed the ability of H-2Aq and H-2Ap molecules (referred to as Aq and Ap) to bind and present collagen type II (CII)-derived glycosylated and non-glycosylated peptides. T cell clones specific for the immunodominant CII 256-270 ...
| Kjent for Collagen‐induced Arthritis | Transgenic Models | Aq Molecule | Structural Basis | C3h Mice |
KOL-Index: 13727
BACKGROUND: Autoantibodies to cyclic citrullinated peptides (anti-CCP) are present in most patients with rheumatoid arthritis (RA), and associate with HLA-DRB1 shared epitope (SE) alleles.
OBJECTIVE: To investigate reactivities of anti-CCP to various citrullinated proteins/peptides, which represent potential autoantigens in RA, and to examine the relationship between such antibodies, and their association with genetic variants within HLA-DRB1 SE alleles.
METHODS: Serum samples from 291 ...
| Kjent for Citrullinated Antigens | Rheumatoid Arthritis | Drb1 Alleles | Ccp Patients | Antibody Reactivities |
Localization of a critical restriction site on the I-A beta chain that determines susceptibility to collagen-induced arthritis in mice
[ PUBLICATION ]
Type II collagen-induced arthritis (CIA) in mice is an autoimmune experimental model for rheumatoid arthritis. Susceptibility to CIA is associated with certain major histocompatibility complex class II haplotypes. The two very closely related haplotypes H-2q and H-2p differ in susceptibility to CIA. Only mice of H-2q (DBA/1, B10G strains) but not mice of H-2p-expressing strains (like strain B10P) develop CIA and an autoimmune response to type II collagen (CII) after immunization with ...
| Kjent for Mice Cia | Beta Chain | Rheumatoid Arthritis | H2q Haplotype | Type Collagen Cii |
KOL-Index: 13513
INTRODUCTION: It has previously been shown that an increased number of antibodies against citrullinated peptides/proteins (ACPA) predate the onset of rheumatoid arthritis (RA). Over time antibody positivity expands, involving more specific responses when approaching the onset of symptoms. We investigated the impact of human leukocyte antigen-shared epitope (HLA-SE) alleles and smoking on the development of ACPA, as well as in combination with ACPA during the state of quiescent ...
| Kjent for Citrullinated Peptides | Onset Symptoms | Development Rheumatoid Arthritis | Combination Acpa | Hlase Smoking |
Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients
[ PUBLICATION ]
OBJECTIVE: High titers of specific anti-citrullinated protein antibodies (ACPAs) are frequently present in the serum of rheumatoid arthritis (RA) patients, but their presence in synovial fluid is less well characterized. The purpose of this study was to compare the levels of antibody to 4 well-defined citrullinated candidate RA autoantigens in serum and synovial fluid and to determine whether antibodies to one citrullinated antigen are dominant over another. Furthermore, we studied their ...
| Kjent for Citrullinated Antigens | Synovial Fluid | Rheumatoid Arthritis Patients | Type Collagen | Antibodies Acpas |
Toll-like receptor 3 upregulation in macrophages participates in the initiation and maintenance of pristane-induced arthritis in rats
[ PUBLICATION ]
INTRODUCTION: Toll-like receptors (TLRs) are involved in both innate and adaptive immune responses and are likely to play a complex role in the pathogenesis of human rheumatoid arthritis (RA) and experimental arthritis. The objective of this study was to identify the key TLR in pristane-induced arthritis (PIA), a rat model for RA, and to clarify its roles in the initiation and maintenance of arthritis.
METHODS: Arthritis in DA rats was induced by pristane and the severity was evaluated ...
| Kjent for Induced Arthritis | Tlr3 Expression | Rats Pristane | Receptor 3 | Inbred Strains Severity |
KOL-Index: 12776
Multiple sclerosis (MS) is a complex chronic neurologic disease with a suspected autoimmune pathogenesis1,2. Although there is evidence that the development of MS is determined by both environmental influences and genes, these factors are largely undefined3,4, except for major histocompatibility (MHC) genes. Linkage analyses and association studies have shown that susceptibility to MS is associated with genes in the human histocompatibility leukocyte antigens (HLA) class II region, but ...
| Kjent for Multiple Sclerosis | Transgenic Mice | Hla Dr2 | Humanized Model | Spontaneous Disease |
KOL-Index: 12721
Polymorphism of the major histocompatibility complex (MHC) influences susceptibility to experimental autoimmune encephalomyelitis (EAE) induced by myelin basic protein (MBP) in rats. Current concepts relate such influences to the capacity of class II molecules to present relevant peptides to autoreactive T cells. We have here analyzed the MHC influence on the immune response and the development of EAE after immunization with the immunodominant peptide MBP-63-88. Analysis of MHC-congenic ...
| Kjent for Myelin Basic Protein | Experimental Autoimmune | Major Histocompatibility | Rats Eae | Immune Response |
Multiplex Analyses of Antibodies Against Citrullinated Peptides in Individuals Prior to Development of Rheumatoid Arthritis
[ PUBLICATION ]
OBJECTIVE: The presence of antibodies against cyclic citrullinated peptides has been demonstrated to precede the onset of symptoms of rheumatoid arthritis (RA) by several years. The aim of this study was to analyze antibodies against 10 citrullinated autoantigen-derived peptides for reactivity before the onset of RA symptoms.
METHODS: A case-control study was conducted within the Medical Biobank of Northern Sweden. The study was performed in 409 individuals, 386 of whom donated 717 blood ...
| Kjent for Citrullinated Peptides | Rheumatoid Arthritis | Onset Symptoms | Antibodies Cep1 | Type Collagen |
KOL-Index: 12510
Antibodies against type II collagen (anti-CII) are arthritogenic and have a crucial role in the initiation of collagen-induced arthritis. Here, we have determined the dependence of T and B cells in collagen-antibody-induced arthritis (CAIA) during different phases of arthritis. Mice deficient for B and/or T cells were susceptible to the CAIA, showing that the antibodies induce arthritis even in the absence of an adaptive immune system. To determine whether CII-reactive T cells could have ...
| Kjent for Collagen Type | Arthritis Mice | Antigen Tcell | Antibodies Cii | Adaptive Immune |
KOL-Index: 12427
The nonobese diabetic (NOD) mouse spontaneously develops autoimmune-mediated diseases such as diabetes and Sjögren's syndrome. To investigate whether NOD genes also promote autoimmune-mediated arthritis we established a NOD strain with an MHC class II fragment containing the A(q) class II gene predisposing for collagen induced arthritis (NOD.Q). However, this mouse was resistant to arthritis in contrast to other A(q) expressing strains such as B10.Q and DBA/1. To determine the major ...
| Kjent for Genetic Control | Complement Factor | Induced Arthritis | Locus Chromosome | Mice Inbred |
Nøkkelpersoner for Rheumatoid Arthritis
Toppkols i verden
Rikard Holmdahl:Ekspertvirkning
Konsepter somRikard Holmdahlhar direkte innflytelse:Rheumatoid arthritis, Induced arthritis, Experimental arthritis, Collagen type, Type collagen, Animal models, Reactive oxygen species, Autoimmune diseases.
Rikard Holmdahl:Kol Impact
Konsepter relatert til arbeidet til andre forfattere somfor which Rikard Holmdahl har innflytelse:Rheumatoid arthritis, Multiple sclerosis, Autoimmune diseases, Oxidative stress, Animal models, Reactive oxygen species, Nadph oxidase.
Tools
Er dette profilen din? Krev profilen din Kopier url Legg inn lenke til profilen din |